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ABSTRACT 
 
 
Clomiphene citrate (CC) is a synthetic oestrogen receptor modulator that may act 
to promote or inhibit oestrogenic responses depending on the type of tissue or 
organism. CC acts as a superovulator and has been widely prescribed in the 
treatment of female infertility. However, pregnancy rates after CC treatment are 
low, possibly due to the CC causing morphological and other unidentified changes 
to the uterus. 
 
This study investigated the changes caused by CC on the progesterone receptor 
(PR), the anti-apoptotic protein, Bcl-2, and the pro-apoptotic protein, Bax. 
PR with its ligand, progesterone, is important for the maintenance of a pregnancy. 
Bcl-2 is a cell survival molecule and acts in opposition to Bax, which promotes 
apoptosis, which is important in allowing an attaching blastocyst to infiltrate the 
maternal endometrium. 
 
A high physiological dose of CC (1.25 mg) was administered to ovariectomised 
rats, either as a single treatment, or prior to a hormonal treatment regime 
characteristic of pre-implantation animals. The single CC treated animals were 
compared with single 5 mg progesterone (P4) treated animals and vehicle controls. 
The animals treated with CC in conjunction with the ovarian hormone milieu 
(CCPPPE treatment) were compared to PPPE treated animals or to the vehicle 
controls. 
The effects of CC, P4, PPPE and SPPPE on the morphology of the uteri were 
investigated by light microscopy. Expression of the PR, Bcl-2 and Bax were 
investigated using immunohistochemistry and enzyme linked immunosorbent 
(ELISA) techniques. 
 
The present study showed that CC treatment affects the microanatomy of the 
uterine compartments, particularly the shape of the lumen and the luminal 
epithelial height. The expressions of PR, Bcl-2 and Bax in the entire uterus were 
 iv
not significantly affected by the various treatments applied to the ovariectomised 
rats, as measured using ELISA. However, expression of the proteins in the various 
uterine compartments was altered by CC treatment. The single CC and CCPPPE 
treatments had an oestrogenic effect with regards to PR expression in the uteri as 
seen in the immunolocalisation, whereas the single P4 treatment decreased the PR 
expression, as expected. CC treatment caused patchiness in both Bcl-2 and Bax 
expression surrounding the endometrial lumen. Moreover, treatment with CC 
maintained expression of Bcl-2 in the luminal epithelium, whereas the expression 
of Bax shifted away from the luminal epithelium. This suggests that CC treatment 
promotes cell survival of the luminal epithelium, which may diminish the ability 
of the blastocyst to infiltrate the maternal tissue. 
 
CC action is both dose sensitive and has a cumulative effect with multiple 
treatments. Future studies would aim to separate the various uterine compartments 
in order to quantitatively assess the actions of CC on expression in the PR, Bcl-2 
and Bax. In addition, it would be interesting to investigate how the accumulation 
of subsequent CC doses affects the expression of apoptotic markers, as this would 
be a more realistic model for human infertility treatment.  
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CHAPTER 1. INTRODUCTION 
 
 
1.1.  Infertility 
 
Childlessness has enormous social, cultural, spiritual and financial implications in 
all human societies, particularly amongst African societies. Little research has 
been done to assess infertility rates in Sub-Saharan Africa, due to the perception 
of high fertility rates in the region (Hollos, 2003, Motseki, 2004). However, there 
is a significant problem regarding infertility in various African societies, with 
regional effects from 10-20% up to as high as 30-40% (Dyer et al., 2002b, 
Motseki, 2004). Infertility is regarded as the inability to conceive after one year of 
unprotected intercourse (Collins et al., 1983, Larson, 2005). 
 
It is estimated that 40% of infertility causes are due to male infertility, 40% are 
due to female infertility, and 20% of cases have unknown etiology (Bernstein, 
1999). Unfortunately, within most traditional and patriarchal societies, blame 
tends to fall most often upon women (Juries, 2005). Studies in South Africa show 
that childless women often feel guilt and are desperate for babies. A childless 
woman may suffer from the threat of marital dissolution or infidelity, verbal or 
physical abuse, loss of social status, loss of economic income, isolation and 
stigmatization from the community and enormous social pressure to get pregnant 
(Dyer et al., 2002a, b, Dyer et al., 2004, Dyer et al., 2005). 
 
The problems with infertility are further compounded by the fact that South 
Africans appear to have a poor understanding of involuntary childlessness, with 
theories such as “dirty wombs”, “God’s will”, “witchcraft”, “weak sperm”, 
“abnormal menstruation”, and “punishment for pre-marital sex” being proposed 
for infertility (Dyer et al., 2002a, Juries, 2005). A lack of education, and low 
economic income diminishes women’s ability to access facilities that treat 
infertility, and diminish their ability to pay for treatments (Juries, 2005). 
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Specific causes of infertility include tubal factors, ovulatory dysfunction, 
endometriosis, diminished ovarian reserves, anovulation, luteal phase defect, 
cervical factors, uterine factors, male factors and unexplained infertility (Sharara 
and McClamrock, 2000, Motseki, 2004, Wright et al., 2007). 
 
Various methods are used to treat infertility. Drugs, such as clomiphene citrate, 
may be used to stimulate egg production and an infertile couple may try to 
conceive “naturally”, or the eggs may be harvested for assisted reproductive 
techniques (ART).  
 
ART involves retrieving eggs from a woman, combining the harvested eggs with 
sperm in a laboratory, fertilising, and transferring the fertilised eggs into a uterus. 
ART is often combined with in vitro fertilisation (IVF), where the implanted 
embryo is generally older than 2 days. Other ART procedures include gamete 
intrafallopian transfer (GIFT), which involves transferring gametes (an 
unfertilized egg and sperm) directly into the uterine tubes, or zygote intrafallopian 
transfer (ZIFT), which involves transferring the single-cell zygote into the 
fallopian tubes. Another ART method used is intracytoplasmic sperm injection 
(ICSI), where a single sperm is injected directly into the egg. ICSI is used most 
commonly to treat male infertility (Wright et al., 2007, Zegers-Hochschild et al., 
2009). 
 
 
1.2. The human female reproductive system 
 
The female reproductive system is characterised by ovulation, followed by 
menstruation if conception does not occur. The ovarian and menstrual cycles run 
for about 28 days in length in the average human (Stevens and Louw, 1992, 
Carlson, 1998, Brosens and Gellersen, 2006). 
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The Ovarian Cycle  
There are three phases of the ovarian cycle: the follicular phase, the ovulatory 
phase and the luteal phase. The follicular phase consists of the development of the 
primordial follicle to the Graafian or tertiary follicle, which is ready for ovulation. 
The ovulatory phase is characterised by the oocyte being released into the uterine 
tube. The luteal phase refers to the period between ovulation and the onset of 
either menses or implantation. The corpus luteum, the remains of the follicle, 
secretes hormones in preparation for implantation (Stevens and Louw, 1992, 
Carlson, 1998). The phases of the ovarian cycle can be seen in Fig. 1.1.  
 
The menstrual cycle 
The uterus is lined by the endometrium which contains a simple cuboidal to 
columnar epithelium and stromal tissue, and is surrounded by three thick muscle 
layers, the myometrium. The menstrual cycle can be divided into three phases; the 
menstrual phase, the proliferative phase and the secretory phase, which 
correspond to the three phases of the ovarian cycle. 
 
Menstruation occurs in the absence of a fertilised ovum, which results in the 
cessation of progesterone and oestrogen secretion by the corpus luteum. 
Menstruation is characterised by sloughing of the endometrium and consequent 
bleeding. The proliferative phase is characterised by the proliferation of the 
endometrial stroma, which becomes thicker and more vascularised, and largely 
under the influence of oestrogen. The simple tubular glands proliferate and 
become secretory at the onset of ovulation. The secretory phase under the 
influence of progesterone occurs subsequent to ovulation and the endometrial 
glands produce a glycogen-rich secretion (Stevens and Louw, 1992, Carlson, 
1998, Young and Heath, 2002).  
 
The phases of the menstrual cycle are shown in Fig. 1.1. 
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Figure 1.1. The menstrual and ovarian cycles  
A new follicle begins to develop around the onset of menses and matures until it has developed 
into the tertiary follicle. The uterus undergoes proliferation at this time. The mature oocyte is 
released from the ovaries at ovulation. During the luteal phase, the corpus luteum produces 
progesterone to maintain a possible pregnancy and the endometrium is concurrently in the 
secretory phase. If the oocyte does not implant, the menstrual and ovarian cycles will be repeated.    
http://www.sw.org/web/patientsAndVisitors/iwcontent/public/womens_inst/en_us/html/womensin
st_endoInfertility_reproSystems.html (Accessed August 2010) 
 
Effect of hormones on the reproductive cycle  
There are four main hormones directly associated with the female reproductive 
cycle: luteinising hormone (LH) and follicle stimulating hormone (FSH) which 
are produced by the pituitary, and oestrodial 17-β (E2) and progesterone (P4) 
which are produced by the ovaries (Stevens and Louw, 1992, Kierszenbaum, 
2002). 
 
The day immediately preceding menstruation usually has extremely low 
concentrations of the ovarian sex steroids. Menses is followed by the follicular 
phase. Gonadatropin-releasing hormone (GnRH) from the hypothalamus causes 
the release of LH and FSH from the anterior pituitary. Follicles are produced and 
the theca interna cells surrounding the developing oocytes produce androgens, 
which are converted to E2 by the granulosa cells. Follicle stimulating hormone is 
necessary for the conversion of androgen into oestrogens. The oestrogens cause 
the endometrium to proliferate. In the pre-ovulatory phase, an LH surge leads to 
an increase in oestrogen levels which spike immediately preceding ovulation. 
During ovulation, the dominant follicle ruptures to release the mature egg, and the 
remains of the follicle that has been ruptured becomes the corpus luteum. During 
the luteal phase, the corpus luteum produces P4, which is necessary to maintain 
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the endometrium for implantation. (The endometrium has now entered its 
secretory phase.) If the corpus luteum is not supported by human chorionic 
gonadatropin (hCG), which is produced by the fertilized embryo, it will involute. 
This involution leads to low levels of ovarian hormones, which leads to the 
menstrual cycle being repeated (Stevens and Louw, 1992, Carlson, 1998, 
Kierszenbaum, 2002). 
The expression of ovarian and pituitary hormones during the menstrual cycle are 
shown in Fig. 1.2. 
 
 
1.3. The rodent female reproductive system 
 
The rodent model has been extensively used to measure uterine tissue 
responsiveness to ovarian steroid stimulation (Baranda-Avila et al., 2009). Like 
humans, rats have a haemo-chorial placentation. The placenta invades deep into 
the maternal decidua, to allow direct contact with maternal blood.  This allows for 
an intimate association between the developing embryo, and the nutritional source 
from its mother (Loke and King, 1995). 
 
Rats and mice have an oestrous cycle, rather than a menstrual cycle, which lasts 
about 4 – 7 days. The oestrous cycle is characterised by 4 phases; proestrus, 
oestrus, metestrus (also referred to as diestrus 1) and diestrus (also referred to as 
diestrus 2) (Mandl, 1951, Marcondes et al., 2002). 
 
The ovarian follicles start to grow during proestrus, which lasts between 12-14 
hours in rats. During oestrus, the female is sexually receptive to the male and 
ovulation occurs during this phase. This phase lasts about 25-27 hours in rats. 
Metestrus lasts about 6-8 hours and diestrous lasts for about 55-57 hours (Long 
and Evans, 1922, Mandl, 1951, Goldman et al., 2007, Westwood, 2008). 
 
 During the oestrous cycle, prolactin, LH and FSH levels remain low and increase 
in the afternoon of the proestrus phase. Estradiol levels begin to increase during 
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metestrus and reach peak levels in the morning of proestrus (Baranda-Avila et al., 
2009), returning to baseline at oestrus. Progesterone secretion increases during 
metestrus and diestrous with a decrease afterwards. Progesterone peaks a second 
time toward the end of proestrus (Smith et al., 1974, Marcondes et al., 2002, 
Baranda-Avila et al., 2009). Wood et al. (2007) found that higher E2 levels in 
mice correlated with an increase in uterine width, proliferation of stromal cells 
and had a lower proliferation of glandular epithelia. In contrast, higher P4 levels 
correlated with a decrease in uterine width and less proliferation in the luminal 
epithelium. Wood et al. (2007) and Baranda-Avila et al. (2009) found that the 
epithelial cells underwent proliferation at the start of metestrus, approximately 40 
hours after E2 levels had peaked. By contrast, ovariectomised rodents had 
proliferation of epithelial cells about 24-48 hours after E2 administration.  
The expression of hormones in a rodent female is shown in Figure 1.2.  
 
 
1.4. Implantation window 
 
Pregnancy is a unique condition in which the tolerance of a genetically dissimilar 
tissue, the foetus, is established in utero (Vigano et al., 2002). A successful 
pregnancy depends on the interaction between a viable embryo in tandem with a 
receptive endometrium (Develioglu et al., 1999, Reese et al., 2001).  
 
Molecular communications between the uterus and a functional blastocyst are 
necessary for successful implantations (Reese et al., 2001, Achache and Revel, 
2006). The window of implantation is defined as the period when the uterus is 
primed to attach to the developing blastocyst under the influence of ovarian 
steroid hormones (Psychoyos, 1973, Develioglu et al., 1999, Reese et al., 2001). 
The process of implantation has been classified into three stages: apposition, 
adhesion and invasion. Apposition involves the trophoblast cells of the blastocyst 
coming into contact with the uterine luminal epithelium; adhesion is  defined as 
the period when the blastocyst anchors onto the endometrium and cannot be 
washed off from the endometrium; and invasion is when the blastocyst penetrates 
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through the endometrial luminal epithelium (Enders and Schlafke, 1967, Achache 
and Revel, 2006).  
 
In humans, the window of receptivity is estimated to occur about 7 – 10 days after 
ovulation (Wilcox et al., 1999, Wang and Dey, 2006) and embryos that implant 
beyond 10 days after conception are at a significantly greater risk of early 
pregnancy loss (Wilcox et al., 1999). The oestrous cycle in rodents is less regular 
than the human menstrual cycle and is therefore more difficult to determine when 
the window of implantation occurs (Wang and Dey, 2006), although there is 
evidence that it usually occurs on day 4 of pregnancy in mice (Abrahamsohn and 
Zorn, 1993, Song et al., 2007) and lasts for about 24 hours (Ma et al., 2003). 
However, Ma et al. (2003) found that lower E2 levels extended the window of 
receptivity, whereas high levels of E2 contracted the window of receptivity.  
 
At implantation, microvilli on the uterine luminal epithelial cells tend to become 
flattened and less dense, whereas they are usually long and regular during estrus, 
suggesting that the uterine epithelium and trophoblast cells have a flattened area 
of contact. It has been suggested that flattened microvilli are necessary for 
pregnancy (Murphy and Shaw, 1994, Murphy, 2004). Other documented changes 
include deeper lateral tight junctions between luminal epithelial cells and 
progesterone affecting the disassembly of some focal adhesion molecules 
(Murphy, 2004, Kaneko et al., 2009). 
Figure 1.2. shows the receptive period for both humans and mice. 
 
Both humans and rodents undergo decidualisation during the reproductive cycle, 
which involves remodeling of the stromal compartment. It occurs especially in 
animals where the implanting embryo invades the maternal tissue (Brosens et al., 
2002). Decidualisation is due to maternal factors in humans, whereas it is driven 
by signals from the implanting blastocyst in rats (Shaw and Murphy, 1996, Dey et 
al., 2004, Brosens and Gellersen, 2006).
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Figure 1.2. Implantation period and expression of P4, E2 and LH during the menstrual cycle 
in humans and oestrous cycle in mice  
In humans there are low concentrations of the ovarian hormones immediately preceding 
menstruation (day -14). During the proliferative phase (or follicular phase), follicles promote the 
production of oestrogens which promote the proliferation of the endometrium. Immediately before 
ovulation (day 0), there is a surge of LH which causes a spike in E2 levels and the mature egg is 
released. The corpus luteum produces P4 during the secretory phase (days 0-14).  
In the mouse, E2 spikes in the morning of proestrus and there is a surge of LH and P4 in the 
afternoon of proestrus and these hormones return to baseline during oestrus. Metestrus and diestrus 
are characterised by high P4 levels. 
The uterus may be divided into a pre-receptive, receptive and refractory (non-receptive) phase 
during implantation. The pre-receptive phase is characterised by the uterus being unable to initiate 
implantation of the blastocyst. During the refractory period, the uterine environment is hostile to 
blastocyst survival.  In humans, the receptive period is about 7-10 days after ovulation, and the 
mice are receptive about 4-5 days after proestrus.  
Reprinted by permission from Macmillan Publishers Ltd:, Wang and Dey, 2006, NATURE 
REVIEWS GENETICS, 7: 185-99 
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1.5. Clomiphene citrate 
 
Clomiphene citrate (CC) is a triphenylethylene compound, belonging to a family 
of synthetic non-steroidal oestrogens/antioestrogens and selective oestrogen 
receptor modulators (SERMS). These compounds, when compared to the natural 
oestrogens, have both agonistic and antagonistic properties and have a chemical 
similarity to oestrogen, seen in Fig. 1.3. (Jordan, 1984, Fritz et al., 1991, Pike et 
al., 1999, Jordan et al., 2001, Shelly et al., 2008). 
        
A. Oestradiol 17 β   B. Clomiphene citrate 
Figure 1.3. Chemical structure of E2 and CC 
The triphenylethylene, clomiphene citrate (B) has a similar structure to Estradiol 17 β (A) and can 
therefore bind as a ligand to the oestrogen receptor. This can result in CC causing oestrogenic 
effects in some tissues, and inhibiting the effects of oestrogen in other tissues. 
Accessed from open software files, Drugbank, www.drugbank.ca, (A) Oestradiol 17 β filed as 
DB00783, and (B) Clomiphene citrate filed as DB00882 
 
The oestrogen ligand-binding domain of the oestrogen receptors is quite large and 
therefore will bind a wide variety of oestrogen compounds and SERMS (Hubbard 
et al., 2000, Pike et al., 2000, Haskell, 2003). Depending on the conformation of 
the receptor after binding to the SERMS, the receptor-ligand complex will elicit 
an agonistic or antagonistic response (Hubbard et al., 2000, Pike et al., 2000, 
Sexton and Gherman, 2001, Haskell, 2003). 
 
The triphenylethylene derivatives bind to the cytoplasmic oestrogen receptors, 
alpha and beta, and are translocated to the nucleus in a similar manner to that of 
the oestrogen receptor bound to oestrogen (Sasson and Notides, 1982, Grese et al., 
1997). Clomiphene binds with a high affinity to oestrogen-receptor systems of 
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target cells, and to anti-oestrogen specific binding sites that have been identified 
in the cytosols of oestrogen-receptor positive tissues, for example, the mammary 
gland and uterus (Gazit et al., 1986). In the reproductive system, this includes 
sites in the hypothalamus, pituitary, ovary, endocervix, and endometrium (Fritz et 
al., 1991). Anti-oestrogens also inhibit the natural binding of estradiol-17β to the 
oestrogen receptor and thereby block oestrogen-regulated processes (Tran et al., 
1997). However, these antagonists fail to fully induce and inhibit the oestrogen–
promoted growth of the target tissues (Sasson and Notides, 1982) and may act as 
both oestrogen agonists as well as antogonists, depending on the species, tissue, 
dose level, and time of administration (Clark and Markaverich, 1982, Hosie, 
1997). Clomiphene may also interact with other hormones, such as progesterone 
(Hosie, 1997). 
 
Clomiphene citrate was introduced into clinical trials in 1960 as a cis/trans isomer 
mixture (6:4) (Greenblatt et al., 1961, Gazit et al., 1986). In 1967 it was 
introduced into clinical practice to treat infertility (Adashi, 1986). Clomiphene 
will induce ovulation in 55% to 90% of women (Aksel et al., 1986), is 
economical, safe, easy to administer and has short-lived side effects (Derman and 
Adashi, 1994, Edwards, 1996). For these reasons, it is commonly prescribed to 
treat infertility. 
 
The problem with CC use is that it results in relatively low pregnancy rates of 
2.7% per cycle (Aksel et al., 1986, Boostanfar et al., 2001). This may be due to 
CC causing a detrimental change in uterine histology and carbohydrate expression 
(Hosie and Murphy, 1992, 1995, Hosie et al., 1999, Hosie et al., 2000) as well as 
causing endometrial abnormalities in terms of development and thickness 
(Cummings et al., 1991, Rogers et al., 1991). These changes in uterine structure 
may affect the ability of CC treated women to have successful implantations, 
which may possibly be related to apoptosis. 
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1.6. Sex steroids and steroid receptors  
 
Sex steroid hormones control cell proliferation and cell differentiation in many 
organs, and the uterus is affected by sex steroid action (Critchley and Saunders, 
2009). Oestrogen (Fig. 1.3.) and progesterone (Fig. 1.4.), acting via steroid 
receptors, oestrogen receptor α (ERα) or β (ERβ) and progesterone receptor (PR) 
A or B cause the adult human female endometrium to undergo cyclic growth and 
development (Gregory et al., 2002). Oestrogen and progesterone are necessary for 
implantation to occur in normal and ovariectomised females (Logeat et al., 1980). 
 
In the follicular phase, ovarian follicles secrete E2 which induces proliferative 
changes and increases endometrial sensitivity to oestrogen and progesterone by 
increasing the levels of ERα and PR (Garcia et al., 2001, Gregory et al., 2002). 
During ovulation, the corpus luteum secretes progesterone which induces 
secretory changes and dampens the response to oestrogen and progesterone 
(Garcia et al., 2001, Gregory et al., 2002). 
 
The ER and PR have been found in the nuclei of uterine epithelial, stromal and 
myometrial cells (Coppens et al., 1993). Coppens et al. (1993) investigated the 
topographical distribution of oestrogen and progesterone receptors in the uterus 
and uterine tubes in women. They found that there were higher concentrations in 
the fundal part of the endometrium and the ampullar region of the uterine tube. 
This gradient persisted through menstruation and after menopause (Coppens et al., 
1993). The highest concentrations of ER and PR occur in the epithelial and 
stromal cells during the late proliferative phase of the menstrual cycle (Nisolle et 
al., 1994) and are significantly lower in the endometrium in the late secretory 
phase (Garcia et al., 2001).    
 
Rats were found to have double the concentration of progesterone and oestrogen 
receptors in the nuclei at implantation sites, when compared to non-implantation 
sites, suggesting that the blastocyst assisted in the delivery of the steroids to the 
endometrium (Logeat et al., 1980). 
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Embryos can remain dormant for prolonged periods in the uteri of ovariectomised 
rats maintained on progesterone alone (in a process known as diapause) and E2 
provides the nidatory impetus (Develioglu et al., 1999). 
 
1.6.1. Progesterone receptors 
 
The progesterone receptor (PR) is a ligand-activated nuclear transcription factor 
that mediates the action of progesterone in target cells (Murata and Higuchi, 2003, 
Gellersen et al., 2009) and is highly conserved among a number of species, 
including humans, chickens, rats, rabbits and mice (Pinter et al., 1996). 
 
It is expressed predominantly in breast tissue, the basal layer of the epithelium, 
stromal cells of the endometrium and smooth muscle cells of the myometrium, as 
well as brain tissue (Graham and Clarke, 1997). Immunostaining shows the 
receptor to be predominantly nuclear (Ohta et al., 1993).  
 
These receptors contain well defined functional domains: the N-terminal 
transactivation domain, which codes for the two known isoforms of the PR, PRA 
and PRB. This is known as the A/B region. A third isoform of PR that lacks the 
AB domain, PRC, has been described. However, the natural occurrence of the  
PRC isoform is debatable (Gellersen et al., 2009). The central region consists of a 
DNA-binding domain, followed by the hinge region and the C-terminal region 
which binds hormones (Pinter et al., 1996, Murata and Higuchi, 2003, Critchley 
and Saunders, 2009). Fig.1.4. shows the structure of the PR isoforms.  
 
Progesterone binds to the receptor, causing a conformational change in the 
receptor from an inactive, non-DNA binding form to a form that binds DNA. This 
is associated with the dimerisation of the receptor. The PR dimer can then bind 
DNA sequences within the promoter region of progesterone responsive genes, 
which are referred to as progesterone response elements (Aksel et al., 1986, 
Chabbert-Buffet et al., 2005). 
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A. Chemical structure of Progesterone 
        1             165              595   933 
   N-        -C PRB 
 
       N-        -C PRA 
 
     N-    -C PRC 
B. Functional domains of PR isoforms 
Figure 1.4. Chemical structure of progesterone and the functional domains of the PR 
isoforms 
A. Chemical structure of progesterone (accessed from openware Drugbank, www.drugbank.ca, 
file DB30096) 
B. Isoforms of PR modified from Gellersen et al., 2009. The functional domains of PRA, PRB 
and PRC are shown. This includes the A/B region at the N-terminal end, the DNA binding 
domain (DBD), the hinge region (H) and the ligand binding domain (LBD) which binds 
progesterone, at the C-terminal end. PRB has 933 amino acids. PRA was translated from 
residue 165 and PRC was translated from residue 595. 
 
Weak DNA-dependent dimerisation of receptors is mediated by the DNA-binding 
domain (region C), whereas strong ligand-dependent dimerisation is mediated by 
the hormone-binding domain (region E) (Aksel et al., 1986). Even in the absence 
of ligand, PRs seem to have a dynamic movement between the nucleus and the 
cytoplasm, with the receptor diffusing into the cytoplasm and being actively 
transported back into the nucleus (Pinter et al., 1996).     
 
The isoforms PRA and PRB have similar ligand and DNA binding activities, but 
have different functions depending on the cell type and context of the target gene 
promoter (Chabbert-Buffet et al., 2005), where PRB is generally a stronger 
transcription activator than PRA. Under some conditions, PRA is inactive as a 
A/B DBD H LBD
A/B DBD H
H
LBD
LBDDBD
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transcription activator, but in response to binding to progesterone agonists or 
antagonists can repress the activities of other steroid receptors, including PRB, ER 
and the androgen receptor (Chabbert-Buffet et al., 2005, Brosens and Gellersen, 
2006). Therefore, PRA may decrease the responsiveness of the tissue to 
progesterone (Graham and Clarke, 1997). PRA can repress ER-mediated 
transcription without heterodimerising with the ER, without interfering with the 
ability of the ERs to interact with DNA and without changing the biochemistry of 
the ERs. PRA may therefore regulate other steroid receptors by competing with 
them for a common binding site for transcription, or for an individual binding site 
of a common factor (Pinter et al., 1996).   
 
Gene expression of PR in the uterus seems to be primarily controlled by 
oestrogen, as expression is greatest during the oestrogen dominated proliferative 
phase (Critchley and Saunders, 2009). Oestrogen induces PR mRNA and protein 
in the uterus in vivo (Pinter et al., 1996). In humans, this regulation appears to be 
at the transcriptional level and may be indirect. Oestrogen is important in the 
synthesis of LH receptors, and so is important for preparing granulosa cells for 
gonadatropin induction of PR synthesis (Pinter et al., 1996, Graham and Clarke, 
1997). Murata and Higuchi (2003) found no significant difference in mRNA 
levels of PR during the oestrous cycle of rat uteri. However, these results did not 
distinguish between the different isoforms of PR (A, B or C), and did not indicate 
translational expression of PRs during the oestrous cycle. In contrast, 
immunohistochemical studies in the rat showed high expression of PRs in the 
epithelial cells nuclei at diestrus, and the stromal cell nuclei at metestrus. The PR 
levels seemed to decrease when oestrogen levels were low (Ohta et al., 1993).  
 
1.6.2. Effect of clomiphene citrate on sex­steroids and steroid receptors 
 
Clomiphene citrate competes with oestradiol for binding to the endometrial 
cytosol oestradiol receptor (Aksel et al., 1986, Homburg, 2008). Oestradiol is only 
available for a few hours. By comparison, CC may be found circulating six weeks 
post administration (Aksel et al., 1986). The extended half life of CC may cause 
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the reduction of ER and PR concentrations in the endometrium (Sasson and 
Notides, 1982, Aksel et al., 1986). Inadequate oestrogen or progesterone receptor 
or abnormal receptor function could result in delayed, inadequate or asynchronous 
endometrial development (Fritz et al., 1991). 
 
However, some studies seem to deny that clomiphene has an adverse effect on the 
endometrium. Hecht et al. (in Fritz et al., 1991) suggested that nuclear oestrogen 
and progesterone receptor levels and binding affinity in normal ovulatory women 
were no different after both low dose (50mg) and high dose (150mg) clomiphene 
treatment compared to spontaneous cycles (Fritz et al., 1991). In contrast to this, 
recent work by Palomino et al. (2005) found that 40% of women treated with CC 
did not have a down regulation of endometrial PR during the window of 
implantation. The down regulation of PR may be important in endometrial 
receptivity which may account for low implantation rates in CC treated 
individuals (Palomino et al., 2005). In addition, production of P4 is higher in 
clomiphene-induced cycles when compared to spontaneous cycles (Fritz et al., 
1991, Palomino et al., 2005). 
 
In the brain, CC seems to interfere with the process of oestrogen receptor 
replenishment at the hypothalamic level, which causes a misinterpretation of 
circulating oestrogen concentrations. This in turn leads to a hypogonadal state. It 
also stimulates the increase of pituitary gonadatropin release and enhanced 
follicular development by changing the availability of gonadotropin-releasing 
hormone (Fritz et al., 1991). 
 
1.7. Programmed cell death  
 
Programmed cell death (PCD) is important in development, tissue homeostasis 
and elimination of damaged cells. It has been classified into three main 
morphologies: type I, apoptosis; type II, autophagy and type III, programmed 
necrosis (Bras et al., 2005, Sun and Peng, 2009), and Galluzzi et al. (2007) also 
classified mitotic catastrophe as a form of PCD. 
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Apoptotic cell death (type I) has been well characterised both genetically and 
biochemically and acts by eliminating damaged, senescent or unwanted (in terms 
of development) cells (Sun and Peng, 2009). Apoptosis will be detailed below 
(section 1.8.). 
 
Autophagy (type II PCD) is Greek for “self eating”. It is a catabolic process that 
is characterised by dilation of the mitochondria, intracellular membrane 
remodeling and the formation of double membrane autophagosomes, which are 
organelles that enclose various cellular constituents. The autophagosomes fuse 
with lysosomes to become autolysosomes where the cellular components are 
digested (Bras et al., 2005, Sun and Peng, 2009). 
 
Programmed necrosis, or oncosis, (type III PCD) is a passive process that 
usually affects a number of cells, rather than an individual cell. It is distinguished 
from type I and type II forms of PCD by the lack of lysosomal and caspase 
involvement. There are two subtypes of Type III PCD, III A and III B. Both 
subtypes are characterised by early swelling of cellular organelles (e.g. 
mitochondria, endoplasmic reticulum, Golgi bodies,) followed by loss of plasma 
membrane integrity. In type III B, less cytoplasmic damage occurs than type III A. 
The organelles are spilled into the surrounding tissue and so this type of cell death 
is associated with an inflammatory response (Bras et al., 2005, Galluzzi et al., 
2007, Sun and Peng, 2009). 
Mitotic catastrophe is the cell death that occurs during or shortly after a failed 
mitotic event (Broker et al., 2005, Galluzzi et al., 2007). It is caused by DNA 
damage and microtubule stabilising or destabilising agents. It is characterised by 
micronucleation and multinucleation (Broker et al., 2005, Galluzzi et al., 2007).  
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1.8. Apoptosis 
 
The term “apoptosis” was first used by Kerr et al. (1972) and is used to describe 
an energy dependant, genetically controlled process that removes damaged or 
unwanted cells without an inflammatory response (Williams and Smith, 1993, 
Thatte and Dahanukar, 1997, Harada et al., 2004). It is a naturally occurring 
process of physiological cell death that is important in normal development and 
homeostasis of a number of tissues, including the uterus (Vaux and Strasser, 1996, 
Tao et al., 1997). 
 
Under specific physiological or pathological conditions, the apoptotic process 
begins. The dying cell separates from its neighbours, usually with the loss of 
specialised membrane structures such as desmosomes and microvilli. It undergoes 
a period of blebbing and contortion. The blebs are membranous extensions of the 
cytosol that are usually devoid of organelles, and that can be reversibly extruded 
and resorbed. The cytoskeleton collapses. This is followed by an irreversible 
condensation of the cytoplasm, concurrent with an increase in cell density. 
Mitochondria swell and become porous. The nuclear chromatin condenses to form 
dense granular caps underlying the nuclear membrane. Nuclear pores disappear 
from the membrane and the nuclear centre separates from its transcription factors. 
The endoplasmic reticulum dilates and forms vesicles that fuse with the plasma 
membranes, leading to the expulsion of the endoplasmic reticulum contents out of 
the cell. The cytoplasm shrinks and the cell becomes highly convoluted. It loses 
contact with neighbouring cells. The cell splices into a number of membrane-
bound bodies that contain a variety of organelles. Phosphatidylserines on the cell 
membranes translocate from the cytoplasmic to the extracellular side of the cells 
and act as a target for phagocytes. Apoptotic cells are phagocytosed by viable 
neighbouring cells or by phagocytes, where they are rapidly digested without an 
accompanying inflammatory response (Thatte and Dahanukar, 1997, Wyllie, 
1997, Inbal et al., 2002, Harada et al., 2004). 
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Apoptosis is activated by a variety of external signals which may trigger the two 
major apoptotic pathways; the extrinsic pathway (death receptor pathway) or the 
intrinsic pathway (mitochondrial pathway) (Jin and El-Deiry, 2005). The extrinsic 
pathway is activated by the binding of death inducing ligands to a specific 
receptor on the cell membrane, for example the Fas / Fas ligand or Tumour 
necrosis factor α (TNFα) / Tumour necrosis factor receptor 1 (TNFR1). The 
intrinsic pathway is activated by intrinsic signals, such as DNA damage, growth 
factor deprivation or oxidative stress. It often involves the mitochondria or the 
endoplasmic reticulum, discussed below (Van Cruchten and Van Den Broeck, 
2002, Jin and El-Deiry, 2005). 
 
Mitochondria 
During apoptosis, the mitochondria become porous and induce cell death by 
releasing pro-apoptotic proteins into the cytosol. Cytochrome c is released from 
the mitochondrion and complexes with apoptosis protease-activating factor 1 
(Apaf-1), dATP and procaspase 9 to form the apoptosome. The apoptosome then 
activates caspases -3 and -7, which then activate further procaspases, and cause 
the apoptotic response (Bras et al., 2005). 
 
Proteins such as apoptosis inducing factor (AIF) and endonuclease G are also 
released from the mitochondria, and promote non-caspase associated DNA 
degradation. AIF translocates from the mitochondria to the nucleus where it is 
involved in large scale DNA fragmentation and chromatin condensation without 
nuclease activity. Endonuclease G seems to work in conjunction with both AIF 
and the caspase activated DNases in chromatin condensation and nuclear 
degradation (Bras et al., 2005). 
 
Permeabilisation of the mitochondrial membrane is considered to be a marker of 
cell death as cells are not expected to survive after the membrane becomes porous 
(Galluzzi et al., 2007). The Bcl-2 and Bax proteins are intimately involved in 
regulating apoptosis in the mitochondria (see section 1.9.). 
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DNA  
DNA fragments during apoptosis and Ca2+- and Mg2+- dependent endonucleases 
are activated (Thatte and Dahanukar, 1997), leading to internucleososomal DNA 
cleavage, which results in DNA fragments of 180 to 200 base pairs and multiples. 
This allows for the “ladder” pattern seen on agarose gel electrophoresis and is 
considered important as a marker for apoptosis (Thatte and Dahanukar, 1997). 
DNA may also be fragmented into 50 to 300 kilobase pair lengths and single-
stranded DNA during apoptosis (Thatte and Dahanukar, 1997). The chromatin 
becomes pyknotic and packs along the nuclear membrane (Majno and Joris, 
1995). 
 
Lysosomes 
Permeabilisation of the lysosomes cause proteolytic enzymes to be released into 
the cytosol. If selective permeabilisation occurs, apoptosis-like cell death will 
occur, whereas an extensive breakdown of the lysosomes results in necrosis. The 
cysteine proteases, cathepsin B and D, which are abundant lysosomal proteins, 
seem to have the greatest effect on programmed cell death. Members of the Bcl-2 
family may be translocated to the lysosomes and induce the formation of pores 
(reviewed in Broker et al., 2005). Alternatively, lysosomal proteases may trigger 
the permeabilisation of the mitochondrial membrane through the Bcl-2 family 
protein Bid, and so cause the release of mitochondrial proteins (Broker et al., 
2005). 
 
Endoplasmic reticulum 
The endoplasmic reticulum can initiate PCD in response to unfolded proteins or 
by releasing calcium into the cytosol which activates caspase 12. Endoplasmic 
reticulum stress can also cause the permeabilisatiom of the mitochondrial 
membrane. The Bcl-2 family members and cytoplasmic calcium influx caused by 
oxidative stress seem to mediate interactions between the mitochondria and 
endoplasmic reticulum (reviewed in Broker et al., 2005). 
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Cytosolic calcium can activate the calpains (calcium activated neutral proteases) 
which can act downstream of caspase activation. Bax appears to be involved in 
the cross talk between the calpains and caspases (reviewed in Broker et al., 2005). 
 
1.8.1. Apoptosis in the human endometrium 
 
Apoptosis seems to maintain homeostasis of the uterine epithelium by eliminating 
senescent cells during the late secretory phase and the menstrual phase (Harada et 
al., 2004).The apoptotic cells in the endometria have characteristic morphological 
features when stained with haematoxylin and eosin. These include cell shrinkage, 
chromatin margination or chromatin condensation with the formation of apoptotic 
bodies (Mereseman et al., 2000, Mereseman et al., 2002). 
 
Havelka et al. (2005) found that the apoptotic index (i.e. apoptotic cells seen) 
increased on the second day after menstruation, mainly in the epithelial cells, 
while the stromal cells had far fewer apoptotic cells. This suggested that apoptosis 
was under the influence of hormones during the menstrual cycle, which was 
independent of menstrual bleeding (Havelka et al., 2005). Stromal cells 
underwent apoptosis subsequent to uterine epithelial apoptosis, with an increased 
proliferation rate and PR expression as well as decreased Bcl-2 levels (Brosens 
and Gellersen, 2006). 
 
Havelka et al. (2005) also found that the number of apoptotic cells increased as 
menstruation approached. They found that there was a relative independence of 
programmed cell death from the levels of steroid hormones as menstruation 
approached, whereas other studies had found that higher estradiol levels had a 
protective effect against apoptosis. 
Apoptosis in the glandular epithelia seems greatest in the late secretory and 
menstrual phase (Harada et al., 2004). 
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1.8.2. Apoptosis in the rodent endometrium 
 
In the rat endometrium, apoptosis is found to be greatest in uterine luminal cells 
during metestrus and lower at oestrus, which corresponds to the reduction of 
oestrogen at metestrus and oestrus. The glandular epithelial cells have the highest 
apoptotic index at oestrus, which diminishes during metestrus. Neither tissue 
showed apoptosic activity during proestrus or diestrus (Sato et al., 1997). There is 
a constant low level of apoptosis in the stromal cells during all phases of the 
oestrous cycle (Sato et al., 1997).  
 
Wood and co-workers (2007) found that circulating P4 had an inverse relationship 
to apoptosis in the stromal cells of the mouse uterus. They also found that E2 
levels were inversely related to apoptosis in the lumen, glands and stroma. 
Interestingly, this data suggests that apoptosis may be regulated in the different 
uterine compartments by both ovarian hormones. 
 
 
1.9. The Bcl­2 family 
 
Bcl-2 was first identified through its involvement in B-cell lymphomas (Brown, 
1996). This association gave it its name; the B Cell Lymphoma/leukemia-2. The 
Bcl-2 gene codes for a 25-26 kDa protein. It has four highly conserved domains, 
BH 1, 2, 3 and 4. (BH refers to the Bcl-2 homology domains). The C-terminal 21 
amino acids are hydrophobic and are required for insertion into membranes 
(Chen-Leavy and Cleary, 1990, Brown, 1996). It has been shown that the ability 
of Bcl-2 to insert into membranes is associated with its ability to regulate 
apoptosis (Hockenbery et al., 1990, Brown, 1996). 
 
Bcl-2 has been found to immunoprecipitate with a number of structurally similar 
proteins that are collectively known as the Bcl-2 family. These proteins are 
defined by having at least one of the BH domains. The Bcl-2 family of genes have 
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been widely conserved both structurally and functionally throughout evolution 
(Tao et al., 1997). One of these proteins is Bax. 
 
Bax stands for the Bcl-2 – Associated X protein. It is a 21 kDa protein. Bax has 
about 45% amino acid homology with Bcl-2. This includes the BH1, BH2 and 
BH3 binding domains, as well as the C-terminal transmembrane domain (Brown, 
1996).  A common feature of the proapoptotic Bcl-2 subfamily is that they have 
the BH1, BH2 and BH3 binding domains, but lack the BH4 domain (Viegas et al., 
2008). 
 
Bax may form homodimers, or it may form heterodimers with Bcl-2 (Oltvai et al., 
1993, Williams and Smith, 1993, Yang et al., 1995, Brown, 1996). 
The Bax protein moves from the cytosol to the mitochondria, where it forms 
selective channels in the outer mitochondrial membrane and facilitates the release 
of cytochrome c into the cytosol. The cytochrome c forms a complex with 
procaspase 9 and Apaf-1 (this complex is called an apoptosome). This leads to an 
ATP-dependent cleavage and activation of pro-caspase 9, which is the initiator 
caspase in mitochondrial apoptosis (Obrero et al., 2002).       
 
Bcl-2 is present on the mitochondrial outer membrane, the nuclear membrane, 
with localization around the nuclear pore complexes and the endoplasmic 
reticulum (Brown, 1996). Bcl-2 is orientated so that most of the protein is on the 
cytosolic face of the ER (Hockenbery et al., 1990, Brown, 1996). 
 
1.9.1. Bcl­2, Bax and apoptosis 
 
Bcl-2 is a proto-oncogene that blocks apoptosis induced by different stimuli 
(Oltvai et al., 1993, Tao et al., 1997, Mereseman et al., 2002). It can protect cells 
against some forms of apoptosis, but does not induce cell proliferation (Oltvai and 
Korsmeyer, 1994).  
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Bcl-2 inserts into the outer membranes of the mitochondria and the nuclear 
envelope, and the endoplasmic reticulum membranes. This insertion helps its 
cytoprotective action (Wyllie, 1997, Viegas et al., 2008). Mitochondrial 
transmembrane potential is known to discharge during apoptosis. Bcl-2 may 
regulate the probability of this (Wyllie, 1997, De Falco et al., 2001). 
 
Overexpression of Bcl-2 has been shown to prevent apoptosis induced by 
physiological, pathological and experimental stimuli in a number of cell types 
(Hockenbery et al., 1990, Bissonnette et al., 1992, Tao et al., 1997). However, 
Bcl-2 cannot prevent apoptosis in all instances, which indicates the existence of a 
Bcl-2 independent pathway to regulate cell death (Tao et al., 1997). A number of 
Bcl-2 related genes that share a significant amino acid homology with Bcl-2 have 
been shown to interfere with the action of Bcl-2 (Yang and Korsmeyer, 1996, Tao 
et al., 1997). 
 
Bax occurs as a monomer in viable cells. Bax acts in opposition to Bcl-2, and co-
expression of Bax with Bcl-2 allows apoptosis to proceed (Williams and Smith, 
1993, Viegas et al., 2008). Bax translocates to the mitochondria during apoptosis 
and oligomerises, which may contribute to the permeabilisation of the outer 
mitochondrial membrane (Assuncao Guimaraes and Linden, 2004, Viegas et al., 
2008). Bcl-2 forms heterodimers with the Bax protein, and the relation of the Bcl-
2/Bax determines the cell’s susceptibility to an apoptotic stimulant (Oltvai et al., 
1993, Antonsson et al., 1997, Tao et al., 1997, Mereseman et al., 2002). Bax can 
also actively induce apoptosis in transfected cells (Hsu and Hsueh, 1998). 
The Bax gene is ubiquitously expressed and represents a protective factor, whose 
expression is activated by different stimuli such as radiation (De Falco et al., 
2001). Bax is a downstream mediator of p53, following sublethal damage of 
DNA. 
 
Mutagenesis studies of the BH1 and BH2 domains in Bcl-2 showed single amino 
acid substitutions disrupted Bcl-2/Bax heterodimers, but not Bcl-2/Bcl-2 
heterodimers. The Bcl-2 mutants that did not bind Bax could not inhibit apoptosis 
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(Yin et al., 1994, Yang et al., 1995). This suggests that the family functions by 
protein-protein interactions. 
 
Pecci et al. (1997) found that when progesterone was removed from rat 
endometrial cell culture, or when antiprogestins were added, apoptosis increased. 
They found that this increase did not affect the mRNA levels of Bcl-2 or Bax, but 
affected the levels of other Bcl-2 family members.    
 
1.9.2. Bcl­2, Bax and the menstrual cycle 
 
The Bcl-2 protein may be regulated by ovarian hormones. Otsuki et al. (1994) 
found that the cyclic proliferation of Bcl-2 was similar to the expression of both 
the progesterone and the oestrogen receptors during the menstrual cycle in human 
females. All three biochemicals had higher concentrations during the proliferative 
or early secretory phase, but the concentrations dropped during the late secretory 
phase. Circulating oestrogens increase the expression of Bcl-2, and progestins 
decrease Bcl-2 expression (Harada et al., 2004). The expression of Bcl-2 was 
greatest in the glandular and stromal tissue during the proliferative phase and 
peaked during the late proliferative phase, but decreased during the late secretory 
and menstrual phases (Medh and Thompson, 2000, Harada et al., 2004).  
 
Havelka et al. (2005) found that uterine myomas had an inverse relationship to 
non malignant uteri; Bcl-2 expression increased in the secretory phase (P4 
regulated) and decreased after progesterone therapy had ceased (Havelka et al., 
2005). Concurrent with the decrease of Bcl-2 was the increase of apoptotic bodies. 
Bax increases in the stroma at the end of the menstrual cycle and the Bcl-2/Bax 
ratio mRNA level decreases (Otsuki et al., 1994, Castro et al., 2002). Tao et al. 
(1997) found Bcl-2 to be confined topographically to the basilis layer during the 
proliferative phase, and the Bax was localized to the epithelial cells of the 
functionalis layer during the secretory phase.  
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Bcl-2 deficient mice were found to have extensive apoptosis in the uterine glands 
and myometrium and therefore Bcl-2 may be important for the survival of 
endometrial and myometrial cells (Daikoku et al., 1998, Harada et al., 2004). 
 
 
1.10. Summary 
 
Infertility has important social, cultural, spiritual and financial implications for 
women. Clomiphene citrate has been used to treat infertility since the 1960s. It is 
a selective oestrogen receptor modulator, and as such causes both oestrogen-
agonist as well as antagonist responses in cells and tissues. In the reproductive 
tissues, clomiphene binds to the oestrogen receptors in the hypothalamus, thus 
blocking their oestrogenic effects. This causes increased levels of the follicle 
stimulating hormone, which causes an increase in the ova released by the ovaries. 
Despite the ovarian hyperstimulation, women treated with CC have relatively low 
pregnancy rates (2.7% per cycle). 
 
The human reproductive cycle is characterised by events in the ovaries (ovarian 
cycle) and uterus (menstrual cycle). The ovarian cycle is characterised by the 
follicular phase, which involves the development of the primordial follicle to the 
tertiary follicle and the production of oestrogen; the ovulatory phase in which the 
oocyte is released into the uterine tube; and the luteal phase, which is the period 
between ovulation and either menses or implantation. During the luteal phase, 
progesterone is produced by the corpus luteum. The menstrual cycle runs 
concurrently with the ovarian cycle. The proliferative phase (follicular) involves 
the endometrium becoming thicker and vascularised and is under oestrogen 
control. The secretory phase (luteal) is under progesterone control and produces a 
glycogen rich secretion.  In the absence of an ovum being fertilised, menstruation 
will occur, which is characterised by sloughing of the endometrium and low levels 
of oestrogen and progesterone.  
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Rodents have an oestrous cycle. Proestus is the period when the follicles develop 
and has a peak in the progesterone and oestrogen hormone levels. These levels 
drop during oestrus, when ovulation occurs. During metestrus and diestrus, 
oestrogen peaks a second time, at a lower level, and progesterone levels increase 
and spike again during proestrus. 
 
Both humans and rats have a “window of implantation”, which is the period 
where the endometrium must be receptive to a viable blastocyst in order for 
implantation to occur. This period is characterised by apposition of the blastocyst 
against the endometrium; adhesion, where the blastocyst cannot be washed off the 
endometrium; and invasion, where the blastocyst invades into the maternal tissue. 
Both humans and rats undergo decidualisation in response to implantation and 
both species have haemochorial placentation. Rats have therefore been 
extensively used as models for infertility studies. 
 
Changes in the concentrations of the progesterone receptor, Bcl-2 or Bax may 
contribute to the low pregnancy rates of CC treated individuals. 
 
Progesterone is important in the maintenance of the endometrium for implantation 
and subsequently for pregnancy. Its effects are induced by binding to the 
progesterone receptor. The progesterone receptor levels are increased by 
oestrogen. Therefore, the SERM, CC, may decrease the levels of PR in the 
endometrium and thus cause the inadequate development of the endometrium. 
Alternatively, CC may inhibit the down regulation of PR during the window of 
implantation. This lack of down regulation may result in the endometrium being 
less receptive to the implanting blastocyst. 
 
Apoptosis is important in tissue homeostasis and has a profound effect on the 
remodeling of the endometrium during the menstrual cycle, implantation and 
pregnancy. The intrinsic (mitochondrial) apoptotic pathway has been well 
characterised in terms of the events and molecules involved. Two important 
biochemicals that regulate the intrinsic apoptotic pathway are Bcl-2 and Bax. The 
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interactions between the pro-survival protein Bcl-2 and pro-apoptotic protein Bax 
regulate cell survival or death. In the endometrium, Bcl-2 predominates during the 
proliferative phase and decreases during the secretory phase and during 
menstruation. Oestrogens increase the levels of Bcl-2 while progestins decrease 
Bcl-2 concentrations. Bax levels increase during the secretory and menstrual 
phases and may be affected by progesterone levels. 
 
 
1.11. Aim and objectives 
 
The aim of this study was to investigate the expression of the progesterone 
receptor, Bcl-2 and Bax in clomiphene citrate treated rat uteri. Changes in the 
expression of these proteins may suggest an apoptotic cause for the low 
implantation rates in clomiphene citrate treated individuals. 
 
Specific aims: 
• To compare the effects of a single CC dose, a single P4 dose, a treatment 
regime that reflects the hormonal actions during pregnancy or CC in 
conjunction with the treatment regime on the general morphology and 
morphometry of ovariectomised rat uteri.  
• To compare the changes in localisation of PR, Bcl-2 and Bax using 
immunohistochemistry caused by a single CC dose, a single P4 dose, a 
hormonal treatment regime or CC in conjunction with the treatment 
regime on ovariectomised rat uteri.  
• To compare the changes in protein expression of PR, Bcl-2 and Bax using 
enzyme linked immunosorbent assays caused by a single CC dose, a single 
P4 dose, a hormonal treatment regime or CC in conjunction with the 
treatment regime on ovariectomised rat uteri.  
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1. Animal model 
 
A total of 48 sexually mature female in-bred Hooded Wistar Rats (12 to 14 weeks 
old) were obtained from the Central Animal Unit at the University of the 
Witwatersrand. The animals weighed, on average, 219.1 g (±10.4 g) prior to 
ovariectomy. Two to three animals were housed per cage, at a constant 
temperature of 23 °C, and fed ad libitum on mouse cubes (Epol, Rainbow Farms 
Pty Ltd, South Africa) and water. Animal ethics clearance was obtained from the 
Animal Ethics committee of the University of the Witwatersrand (AEC No: 
2002/80/04). 
  
2.1.1. Ovariectomy 
 
The rats were bilaterally ovariectomised under Xylazine: Ketamine (1:4) 
anaesthesia (0.1 ml per 100 g) (Bayer Pty Ltd, Isando, South Africa). Surgery was 
performed by the resident veterinary surgeon at the Animal Unit at the University 
of the Witwatersrand. The animals were left to recover for four to six weeks 
following surgery, to ensure that no residual ovarian hormones remained in the 
system before experimentation. Ljungkvist (1971a) found no residual effects of 
the ovarian hormones after 10 days. 
 
The animals were randomly divided into eight groups of 6 animals per group. The 
animals weighed, on average, 289.2 g (±33.1 g) before treatment and 289.3 g 
(±32.8 g) at the end of the treatments. The groups of 6 rats were treated as 
follows: 
Group A was a negative control and therefore the animals received no treatment. 
Group B, 0.1 ml 0.9% saline was administered to each animal as a carrier control. 
Group C, 0.1 ml of peanut oil was administered as a carrier control. 
Group D, a single 0.1 ml dose of 1.25 mg Clomiphene (CC) dissolved in saline 
was administered. 
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Group E, a single 0.1 ml dose of 5 mg progesterone (P4) dissolved in peanut oil 
was administered (Table 2.1.). 
Group F, the animals were treated with saline on the first day followed by oil on 
the second, third and fourth day. This acted as a carrier control. 
Group G, the animals were hormonally primed by administering saline on the first 
day, 5 mg P4 on the second day, 5 mg P4 on the third day, 5 mg P4 and 0.5 μg 
oestrogen (E2) on the fourth day (PPPE). 
Group H administered 1.25 mg clomiphene on the first day to PPPE treated 
animals (Table 2.2.).      
 
 
2.2. Drug preparation and administration 
 
2.2.1. Clomiphene citrate treatment 
 
The treatment regime used was based on that of Hosie et al. (1992, 1995). The 
ovariectomised rats were injected with a single 1.25 mg dose of Clomiphene 
Citrate (CC) (40% cis- / 60% trans-isomers). This gave a concentration of 
approximately 4 mg/kg, which is considered a physiological dose level (Young et 
al., 1991). Newberne et al. (1966) found that the LD50 for clomiphene in rats is 
530 mg/kg. 
 
Clomiphene was prepared by dissolving 5 mg CC (2-[4-(2-Chloro-1,2-diphenyl-
ethenyl)phenoxy]-N,N-diethylethanamine) (Sigma-Aldrich Inc., St Louis, Mo., 
USA) in 100 μl absolute ethanol and 300 μl of 0.9% medical grade saline 
(Saarchem, Gauteng, South Africa), to give a final volume of 0.4 ml and a final 
concentration of 1.25 mg/ 0.1 ml. CC was administered by a 0.1 ml intraperitoneal 
injection using a 1 ml syringe (Surgi Plus Sterile Syringes, China) and 25 gauge 
needle (New Promex Corporation, Bergvlei, South Africa). (Group D). 
Placebo treatment consisted of treating animals intraperitoneally with carrier alone 
(Group B). 
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2.2.2. Steroid hormone treatment 
 
2.2.2.1. Progesterone treatment 
 
The treatment regime used was based on that of Hosie et al. (1992, 1995). 
Progesterone (P4) (17α-hydroxy-6α-methylpregn-4-ene-3,20-diole) was 
administered as a 5 mg dose. Ljungkvist (1971a), Psychoyos (1973), and Huet and 
Dey (1987) have shown this dose to elicit a normal physiological response in the 
rat uterus.   
 
The progesterone was prepared by dissolving 120 mg P4 (Sigma-Aldrich) in 
0.9 ml benzyl alcohol (BDH, Poole, England). Once the P4 had been dissolved, 
3.9 ml peanut oil was added. Each animal was injected subcutaneously in the 
scruff of the neck with 0.2 ml of this solution to give a concentration of 5 mg/ml 
using a 1 ml syringe (Group E). 
Placebo animals were treated subcutaneously in the scruff of the neck with carrier 
alone (Group C). 
 
2.2.2.2. Oestrogen treatment 
 
The treatment regime used was based on that of Brown-Grant et al. (1972), 
Murphy and Rogers (1981) and Hosie et al. (1992, 1995). 17-β Estradiol (E2) 
(1,3,5[10]-Estratriene-3,17β-diol) was administered as a 0.5 μg dose. This dose 
has been shown to induce implantation in the pseudo-pregnant rat (Ljungkvist, 
1971b, Psychoyos, 1973).    
 
Oestrogen was prepared by dissolving 0.2 mg E2 (Sigma-Aldrich) in 8 ml benzyl 
alcohol and then diluted in 32 ml peanut oil to give a concentration of 5 μg/ml.  
Placebo animals were treated subcutaneously in the scruff of the neck with carrier 
alone. 
 
 31
2.2.2.3. PPPE hormonal priming  
 
Psychoyos (1966, 1967, 1973) developed a treatment regime in ovariectomised 
rats that replicated the expression of hormones in pregnant rats by a 3 day 
sequence of daily hormonal injections. This involved treating the animals for 3 
days with 5 mg P4 and treated on the third day with 0.5 μg E2 (PPPE treatment) 
(Group G). 
 
One group of animals received CC prior to the PPPE regime (group H), another 
group of animals received a saline treatment prior to the PPPE regime (Group G), 
and one group received carrier relevant to both CC and the hormones (Group F) 
(SOOO) (see Table 2.2). 
 
 
2.3. Treatment regimes 
 
Table 2.1.:   Single Treatments  
Animals were ovariectomised and given a single subcutaneous (SC) injection of 
5 mg P4, in carrier oil (O); or an intraperitoneal (IP) injection of 1.25 mg CC in 
saline (S) carrier. Control animals were given carrier alone or were untreated.   
The animals were killed (Kill) 24 hours after the last treatment. Groups A, B and 
C form part of the negative controls. 
Group No. of 
Animals 
Day 1 Day 2 Carrier Administration
A 6 - Kill - - 
B 6 Saline Kill Saline IP 
C 6 Oil Kill Oil SC 
D 6 1.25 mg CC Kill Saline IP 
E 6 5 mg P4 Kill Oil SC 
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Table 2.2:   Hormonally primed animals 
The animals were ovariectomised, allowed to recover, then treated with a 3 day 
regime of hormones. The rats were given a series of SC injections of 5 mg P4 in 
carrier oil over 3 days and a single injection of 0.5 μg E2 on the third day and 
killed on day 4 (day of implantation receptivity). Clomiphene experimental 
animals: PPPE animals were given a single IP injection of 1.25 mg CC on day 
one. Control animals were given placebos. Animals were killed 24 hours after the 
final treatment. 
Group No Day 1 Day 2 Day 3 Day 4 Day 5.5 Carrier Admin. 
F 6 S O O O Kill O / S SC / IP 
G 6 - 5 mg P4 5 mg P4 5 mg P4 / 
0.5 μg E2 
Kill O / S SC / IP 
H 6 1.25 mg 
CC 
5 mg P4 5 mg P4 5 mg P4 / 
0.5 μg E2 
Kill O / S SC / IP 
 
 
2.4. Sacrifice of animals 
 
The animals were weighed and injected intraperitoneally with a 500 μl lethal dose 
of sodium pentabarbotone (Eutha-naze, Centaur Labs, Isando, South Africa). A 
central ventral incision was made to expose the uteri. Uteri were dissected from 
the attached fat and mesentery, cut above the cervix and removed. The tissue was 
cut into approximately 6 mm pieces. The combined pieces of tissue were all 
rinsed in phosphate buffered saline in a single container. Arbitrary pieces were 
removed for the following techniques: 
1. Light microscopy: the tissue was cut into 2-3 mm pieces for histological 
sections analysed using H&E for morphometry;  
2. Immunohistochemistry, and 
3. Protein extraction: the proteins were analysed by ELISA. 
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2.5. Tissue preparation for light microscopy 
 
2.5.1. Fixation 
 
Arbitrary pieces (3 to 6 mm) of rat uteri were rinsed in phosphate buffered saline 
(PBS), pH 7.4 (appendix) and fixed in fresh 4% paraformaldehyde (Merck, 
Darmstadt, Germany) made up in PBS for 3 hours. The sections were rinsed 3 
times in PBS x 2 minutes each and processed for wax embedding in an automatic 
tissue processor (Shandon Citadel 1000, Thermo Fisher Scientific, MA, USA). 
 
2.5.2. Processing schedule 
 
The tissue was dehydrated in 70% alcohol for half an hour to overnight, 95% 
alcohol for 2 hours followed by 2 changes of 95% alcohol for 1½ hours each, 3 
changes of absolute alcohol; the first for 1 hour, the second for 2 hours and the 
final for 1 hour. The sections were cleared in two changes of chloroform, the first 
for 1 hour and the second for 2 hours, and finally the sections were left in 2 
changes of paraffin wax for 2 hours each. 
 
The tissue was embedded in fresh paraffin wax and orientated so cross sections of 
uteri could be cut. Sections (4-5 μm) were cut on a sledge microtome (Leica 1400, 
Germany) onto APES (3-aminopropyltriehoxysilane) treated slides (see Appendix 
B.1.). The sections were used either for Haemotoxylin and Eosin staining, or for 
immunohistochemistry. 
 
 
2.6. Haematoxylin and eosin staining 
 
The method was adapted from Mayer (1903) in Wilson and Gamble (2002). The 
sections were dewaxed in 2 changes of xylene for 5 minutes each and rehydrated 
through decreasing concentrations of alcohol (absolute alcohol 2 x 2 minutes, 
95% alcohol for 2 minutes; and washed in water for 1 minute. 
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The sections were immersed in haematoxylin for 5 minutes, blued in running tap 
water, dipped once or twice in acid alcohol to differentiate the nuclei, left in 
running tap water, stained in 0.2% eosin for 1 minute and rinsed in running tap 
water. 
 
The sections were then dehydrated through increasing concentrations of alcohol 
(95% alcohol for 2 minutes, 100% alcohol, 2 x 2 minutes), cleared in two changes 
of xylene (for 5 minutes each) and mounted in Entellan (Merck). 
 
 
2.7. Morphometry 
 
Morphometry was carried out on light microscopy sections stained with 
Haematoxylin and Eosin. 
 
Two blocks were selected for each animal. Measurements were made on a 
binocular microscope (Kyowa, Tokyo). Measurements were made using a 5 x, 10 
x or 40 x planar objective, with eyepiece micrometers. The eyepiece micrometers 
were always inserted into the left hand eyepiece tube. The diopter was maintained 
at a constant setting and the distance between the eyepieces was kept constant. 
These parameters were kept constant to minimise small magnification differences.  
When the 5 x and 10 x planar objectives were used, a 10 x eyepiece micrometer 
(Meopta) was used. The eyepiece micrometer was calibrated against a stage 
micrometer (Graticules Ltd, England) that was divided into 100 x 10 μm 
divisions. It was found that the eyepiece micrometer (Meopta) measured 385 μm 
per arbitrary unit using the 5 x planar objective. The eyepiece micrometer 
measured 147 μm per arbitrary unit using the 10 x planar objective 
A 10 x  Kellner (Kellner, patent 8395/75) eyepiece system was used when 
measurements were taken using the 40 x planar objective. The arbitrary units from 
the Kellner system measured 0.2167 μm when calibrated with the stage 
micrometer (Graticules Ltd., England). 
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2.7.1. Parameters measured 
 
Fig. 2.7.1. shows the areas where measurements were taken. The measurements 
have been presented in μm.  
 
The long (1) diameter and short (2) diameter of the entire uterus extending from 
the external myometrial layers were measured using the 10 x eyepiece micrometer 
from Meopta and the 10 x planar objective by default, or the 5 x objective if the 
sections were extremely large. The long (3) and short (4) internal diameters of the 
lumen were measured under the 10 x objective. Measurements were taken along 
the central axis as far as possible. 
 
The stromal tissue extending from the basement membrane of the luminal 
epithelium to the inner myometrial layer was measured using the 10 x objective 
and 10 x micrometer eyepiece. Two measurements were taken when the axis was 
perpendicular to the mesometrial/anti-mesometrial pole (5), and one measurement 
each was taken for the stromal tissue at the mesometrial side (6) and anti-
mesometrial side (7).  
 
The luminal epithelial height (8) was measured with the Kellner micrometer 
eyepiece using the 40 x objective. 
 
The total number of glands per section were counted (9); groups of glands 
together (10) indicating possible coiling of glands and glands that occurred singly 
were counted (11). These measurements were done using the 10 x planar 
objective. Glands that opened up into the luminal epithelium (12) were counted 
using the 40 x planar objective. 
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.  
 
Figure 2.7.1. Parameters measured for morphometric analysis 
The long (1) and short (2) diameters of the entire uterus as well as the internal lumen length (3) 
and lumen width (4) are indicated on the micrograph. The stroma was measured between the 
lumen and myometrium. Two measurements were taken perpendicular to the mesometrial/anti-
mesometrial axis (5), one measurement taken at the mesometrial pole (6) and one measurement 
was taken at the anti-mesometrial pole (7).  
All of the glands in the section were counted. The glands that existed in a group (10) as well as the 
glands that occurred alone (11) were counted. 
The luminal epithelial height (8) was measured, and the glands that opened into the lumen were 
counted (12) using a 40 x objective.  
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2.7.2. Statistical analysis 
 
The statistical analysis was performed using the JMP 5.0.1. statistical program 
(version 3.1.6.2., SAS Institute, Cary, NC). The data were analysed using non-
parametric statistical methods as the sample size of each group was less than 
thirty individuals. The descriptive statistics were presented as medians with the 
upper (75%) and lower (25%) quartiles.  
 
The data were first tested using the Wilcoxon / Kruskal-Wallis test (rank sums), 
followed by a 1-way Chi-squared approximation. If the value was significant, a 
Tukey-Kramer test was used to show the differences between groups. Significant 
results were presented with the means and standard error of the mean in addition 
to the medians and interquartiles.  
The data have been presented in the text in a table or graphs in the Results. 
 
 
2.8. Immunohistochemistry against the progesterone 
receptor (PR), Bcl­2 and Bax 
 
Immunohistochemistry (IHC) was used to determine the immunolocalisation of 
the progesterone receptor, Bcl-2 and Bax in the rat endometrium. (Appendix C.1. 
shows the optimisation steps carried out.)  
 
Two sections per animal were used. The uterine sections (4 μm) on 
3-aminopropyltriehoxysilane coated (APES) slides were dewaxed and rehydrated 
and washed in distilled water for 1 minute, with stirring. The excess liquid was 
aspirated. 
 
Antigen retrieval, adapted from Shi et al. (1995), was performed by placing the 
sections in a plastic container with Tris-EDTA buffer pH 9.0 (10 mM Tris Base,  
1 mM EDTA, 0.05% Tween-20), (see appendix A.3.) and microwaved twice at 
720 Watts for 6 minutes each and left to cool for at least 20 minutes.  
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After the slides had cooled, the area around the sections was wiped dry and the 
sections were delineated with a Dako pen (Dako, Glostrup, Denmark). The 
sections were washed 3 times in 0.01 M PBS, pH 7.2 (see appendix A.1.) with 
stirring for 2 minutes each. Endogenous peroxidase activity was quenched by 
incubating the sections in 1% H2O2 (Merck) in 0.01 M PBS for 10 minutes, 
washed with PBS (2 x 5 minutes) with stirring and aspirated. The sections were 
then incubated for 20 minutes in 1% goat serum made up in PBS. 
 
The serum block was aspirated off the sections, but the sections were not washed. 
The antibodies, 1/50 anti-PR (A-0098, Dako), 1/50 anti-Bcl-2 (A-3533, Dako) and 
1/50 anti-Bax (A-3533, Dako) were made up in antisera diluent (0.25% (w/v) 
sodium azide; 0.005% (w/v) BSA; 0.005% (w/v) thyroglobulin; 0.04% (w/v) EDTA; 
1% (w/v) swine serum made up in Tris-Saline, (appendix A.1.) and left overnight 
at 4 ºC. 
 
The following day, the sections were rinsed with PBS and then washed twice with 
PBS for 2 minutes each, with stirring. Excess liquid was aspirated and the sections 
were incubated for an hour at room temperature in 1/250 goat-anti-rabbit 
IgG/HRP (for PR), 1/200 goat-anti-mouse IgG/HRP (Dako, P-0447) (for Bcl-2) 
and 1/200 goat-anti-rabbit IgG/HRP (horse radish peroxidase) (Dako, P-0448) (for 
Bax) made up in PBS.  The sections were rinsed with PBS and then washed with 
PBS (2 x 2 minutes with stirring). 
 
The sections were incubated for 5 minutes in diaminobenzidine (DAB) (Roche 
Diagnostics Ltd., Mannheim, Germany) and rinsed in distilled water for 2 minutes 
with stirring, then dehydrated and cleared in 95% alcohol for 2 minutes, absolute 
alcohol 2 x 2 minutes, xylene 2 x 5 minutes and then mounted in Entellan 
(Merck). 
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Control sections used for IHC: 
A pregnant rat uterus or colon tissue was used as a positive control.   
The primary antibody was omitted, and diluent was used, on an adjacent section 
for every treated section as a negative control. The other negative controls used an 
adjacent section from the pregnant uterus or colon, incubated the primary 
antibody but did not incubate with the secondary antibody; or the adjacent section 
from the pregnant uterus or colon was incubated without either primary antibody 
or secondary antibodies. 
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Figure 2.8.1. Flow chart showing the steps for IHC against PR, Bcl-2 and Bax 
 
Dewax and rehydrate 
Aspirate excess liquid 
 
*Antigen unmasking 
Tris-EDTA buffer, pH 9.0 
Microwave 2 x 6 mins 
 
Cool for 20 mins 
Aspirate excess liquid 
Mark with Dako pen 
 
PBS wash, 3 x 2 mins 
 
Quench endogenous peroxidase activity 
1% H202 in PBS, 10 mins 
 
PBS wash, 2 x 5mins 
 
Serum block 
1% goat serum in PBS, 20 mins 
Aspirate excess liquid 
 
*Primary antibody made up in diluent 
4 °C, overnight 
 
1/50 anti-PR 1/50 anti-Bcl-2   1/50 anti-Bax  
(Use diluent for -1° antibody control) 
 
Rinse with PBS 
Wash PBS, 2 x 2 mins 
 
*Secondary antibody made up in PBS 
*Room temperature, 1 hour 
 
1/250 goat-anti-rabbit 1/200 goat-anti-mouse 1/200 goat-anti-rabbit 
 for PR   for Bcl-2   for Bax 
(Use PBS for -2° antibody control) 
 
Rinse with PBS 
Wash PBS, 2 x 2 mins 
 
DAB, 5 mins 
 
Rinse with dH20 
Wash with dH20, 1 x 2 mins 
 
Dehydrate, clear and mount 
 
*The steps that were optimised were antigen retrieval, primary antibody, secondary antibody 
and DAB, which have been included in appendix C.1. 
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2.9. Protein extraction 
 
Arbitrary pieces of tissue from the uterine horns were selected for protein 
extraction. The tissue was washed in cold PBS, pH 7.4, weighed, and cut up with 
sterile scissors. The tissue was placed in a clean Dounce homogeniser with 10 
volumes of homogenising buffer (10% (v/v) glycerol, 5 mM magnesium acetate, 
0.2 mM EDTA, 1% Triton-X-100, 50 mM Tris-HCl, pH 7.5, 0.5 M dithiothreitol, 
0.5% Protease Inhibitor cocktail (Sigma-Aldrich). 
 
The tissue was homogenised and then put into a microcentrifuge tube and 
centrifuged (HM2E Microfuge, Hagar Designs, Widerness, South Africa) at 
15 000 g for 30 minutes at 4 ºC. The supernatant was removed, aliquoted and 
stored at -70 ºC. 
 
The concentration of the protein homogenates was calculated using the Lowry-
Folin method, and the relative expressions of the progesterone receptor, Bcl-2 and 
Bax was determined using the enzyme linked immunosorbent assay (ELISA). 
 
 
2.10. Lowry­Folin method for protein determination 
 
This assay was used according to manufacturer’s instructions (Sigma-Aldrich) 
and based on the method of Lowry and co workers (1951). Bovine serum albumin 
(BSA) (Sigma-Aldrich) was used to make concentration standards (0, 31.25, 62.5, 
125, 250, 500, 1 000 and 2 000 μg/ml BSA in PBS, pH 7.4). The protein samples 
were diluted 10 x or 20 x in PBS, pH 7.4.  
 
Each sample of protein homogenate or BSA standard (50 μl) was added to an 
ELISA plate (96 well Nunc maxisorb plates, Nunc A/S, Roskilde, Denmark). 
Subsequently, 200 μl of 2% sodium carbonate in 0.1 M sodium hydroxide, 0.01% 
copper sulphate and 0.02% sodium potassium tartrate was added to the sample 
and incubated for 10 minutes with shaking. The samples were then incubated in 
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50 μl Folin-Ciocalteu’s phenol Reagent (Sigma-Aldrich) diluted 1:4 in dH2O and 
left on a shaker for 30 minutes. Absorbance was read on a plate reader (Multiskan 
Ascent, Helsinki, Finland) at 690nm. 
 
 
2.11. Enzyme linked immunosorbent Assay (ELISA) 
 
The ELISA method was used to determine the relative expression of PR, Bcl-2 
and Bax. Section 10.1 shows the technique used, and appendix C.2. shows the 
optimisation steps used. 
 
2.11.1. ELISA against PR, Bcl­2, Bax 
 
Protein from the rat uterus was incubated in a 96 well Nunc maxisorb plates 
(Nunc A/S). The plates were coated with 100 μl of 10 μg/ml protein sample and 
incubated overnight at 4 ºC in a humidified chamber. 
 
The following day, the plates were aspirated and washed 3 times with 0.9% saline, 
then blocked with 200 μl 0.1% BSA in PBS (appendix A.1.) and left on a shaker 
for an hour. The block was aspirated off and the wells washed 3 times in 0.9% 
saline. 100 μl primary antibody (1/100 anti-PR, sc-538; 1/500 anti-Bcl-2; 1/100 
anti-Bax, sc-7480) (antibodies from Santa Cruz Biotechnology, Inc, Santa Cruz, 
Ca, USA) made up in block (0.1% BSA in PBS) was added to the wells and left to 
incubate overnight at 4 ºC in a humidified chamber. 
 
On the third day, the primary antibodies were aspirated and the plates were 
washed x 4 with 0.9% saline. 100 μl secondary antisera made up in block (1/1000 
donkey-anti-rabbit for Bax and PR, sc-2313, Santa Cruz; 1/1000 goat-anti-mouse 
for Bcl-2, sc-2005, Santa Cruz) was incubated for 1½ hours at room temperature 
on a shaker. The secondary antibodies were aspirated and the plate was washed 5 
times with 0.9% saline. 70 μl soluble BM Blue POD substrate was added (Roche) 
and left to incubate in the dark. The reaction was stopped by adding 50 μl 0.5 M 
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sulphuric acid (see appendix A.5.) and optical density was read at 450nm 
(Multiskan Ascent, Labsystems, Helsinki, Finland).  
 
2.11.2. Statistical analysis 
 
The statistical analysis was performed using the JMP 5.0.1. statistical program 
(version 3.1.6.2., SAS Institute, Cary, NC). The data were analysed using non-
parametric statistical methods as the sample size of each group was less than 
thirty individuals. The descriptive statistics were presented as medians with the 
upper (75%) and lower (25%) quartiles.  
The data were first tested using the Wilcoxon / Kruskal-Wallis test (rank sums), 
followed by a 1-way Chi-squared approximation. The data have been presented in 
Table 3.4.1.1. in the Results section. 
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Figure 2.11. Flow chart for ELISA method used against PR, Bcl-2 and Bax 
 
100 μl of 10 μg/ml uterus protein sample 
incubated in a well of a 96 well Nunc maxisorb plate 
overnight at 4 ºC in a humidified chamber 
 
Aspirate plate 
 
Wash 0.9% saline, 3x 
 
Block 
200 μl 0.1% BSA in PBS  
on a shaker, 1 hour 
 
Aspirate 
 
Wash 0.9% saline, 3x 
 
100 μl primary antibody made up in block (0.1% BSA in PBS) 
incubate overnight, 4°C, humidified chamber 
 
1/100 anti-PR   1/500 anti-Bcl-2, 1/100 anti-Bax   
 
Aspirate 
 
Wash 0.9% saline, 4x 
 
100 μl secondary antibody made up in block (0.1% BSA in PBS) 
Incubate for 1½ hours at room temperature on a shaker 
 
1/1000 donkey-anti-rabbit 1/1000 goat-anti-mouse 
   for Bax and PR   for Bcl-2 
 
Aspirate 
 
Washed with 0.9% saline, 5x 
 
Add 70 μl soluble BM Blue POD substrate 
Leave to incubate in the dark 
 
Stop reaction with 50 μl 0.5 M sulphuric acid 
 
Read A450 
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CHAPTER 3. RESULTS 
 
3.1.   Morphometric analysis of haematoxylin and eosin 
treated slides 
 
3.1.1. Overview of the uterus measurements 
 
Two random sections were analysed per animal. The uterine parameters measured 
included the long (1) and short (2) uterus diameters, the long (3) and short (4) 
luminal diameters, stroma perpendicular to the mesometrial plane (5), stroma at 
the mesometrial pole (6) and at the anti-mesometrial pole (7), the height of the 
luminal epithelium (8), total glands per section (9), groups of glands(10), single 
glands(11) and glands opening into the luminal epithelium (12). Wilcoxon / 
Kruskal Wallis rank sums tests were used to determine significance between the 
treatment groups, and the results have been presented in Table 3.1.1.1. 
The level of significance was set at 5% level of significance. Significant 
differences were found between the samples for the uterine diameter 
measurements (1 and 2), the long luminal diameter (3), the perpendicular stroma 
(5) and the luminal epithelium height (8). These parameters were further tested 
using Tukey-Kramer post hoc analysis. 
 
The results are presented in tables 3.1.1.1 to 3.1.2.6 and graphs 3.1.2.1 to 3.1.2.6. 
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Table 3.1.1.1. Results of the χ2 approximation of the uterine measurements 
using the Wilcoxon / Kruskal Wallis rank sums tests 
Two arbitrary sections were taken per animal, and the various uterine parameters 
were measured using an eye piece micrometer and light microscope, then tested 
using the Wilcoxon / Kruskal Wallis ranks sums at the 5% level of significance. 
For probability less than 0.05, the chi-squared approximation was used. Results 
that were significantly different have been indicated in bold type.  
 
 Parameter χ2 Approximation 
P> χ2 
1 Long diameter uterus <0.001 
2 Short diameter uterus <0.001 
3 Long diameter lumen <0.001 
4 Short diameter lumen 0.117 * 
5 Stroma perpendicular to mesometrial plane <0.001 
6 Stroma at mesometrial pole 0.0111 
7 Stroma at anti-mesometrial pole 0.1789 
8 Luminal epithelial height <0.001 
9 Total number of glands per section 0.0104 
10 Groups of glands 0.3044 
11 Single glands 0.119 
12 Glands opening into luminal epithelium 0.4575 
 
* The lumens of the CCPPPE treated animals were very convoluted. It was 
therefore not valid to measure the internal luminal diameter, as this could vary 
greatly depending on where the measurement was taken.  
 47
3.1.2. Results of the Tukey­Kramer post hoc analysis for the parameters 
that were significantly different  
 
3.1.2.1. Tukey­Kramer post hoc analysis of uterine length 
 
Uterine length refers to the long diameter of the cross section of the uterus, as 
seen in Fig 2.7.1. (1). The uterine lengths of the CCPPPE treated animals were not 
significantly different to SPPPE treated animals, but both were significantly 
different to SOOO treated animals. Therefore, the PPPE treatments appeared to 
increase uterine length, but CC with PPPE had no significant effects on uterine 
lengths. 
 
CC alone did not significantly affect uterine length compared to saline treatment, 
and neither were significantly different to the ovariectomised treated group. 
Similarly, the uterine lengths of P4 treated animals, oil treated animals and 
ovariectomised animals were not significantly different. 
 
Generally, the CC treatment seemed to dampen the effect of the SPPPE treatment.  
 
Table 3.1.2.1. and graph 3.1.2.1 show the mean and SEM (standard error of the 
mean) of the treatment groups. These show that the SPPPE treatment exhibited 
the greatest increase in uterine length, followed by CC alone and then CCPPPE. 
CC on its own seems to have an oestrogenic effect, whereas it seems to have an 
anti-oestrogenic effect when administered with PPPE. 
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Table 3.1.2.1. The median and mean for cross sectional uterine length by 
treatment and comparisons for all pairs using Tukey-Kramer post hoc 
analysis. 
N indicates the number of samples, 25Q, the 25th interquartile, 75Q, the 75th 
interquartile, SEM, the standard error of the mean. Measurements in μm. For the 
Tukey Kramer post hoc analysis, levels that were not connected by the same letter 
are significantly different. 
Treatment N 
Median and 
interquartiles Mean and SEM 
Tukey Kramer 
post hoc analysis 
  Median 25Q 75Q Mean SEM Level 
Untreated 11 1352 1147 1470 1294 55   B C 
Saline  11 1397 1235 1470 1380 43   B C 
Oil 12 1301 1088 1580 1327 77   B C 
CC 11 1579 1323 1810 1588 78 A B   
P4 17 1323 1117 1636 1374 58   B C 
SOOO 11 1147 1058 1382 1196 48     C 
SPPPE 12 1733 1485 1848 1734 73 A     
CCPPPE 9 1419 1286 1713 1466 82 A B C 
 
 
Graph 3.1.2.1. The mean and SEM (black lines) for the uterine length by 
treatment.  
Measurements in μm. For the Tukey Kramer post hoc analysis, levels that were 
not connected by the same letter (above graph) are significantly different. 
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3.1.2.2. Tukey­Kramer post hoc analysis of uterine width 
 
The uterine width refers to the short diameter of the cross section of the uterus, as 
seen in Fig. 2.7.1. (2). The uterine widths of the CCPPPE and SPPPE treated 
animals were not significantly different to each other, but were different to 
SOOO. Therefore, the hormonal treatments increased the width of the uterus, but 
CC treatment had no significant effect. 
 
CC treatment alone had a significantly higher median value for uterine width than 
the saline treated animals, whereas the other single treatments were not 
significantly different. 
 
Generally, the CC alone seemed to mimic the effect of the PPPE treatment for 
uterine width, but CC in conjunction with PPPE seemed to diminish the uterine 
width. 
 
Table 3.1.2.2. and graph 3.1.2.2. show the mean and SEM of the treatment groups. 
These show that the SPPPE treatment displayed the greatest increase in uterine 
width, followed by CCPPPE and then CC alone. CC on its own seems to have an 
oestrogenic effect, whereas it seems to have an anti-oestrogenic effect when 
administered with PPPE. 
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Table 3.1.2.2. The median and mean for the uterine width by treatment and 
comparisons for all pairs using Tukey-Kramer post hoc analysis. 
N indicates the number of samples, 25Q, the 25th interquartile, 75Q, the 75th 
interquartile, SEM, the standard error of the mean. Measurements in μm. For the 
Tukey Kramer post hoc analysis, levels that were not connected by the same letter 
are significantly different. 
Treatment N 
Median and 
interquartiles 
Mean and 
SEM 
Tukey Kramer 
post hoc analysis 
    Median 25Q 75Q Mean SEM Level 
Untreated 10 1014 911 1055 998 28 A B 
Saline  12 904 764 1029 908 46   B 
Oil 11 956 911 1205 1006 44 A B 
CC 12 1154 1047 1246 1237 83 A   
P4 18 1047 1018 1165 1078 44 A B 
SOOO 12 849 680 1040 861 51   B 
SPPPE 12 1198 1088 1308 1205 35 A   
CCPPPE 10 1161 957 1409 1174 87 A   
 
 
Graph 3.1.2.2. The mean and SEM (black lines) for the uterine width by 
treatment.  
Measurements in μm. For the Tukey Kramer post hoc analysis, levels that were 
not connected by the same letter (above graph) are significantly different. 
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3.1.2.3. Tukey­Kramer post hoc analysis of luminal length 
 
Luminal length refers to the long diameter of the internal lumen, as seen in Fig. 
2.7.1. (3). The luminal lengths of the CCPPPE and SPPPE treated animals were 
significantly different to SOOO, but not to each other. Any effect, therefore, was 
influenced by the PPPE treatment, and not by the addition of CC. 
 
The luminal length of the single CC treatment was significantly different to the 
saline treatment and the untreated, ovariectomised animals. Therefore, a single 
CC treatment significantly increased the length of the lumen. 
 
The P4, oil treated and the ovariectomised animals did not have significantly 
different luminal lengths. Therefore, P4 did not appear to cause a significant 
change to the length of the lumen. 
 
Table 3.1.2.3. and graph 3.1.2.3. show the mean and SEM of the treatment groups. 
These show that the CC treatment appeared to have the greatest increase in 
luminal length, followed by SPPPE and then CCPPPE. CC on its own seems to 
have an oestrogenic effect, whereas it seems to have an anti-oestrogenic effect 
when administered with PPPE. 
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Table 3.1.2.3. The median and mean for the lumen length by treatment and 
comparisons for all pairs using Tukey-Kramer post hoc analysis. 
N indicates the number of samples, 25Q, the 25th interquartile, 75Q, the 75th 
interquartile, SEM, the standard error of mean. Measurements in μm. For the 
Tukey Kramer post hoc analysis, levels that were not connected by the same letter 
are significantly different.  
Treatment N 
Median and 
interquartiles 
Mean and 
SEM 
Tukey Kramer 
post hoc analysis 
    Median 25Q 75Q Mean SEM Level 
Untreated 10 411.6 376.7 457.5 414.5 15.7     C 
Saline  11 485.1 411.6 529.2 477.1 27.3   B C 
Oil 11 411.6 323.4 588.0 459.0 48.1     C 
CC 11 690.9 602.7 793.8 673.5 43.0 A     
P4 18 573.3 396.9 635.8 513.7 32.7   B C 
SOOO 12 441.0 402.4 531.0 457.5 26.7     C 
SPPPE 11 676.2 588.0 690.9 660.2 19.6 A     
CCPPPE 10 617.4 518.2 690.9 626.2 43.3 A B   
 
 
Graph 3.1.2.3. The mean and SEM (black lines) for the lumen length by 
treatment.  
Measurements in μm. For the Tukey Kramer post hoc analysis, levels that were 
not connected by the same letter (above graph) are significantly different. 
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3.1.2.4. Tukey­Kramer post hoc analysis of the stroma perpendicular to 
mesometrial / anti­mesometrial pole 
 
The wide stroma of the animals treated with CCPPPE and SPPPE were 
significantly different to SOOO, but not to each other. The hormonal treatments 
appeared to increase the stroma width, but CC in conjunction with SPPPE had no 
significant effect on stromal width. 
 
The CC alone had significant differences to the stromal width compared to the 
saline control and the ovariectomised treated animals. Therefore, a single CC 
treatment demonstrably increased the stromal width. 
However, P4, oil and the ovariectomised animals did not have significantly 
different stromal widths from each other. 
 
Table 3.1.2.4. and graph 3.1.2.4. show the mean and SEM of the treatment groups. 
These show that the SPPPE treatment displayed the greatest increase in stromal 
width, followed by CC alone and then CCPPPE. CC on its own seems to have an 
oestrogenic effect, whereas it seems to have an anti-oestrogenic effect when 
administered with PPPE. 
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Table 3.1.2.4. The median and mean for the stroma width by treatment and 
comparisons for all pairs using Tukey-Kramer post hoc analysis. 
N indicates the number of samples, 25Q, the 25th interquartile, 75Q, the 75th 
interquartile, SEM, the standard error of the mean. Measurements in μm. For the 
Tukey Kramer post hoc analysis, levels that were not connected by the same letter 
are significantly different.  
Treatment N 
Median and 
interquartiles 
Mean and 
SEM 
Tukey Kramer 
post hoc analysis 
    Median 25Q 75Q Mean SEM Level 
Untreated 11 286.7 242.6 301.4 277.6 14.2     C D E 
Saline  11 220.5 176.4 279.3 227.2 18.2         E 
Oil 12 294.0 250.8 363.8 300.7 20.0   B C D E 
CC 12 371.2 338.1 464.9 387.1 23.4 A         
P4 18 330.8 284.8 428.1 353.2 17.8 A B C     
SOOO 11 257.3 220.5 338.1 268.9 20.1       D E 
SPPPE 12 393.2 314.2 433.7 381.6 17.0 A B       
CCPPPE 10 341.8 283.0 380.4 336.6 20.3 A B C D   
 
 
Graph 3.1.2.4. The mean and SEM (black lines) for the stroma width by 
treatment.  
Measurements in μm. For the Tukey Kramer post hoc analysis, levels that were 
not connected by the same letter (above graph) are significantly different.  
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3.1.2.5. Tukey­Kramer post hoc analysis of the stroma at the 
mesometrial pole 
 
The SPPPE treatment and P4 treatment alone were significantly different from 
each other in terms of the stromal length at the mesometrial pole. SPPPE was not 
significantly different to the other treatments. P4 was not significantly different to 
the other treatments. 
 
Table 3.1.2.5 and graph 3.1.2.5 show the mean and SEM of the treatment groups. 
The stroma with the CCPPPE treatment was smaller than that seen in the controls 
and seemed to approach the stromal length at the mesometrial side of the uterus at 
a level similar to that seen in P4 treatment alone. It almost appeared to have an 
effect similar to that of P4 alone.  
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Table 3.1.2.5. The median and mean for the stroma at the mesometrial pole, 
by treatment and comparisons for all pairs using Tukey-Kramer post hoc 
analysis. 
N indicates the number of samples, 25Q, the 25th interquartile, 75Q, the 75th 
interquartile, SEM, the standard error of the mean. Measurements in μm. For the 
Tukey Kramer post hoc analysis, levels that were not connected by the same letter 
are significantly different.  
Treatment N 
Median and 
interquartiles 
Mean and 
SEM 
Tukey Kramer 
post hoc analysis 
    Median 25Q 75Q Mean SEM Level 
Untreated 11 102.9 88.2 102.9 96.2 7.5 A B 
Saline  12 102.9 66.2 132.3 104.1 11.4 A B 
Oil 11 102.9 73.5 161.7 114.9 14.5 A B 
CC 12 110.3 102.9 176.4 131.1 16.1 A B 
P4 17 88.2 73.5 102.9 88.6 3.7   B 
SOOO 12 102.9 77.2 128.6 107.8 10.3 A B 
SPPPE 10 147.0 117.6 161.7 147.0 10.3 A   
CCPPPE 12 91.9 77.2 154.4 110.3 12.9 A B 
 
 
Graph 3.1.2.5. The mean and SEM (black lines) for the stroma at the 
mesometrial pole by treatment.  
Measurements in μm. For the Tukey Kramer post hoc analysis, levels that were 
not connected by the same letter (above graph) are significantly different.  
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3.1.2.6. Tukey­Kramer post hoc analysis of the luminal epithelium 
height  
 
The CCPPPE and SPPPE treatments had significantly greater luminal epithelial 
heights than the SOOO control, but were not significantly different to each other. 
Therefore, the PPPE treatment had an effect on luminal epithelial height, and the 
effect of CC in conjunction with the hormonal treatments was negligible. 
 
The effect of CC alone on uterine luminal epithelial height was significantly 
different to the saline and ovariectomised treated animals. A single dose of CC 
increased the height of the luminal epithelium (LE), almost by double. 
 
The P4 treatment significantly increased epithelial height when compared to the 
oil vehicle and ovariectomised treated animals 
 
Table 3.1.2.6. and graph 3.1.2.6. show the mean and SEM of the treatment groups. 
These show that the CC treatment alone had the greatest increase in epithelial 
height, followed by CCPPPE and then SPPPE. CC on its own seemed to have an 
oestrogenic effect, whereas it seemed to have an anti-oestrogenic effect when 
administered with PPPE. The progesterone on its own was significantly different 
to the controls.  
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Table 3.1.2.6. The median and mean for the luminal epithelial height by 
treatment and comparisons for all pairs using Tukey-Kramer post hoc 
analysis. 
N indicates the number of samples, 25Q, the 25th interquartile, 75Q, the 75th 
interquartile, SEM, the standard error of the mean. Measurements in μm. For the 
Tukey Kramer post hoc analysis, levels that were not connected by the same letter 
are significantly different.  
Treatment N 
Median and 
interquartiles 
Mean and 
SEM 
Tukey Kramer 
post hoc analysis 
    Median 25Q 75Q Mean SEM Level 
Untreated 11 6.501 5.905 7.801 6.604 0.296       D 
Saline  12 6.366 5.851 7.219 6.551 0.232       D 
Oil 11 6.230 6.122 6.826 6.457 0.177       D 
CC 11 11.431 10.185 12.352 11.337 0.315 A       
P4 15 8.451 7.747 8.614 8.336 0.170     C   
SOOO 12 6.095 5.661 6.677 6.203 0.158       D 
SPPPE 10 9.968 8.803 11.485 10.104 0.438   B     
CCPPPE 11 10.239 9.968 10.618 10.441 0.266 A B     
 
 
Graph 3.1.2.6. The mean and SEM (black lines) for the luminal epithelial 
height by treatment.  
Measurements in μm. For the Tukey Kramer post hoc analysis, levels that were 
not connected by the same letter (above graph) are significantly different.  
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3.2. Descriptive analysis of H&E stained slides 
 
3.2.1. H&E of control animals 
 
The morphometric analysis of the uterine parameters measured showed no 
significant differences using rank sums analyses between the ovariectomised 
(Group A), saline treated (Group B), oil treated (Group C) and SOOO treated 
(Group F) animals, as evident in tables 3.1.1.1. to 3.1.2.6. Therefore, the control 
groups have been presented together. The results reported here concur and extend 
those reported by Ljungkvist (1971a, 1971b), Hosie and Murphy (1995), Hosie 
(1997).  
 
The overall size of the uterine profile was small, showing a short diameter at a 
median (interquartile range) of 941 μm (790-1043 μm) and long diameter of 1294 
μm (1117-1470 μm).  The oil control demonstrated a slightly larger average 
diameter when compared to the other control tissue.  
 
The uterine lumens in this group of animals were generally narrow and straight 
with no evidence of closure or tissue folding. An expansion at the mesometrial 
pole of the lumen was noted, which was often T-shaped. More stromal tissue was 
present at the antimesometrial pole than the mesometrial pole. Fig. 3.2.1., of an 
SOOO treated animal, shows a typical low power uterine profile from a control 
animal.  
 
The uterine luminal epithelium seen in this group of animals typically had a single 
layer of low cuboidal cells with central to apically placed round nuclei. A narrow 
band of pale eosinophilic cytoplasm was seen above and below the nucleus. 
Fig. 3.2.2. shows the uterine luminal epithelium typically seen in this group of 
animals. 
 
The stroma was indistinctly divided into two zones; a narrow darkly stained zone 
of six to eight cell layers directly below the epithelium (dark layer, DL, 
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Fig. 3.2.2.) where the fibroblasts were generally triangular or elongated; and a 
wider, paler stained layer radiating out to the myometrial layers. In this layer the 
fibroblasts were more flattened in appearance and not as densely packed with 
more ground substance evident. 
 
Glands were generally seen more often at the antimesometrial pole of the uterus, 
as seen in Fig. 3.2.1. The glands generally had wide lumens that sometimes 
showed evidence of secretion (Fig. 3.2.3.). The epithelium lining the glands was 
cuboidal in shape with central to basally placed nuclei. There was little evidence 
of mitosis or apoptosis in the epithelium.  The glands were straight with coiling 
evident in the deeper stroma as groups of gland profiles are clustered together 
(Figs. 3.2.1 and 3.2.3.). 
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Figure 3.2.1.  
Uterine profile of an SOOO 
control animal 
The lumen of a control animal 
was narrow and had an 
expansion at the mesometrial 
pole. Glands were more 
concentrated at the anti-
mesometrial pole.   
 
 
DL 
Figure 3.2.2.  
Luminal epithelium of an oil 
control animal 
The luminal epithelial cells 
were cuboidal, with central to 
apical nuclei.  
The dark layer (DL) of the 
stroma was about six to eight 
layers, directly surrounding the 
luminal epithelium. 
Figure 3.2.3.  
Glandular tissue of an oil 
treated control 
The epithelium lining the 
glands was cuboidal with 
basally placed nuclei. 
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3.2.2. H&E of animals treated with a single 1.25 mg CC dose  
 
The overall size of the uterine profile of CC treated animals was large compared 
to the controls and the P4 treated tissue. The short diameter showed a median 
(interquartile range) of 1154 μm (1047-1246 μm) and long diameter of 1579 μm 
(1323-1810 μm). The uterine lumens in this group of animals were generally wide 
and extended at the mesometrial pole of the uterus.  Fig. 3.2.4. shows a typical 
low power uterine profile from a CC treated animal.  
 
The uterine luminal epithelium seen in this group of animals was typically a 
single layer of columnar cells which sometimes appeared closely packed and 
pseudostratified or stratified, indicative of hyperplasia. The epithelium had a 
beaded appearance with basally placed ovoid nuclei with darkly stained nuclear 
membranes and prominent nucleoli. A wide band of eosinophilic cytoplasm was 
seen above the nucleus. Long dense microvilli were evident on the surface of this 
epithelium. Fig. 3.2.5. is typical of the luminal epithelium of this group. 
 
The stroma was indistinctly divided into two zones, a wide darkly stained zone 
(DL) extending more than half way into the tissue (Fig. 3.2.4.), where the 
fibroblasts were generally quite densely packed and rounded. The external stromal 
layer was less densely stained and quite cellular (Fig. 3.2.4.). The fibroblasts in 
this layer were flattened. Blood vessels were numerous and seen throughout the 
stroma (Fig. 3.2.5.). 
 
Gland profiles were more numerous in this tissue when compared to the control 
and P4 treated uteri, as the glands were more dispersed throughout the stroma, 
rather than clumped at the anti-mesometrial pole of the uterus. Coiling also 
appeared more extensive when compared to the other single treatment animals. 
The epithelium lining the glands was columnar in shape, although generally not as 
tall as the uterine luminal epithelium (Fig. 3.2.6.). The glandular cells had basally 
placed nuclei and darkly stained nuclear membranes. Nucleoli were also present 
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in this epithelium. Apoptotic bodies were also noted (not shown). Flattened 
fibroblasts often surrounded the gland profiles (Fig. 3.2.6.). 
 
Figure 3.2.4.  
Uterine profile of a 1.25 mg 
CC treated animal 
The uterine lumens of CC 
treated animals were generally 
larger than the control or P4 
treated animals. The dark layer 
(DL) extended more than half 
way into the stroma, and the 
glands (gl) were dispersed 
throughout the stroma, and not 
concentrated towards the anti-
mesometrial pole. 
DL 
gl 
gl 
Figure 3.2.5.  
Luminal epithelium of a CC 
treated animal 
The columnar luminal 
epithelial cells showed some 
pseudostratification. Microvilli 
were evident on the edge of 
these cells. The nuclei were 
basally situated, with dark 
nuclear membranes and 
prominent nucleoli. Capillaries 
were seen in this micrograph. 
 
Figure 3.2.6.  
A gland of a single CC 
treated animal 
The glandular cells were 
elongated, with basally placed 
nuclei that had prominent 
nuclear membranes and 
nucleoli. 
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3.2.3. H& E of a single dose of 5 mg P4 
 
The overall size of the uterine profile of a P4 treated animal was small and not 
significantly different to those seen in the control animals (tables 3.1.2.1. and 
3.1.2.2.) showing a short diameter with a median (interquartile range) of 1047 μm 
(1018-1165 μm) and long diameter 1323 μm (1117-1636 μm). The uterine lumens 
in this group of animals were generally narrow and straight and usually occluded 
with no tissue folding, in accordance with the work by Ljunkvist (1971a). At the 
mesometrial pole of the tissue the lumen was T-shaped. Fig. 3.2.7. shows a typical 
low power uterine profile from a P4 treated animal.  
 
The uterine luminal epithelium seen in this group of animals was typically a 
single layer of cuboidal cells with central to basally placed round nuclei, with a 
darkly stained nuclear membrane often displaying nucleoli. A narrow band of 
eosinophilic cytoplasm was seen above and below the nucleus, as seen in 
Fig. 3.2.8. 
 
The stroma was indistinctly divided into two zones, a narrow darkly stained zone 
(DL) of six to eight cell layers directly below the epithelium (Figs. 3.2.7. and 
3.2.8.) where the fibroblasts were generally rounded, and a wider paler stained 
layer radiating out to the myometrial layers. Numerous small blood vessels were 
seen just below the luminal epithelium. 
 
As seen in the control tissue, the majority of gland profiles were seen at the anti-
mesometrial pole of the uterus (Fig. 3.2.7.) with similar wide lumens sometimes 
showing evidence of secretion. The epithelium lining the glands was more 
columnar in shape with more basally placed nuclei, and darkly stained nuclear 
membranes (Fig. 3.2.9.). Nucleoli were also present in this epithelium. Apoptotic 
bodies were also noted (Fig. 3.2.9.). The glands were straight with less coiling 
evident in the deeper stroma when compared to the control tissue. Flattened 
fibroblasts often surrounded the gland profiles (Fig. 3.2.9). 
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Figure 3.2.7. 
Uterine profile of a 5 mg P4 
treated animal 
The lumen of the P4 treated 
animals tended to have a T-
shape at the mesometrial pole, 
with occlusion of the luminal 
epithelium further into the 
stroma. The dark layer (DL) 
was about six to eight cell 
layers beneath the luminal 
epithelium. Glands tended to 
concentrate at the anti-
mesometrial pole. 
Figure 3.2.8. 
Luminal epithelium of a P4 
treated animal 
The nuclei of the luminal 
epithelia tended to be basally to 
centrally positioned with dark 
nuclear membranes. 
Eosinophilic cytoplasm 
surrounded the nuclei.  
The fibroblasts surrounding the 
luminal epithelium tended to be 
rounded. 
DL 
Figure 3.2.9. 
Glands of a 5 mg P4 treated 
animal 
The epithelia lining the glands 
was columnar, with basally 
placed nuclei. 
An apoptotic cell (ApC) has 
been indicated with the arrow. 
Flattened fibroblasts 
surrounded the tissue. 
ApC 
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3.2.4. Hormonally induced receptivity, SPPPE 
 
The results concur and extend those reported by Ljungvist (1971a). 
The overall size of the uterine profile of SPPPE treated animals was large when 
compared to the control tissue, with a short diameter median (interquartile range) 
of 1198 μm (1088-1308 μm) and long diameter of 1733 μm (1485-1848 μm). 
The uterine lumens in this group of animals were generally narrow and straight 
and were largely occluded. At the mesometrial pole of the tissue the lumen was 
expanded. Fig. 3.2.10. shows a typical low power uterine profile from an SPPPE 
treated animal.  
 
The uterine luminal epithelium seen in this group of animals was typically a 
single layer of cuboidal cells with basally placed round nuclei surrounded by a 
darkly stained nuclear membrane. A narrow band of eosinophilic cytoplasm was 
prominent above the nucleus, as seen in Fig. 3.2.11. 
 
The stroma was divided into two zones, a narrow darkly stained zone of six to 
eight cell layers directly below the epithelium (dark layer DL) and extending with 
the glandular epithelium and so surrounding it. The fibroblasts in this area were 
generally rounded. Surrounding the DL was a wider paler stained layer radiating 
out to the myometriun where the fibroblasts also appeared somewhat rounded and 
active. Large blood vessels were evident in the stroma. Fig. 3.2.11. shows the 
stroma surrounding the luminal epithelium. 
 
In this tissue, the majority of gland profiles were seen at the anti-mesometrial pole 
of the uterus, although in some sections, gland profiles were also seen at the 
mesometrial pole. The glands had wide lumens mostly filled with secretions 
(Fig. 3.2.12.). The epithelium lining the glands was more columnar in shape than 
that of the luminal epithelium, with basally placed nuclei, and darkly stained 
nuclear membranes. The gland profiles were numerous, demonstrating extensive 
coiling when compared to the control tissue and single treatment tissue 
(Fig. 3.2.12.).  
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Figure 3.2.10.  
Uterine profile of an SPPPE 
animal 
The lumen was expanded at the 
mesometrial pole.  
The dark layer (DL) 
surrounding the lumen was 
about six to eight layers deep. 
There were numerous gland 
profiles, concentrated mainly at 
the anti-mesometrial pole. 
Figure 3.2.11.  
Luminal epithelium of an 
SPPPE animal 
The uterine epithelium had 
cuboidal cells with round 
nuclei and darkly stained 
nuclear membranes. Prominent 
eosinophilic cytoplasm was 
evident above the nuclei. The 
fibroblasts surrounding the 
uterine luminal epithelium 
were generally rounded. 
Figure 3.2.12.  
Gland profile of an SPPPE 
animal 
The glands generally had wide 
lumens filled with eosinophilic 
secretions. The glandular 
epithelia had rounded, basally 
placed nuclei with dark nuclear 
membranes and the glandular 
cells were more columnar than 
the luminal epithelial cells. 
  
DL 
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3.2.5. CCPPPE  Hormonally induced receptivity 
 
The overall size of the uterine profile of the CCPPPE treated tissue was smaller 
when compared to the SPPPE treated tissue, but not significantly smaller (tables 
3.1.2.1 – 3.1.2.2). The short diameter median (interquartile range) was 1161 μm 
(957-1409 μm) and long diameter was 1419 μm (1286-1713 μm). 
 
The uterine lumens in this group of animals were invaginated, forming pockets or 
large diameter glandular structures and to some extent folding was apparent. 
There was also no obvious expansion of the lumen at the mesometrial pole as seen 
in the other tissue analysed in this study. Fig. 3.2.13. shows a typical low power 
uterine profile from a CCPPPE treated animal.  
 
The uterine luminal epithelium seen in this group of animals was typically a 
single layer of tall columnar cells, sometimes appearing pseudostratified. The 
cells displayed centrally to basally placed granular nuclei that were oval to 
irregularly shaped. The nuclei had a darkly stained nuclear membrane and 
nucleoli were also noted. A band of eosinophilic cytoplasm was prominent below 
the nucleus. The cytoplasm of these cells appeared bubbly or granular. The cells 
also displayed a prominent band on the apical membrane indicative of a brush 
border or at least dense long microvilli as reported by Hosie and Murphy (1992) 
and Hosie (1997). Fig. 3.2.14. shows a typical micrograph of a CCPPPE treated 
luminal epithelium. 
 
The dark layer (DL) of the stroma extended to the end of the glands as seen in the 
SPPPE treated tissue. Similarly, the fibroblasts in this area were rounded, 
suggestive of activity. Surrounding the DL was a wider, paler stained layer of 
stroma radiating out to the myometrium, where the fibroblasts also appeared 
rounded and active (Fig. 3.2.13.).  
 
In this tissue the majority of gland profiles were seen at the anti-mesometrial pole 
of the uterus, or dispersed throughout the stroma, with few or no gland profiles 
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seen at the mesometrial pole (Fig. 3.2.13.). The glands had wide lumens that 
usually lacked eosinophilically stained secretions (Fig. 3.2.15.). The epithelium 
lining the glands was cuboidal in shape with darkly stained basally placed nuclei. 
In contrast, the SPPPE treated tissue had more columnar glandular epithelia. 
Apoptotic cells were often seen in this tissue (Fig. 3.2.15.). Gland profiles were 
numerous, demonstrating extensive coiling when compared to other tissue 
examined in this study (Fig. 3.2.10 and 3.2.12. of SPPPE treated tissue, and 3.2.13 
and 3.2.15 of CCPPPE treated tissue).  
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Figure 3.2.13.  
Uterine profile of a CCPPPE 
treated animal 
At low power, the lumen 
showed extensive folding. 
The gland profiles were found 
at the anti-mesometrial pole, or 
dispersed through the stroma. 
The dark layer (DL) of 
fibroblasts extended to the 
glands. 
Figure 3.2.14.  
Luminal epithelium of 
CCPPPE treated tissue 
The luminal epithelial (LE) 
cells were columnar in shape. 
They had centrally placed 
nuclei with dark nuclear 
membranes and dark nucleoli. 
The cells had a prominent 
apical membrane. Fibroblasts 
surrounding the LE were 
rounded, suggesting that they 
were active. 
 
Figure 3.2.15.  
Glandular tissue of a 
CCPPPE treated animal 
The glands had wide lumens 
that usually lacked secretions. 
The epithelium lining the 
glands was cuboidal in shape 
with darkly stained, basally 
placed nucleoli. Two apoptotic 
cells (ApC) situated next to 
each other have been indicated 
with the arrow. 
DL 
DL 
ApC 
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3.3.   Immunohistochemistry against the progesterone 
receptor, Bcl­2 and Bax 
 
3.3.1. Immunohistochemistry (IHC) of the Progesterone Receptor (PR)  
 
3.3.1.1. PR expression in ovariectomised, control or placebo rat uteri 
 
The results of immunohistochemistry against the progesterone receptor for the 
ovariectomised, saline treated, oil treated and SOOO treated control animals were 
generally similar and have been presented together.  
 
PR expression in the control tissues was generally most concentrated in the 
luminal epithelium, less concentrated in the stromal tissue and least concentrated 
in the glandular tissue. In the stromal tissue, PR tended to be concentrated in the 
dark layer immediately surrounding the lumen. Fig. 3.3.1.1. of an ovariectomised, 
untreated animal shows a typical uterine profile of a control animal.     
 
In the luminal epithelium, PR expression was localised in the nuclei, with a 
concentration of expression in the nuclear membrane. (Fig. 3.3.1.2 of a saline 
treated control animal shows a high power micrograph of PR expression in the 
luminal epithelium.) In the ovariectomised untreated and saline treated controls, 
there was little expression of PR in the cytoplasm of the uterine luminal 
epithelium (Fig. 3.3.1.2). By contrast, the oil and SOOO controls had PR 
expression in the cytoplasm which was lower than in the nuclei. The oil controls 
and SOOO controls also had PR expression concentrated at the apical membrane 
of the luminal epithelium (Fig. 3.3.1.3.). 
 
PR expression in the glandular epithelium of the control tissues was concentrated 
in the nuclear membranes (Fig. 3.3.1.4.). Expression of PR was greater in the  
nuclei than the cytoplasm for the ovariectomised, saline treated and oil treated 
controls (Fig. 3.3.1.4.). The SOOO controls had a similar expression of PR in the 
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nuclei and the cytoplasm, and the SOOO controls tended to have a frothy 
appearance at high power (Fig. 3.3.1.5.). 
 
 
Figure 3.3.1.1.  
IHC of PR in an 
ovariectomised, untreated 
control rat uterus 
Generally, the PR expression in 
the control tissues was greatest 
in the luminal epithelium, 
followed by the stroma, and the 
least expression in the glands. 
In the stroma, PR expression 
was greatest in the area 
immediately surrounding the 
lumen. 
Figure 3.3.1.2.  
Expression of PR in the 
luminal epithelium of a saline 
treated control animal 
The PR was localised in the 
nucleus of the luminal 
epithelium, with a 
concentration at the nuclear 
membrane.  
Ovariectomised and saline 
treated control animals had low 
expression of PR in the 
cytoplasm. 
10μm 
100μm 
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Figure 3.3.1.4.  
Expression of PR in the 
glandular epithelium of an oil 
treated control animal 
PR expression in the glandular 
epithelium was concentrated in 
the nuclei, with distinct nuclear 
membranes. In the untreated, 
saline and oil treated animals, 
the PR expression was greater 
in the nuclei than in the 
cytoplasm. PR expression in 
the cytoplasm was 
concentrated to the apex of the 
glandular cells. 
Figure 3.3.1.5.  
Expression of PR in the 
glandular epithelium of an 
SOOO treated control animal 
Expression of PR in SOOO 
animals was similar in the 
nuclei and cytoplasm. This 
gave the glands a frothy 
appearance. 
10μm 
10μm 
10μm 
Figure 3.3.1.3.  
Expression of PR in the 
luminal epithelium of an oil 
treated control animal 
PR expression in cytoplasm of 
the oil and SOOO treated 
animals was greater than that in 
the ovariectomised, untreated 
and saline treated controls. The 
expression of PR in the 
cytoplasm was concentrated at 
the apex of the luminal cells. 
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3.3.1.2. PR expression in 1.25 mg CC treated rat uteri 
 
Expression of PR in the 1.25 mg CC treated rat uteri was greatest in the stroma, 
followed by the luminal epithelium, and the glands had the lowest expression of 
PR. In the stroma, PR expression had the greatest intensity immediately 
surrounding the lumen, with a decrease of expression in the stroma between the 
glandular tissue and myometrium. Fig. 3.3.1.6. shows a typical uterine profile of a 
single CC treated animal. The control tissues differed from the single CC treated 
tissue, as the controls had the greatest expression of PR in the luminal epithelium, 
followed by the stromal tissue and least expression in the glandular tissue (Fig. 
3.3.1.1.). 
 
PR expression in the luminal epithelium of single CC treated animals was 
localised in the nuclei, which had a granular appearance, and was concentrated at 
the nuclear membrane (Fig. 3.3.1.7.). Some nuclei in the luminal epithelium 
contained a distinct, dark, concentrated spot when treated with PR antibody, 
which may have been a concentration of PR expression at the nucleolus. The 
cytoplasm of the uterine luminal epithelium had the greatest expression of PR at 
the apex of the cell membrane. By contrast, the base of the cells below the 
epithelium did not appear to express PR. 
 
In the glandular epithelium, as with the uterine luminal epithelium, PR expression 
was greater in the nuclei than in the cytoplasm (Fig. 3.3.1.8.). The nuclei in the 
glands appeared granular with a dark membrane and some nuclei expressed PR in 
the nucleolus. 
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Figure 3.3.1.6.  
IHC of PR in a 1.25 mg CC 
treated rat uterus 
The expression of PR in the CC 
treated rat uterus was greatest 
in the stroma, less in the 
uterine luminal epithelium and 
least in the glands. PR 
expression in the stroma was 
greatest in the dark layer 
surrounding the lumen, and 
diminished in intensity past the 
glands. 
Figure 3.3.1.7.  
Expression of PR in the 
luminal epithelium of a CC 
treated animal 
PR expression was greatest in 
the nuclei of the luminal 
epithelial cells, with a 
concentration at the nuclear 
membranes. In the cytoplasm, 
PR was expressed at the apex 
of the cells, but not at the base 
of the cells. The stromal cells 
surrounding the lumen had a 
greater expression of PR than 
the luminal epithelium. 
Figure 3.3.1.8.   
Expression of PR in the 
glandular tissue of a CC 
treated animal 
PR expression in the glandular 
epithelium was greatest in the 
nucleus, with a concentration at 
the nuclear membranes. In the 
cytoplasm, there was a 
concentration of PR expression 
at the apex of the cells. 
10μm 
10μm 
100μm 
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3.3.1.3. PR expression in 5 mg progesterone treated rat uteri 
 
Expression of PR in the 5 mg P4 treated animals was slightly greater in the 
luminal epithelium than the glands and both structures had greater P4 expression 
than the stroma. PR expression in the stroma was localised around the lumen. This 
was similar to the expression of PR in the control tissues (Fig. 3.3.1.1.), but 
different to the expression in the single CC treated animals (Fig. 3.3.1.6.).  Fig. 
3.3.1.9. shows a typical uterine profile of PR expression in a P4 treated animal. 
 
Generally, PR in the luminal epithelium was expressed as a granular nuclear stain. 
In some sections, the PR expressed in the nuclei, and in other sections it did not 
appear to localise (Fig. 3.3.1.10.). PR in the cytoplasm concentrated toward the 
apex of the cells (Fig. 3.3.1.10.). 
 
In the glandular epithelium of P4 treated animals, the nuclei were similar in 
intensity of expression of PR when compared to the cytoplasm (Fig. 3.3.1.11.).  
Some animals showed expression of PR in the apex of the glandular cells (Fig. 
3.3.1.11.), whereas some animals did not (not shown), and some of the glandular 
secretions expressed PR (not shown).  
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Figure 3.3.1.9.  
IHC of PR in a 5 mg P4 
treated rat uterus 
Expression of PR was similar 
in the luminal epithelium and 
the glands, and lower in the 
stroma in a single P4 treated 
animal. Expression in the 
stroma occurred in the dark 
layer surrounding the uterine 
lumen.   
Figure 3.3.1.10.  
Expression of PR in the 
luminal epithelium of a P4 
treated animal 
PR in the luminal epithelial 
cells was generally expressed 
in the nuclei.  
Figure 3.3.1.11.  
Expression of PR in the 
glandular tissue of a P4 
treated animal 
Expression of PR in the glands 
was similar in the nuclei and 
the cytoplasm. This section 
shows a concentration of PR 
towards the apex of the cells. 
10μm 
10μm 
100μm 
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3.3.1.4. PR expression in SPPPE treated rat uteri 
 
Expression of PR in SPPPE treated animals was greatest in the stroma, followed 
by the luminal epithelium and the least expression was in the glands. This profile 
was similar to that of the single CC treatment (Fig. 3.3.1.6.). In the stroma of 
SPPPE animals, PR expression was diffused, with the greatest concentration 
around the uterine luminal epithelium, less expression around the glandular 
epithelium and low (or absent) expression immediately below the myometrium. 
Fig. 3.3.1.12. shows a typical profile of PR expression in an SPPPE treated rat 
uterus. 
 
PR expression in the uterine luminal epithelium was greatest at the nuclear 
membranes (Fig. 3.3.1.13.). The nuclei in the epithelial cells had greater or similar 
expression of PR to the cytoplasm, although both were pale (Fig. 3.3.1.13.). There 
was an intermittent expression of PR at the apex of the cells and there was no 
expression of PR in the basement membrane below the luminal epithelium. 
 
In some of the glands, the nuclei had greater expression of PR and the cytoplasm 
had less expression, whereas in other glands, expression of PR was greater in the 
cytoplasm than the nuclei (Fig. 3.3.1.14.). The nuclei was generally pale in 
comparison to the nuclear membrane, although sometimes one could not 
distinguish between the cytoplasm and nucleus, as both structures were pale. 
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Figure 3.3.1.12.  
IHC of PR in an SPPPE 
treated rat uterus 
Expression of PR in SPPPE 
treated animals was greatest in 
the stroma, and equivalent in 
the luminal epithelium and the 
glands. In the stroma, PR 
expression was greatest in the 
area surrounding the lumen and 
was less concentrated towards 
the myometrium.  
Figure 3.3.1.13.  
Expression of PR in the 
luminal epithelium of an 
SPPPE treated animal 
PR was most concentrated at 
the nuclear membranes in the 
luminal epithelium. Expression 
of PR in the nuclei was slightly 
greater than the cytoplasm. 
There was a concentration of 
PR towards the apex of the 
cells. 
 
Figure 3.3.1.14.  
Expression of PR in the 
glandular tissue of an SPPPE 
treated animal 
PR expression was equivalent 
in the nuclei and cytoplasm of 
the glandular epithelium, with 
greater expression at the 
nuclear membranes.  
10μm 
10μm 
100μm 
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3.3.1.5. PR expression in CCPPPE treated rat uteri 
 
Expression of PR was greatest in the stroma of CCPPPE treated animals, followed 
by the luminal epithelium and least in the glandular epithelium. Expression of PR 
in the stroma was most concentrated around the lumen, and diminished in the 
stromal tissue in the region between the glands and the myometrium. This result 
was similar to the expression of PR in SPPPE treated animals (Fig. 3.3.1.12.). Fig. 
3.3.1.15. shows a typical profile of PR expression in a CCPPPE  treated rat uterus. 
 
The nuclei in the luminal epithelium of CCPPPE treated animals had greater 
expression of PR than the cytoplasm (Fig. 3.3.1.16.). There was a concentration of 
PR expression at the apex of the cells (Fig. 3.3.1.16.). This was in contrast to the 
SPPPE treated animals, which had less intense expression of PR in the luminal 
epithelium and did not show much difference in expression between the nuclei 
and cytoplasm. 
 
Similarly to the luminal epithelium, PR expression in the glandular epithelium 
was more concentrated in the nuclei than in the glands (Fig. 3.3.1.17.).  The nuclei 
appeared granular and had a concentration of PR expression at the nuclear 
membranes, although the nuclei did not always express PR (Fig. 3.3.1.17.).  PR 
expression in the cytoplasm was greater towards the apex of the cells 
(Fig. 3.3.1.17.).  
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Figure 3.3.1.15.  
IHC of PR in a CCPPPE 
treated rat uterus 
Expression of PR was greatest 
in the stroma, followed by the 
luminal epithelium and the 
glands. PR expression in the 
stroma was greatest around the 
lumen and diffused past the 
glands.  
Figure 3.3.1.16.  
Expression of PR in the 
luminal epithelium of a 
CCPPPE treated animal 
PR expression in the luminal 
epithelium was greater in the 
nuclei than the cytoplasm. 
There was a concentration of 
PR expression at the apical 
membranes.  
Figure 3.3.1.17.  
Expression of PR in the 
glandular tissue of a 
CCPPPE treated animal 
PR expression in the glands 
was greater in the nucleus than 
the cytoplasm and PR 
aggregated at the nuclear 
membranes. PR expression in 
the cytoplasm was most 
concentrated at the apex of the 
cells. 
10μm 
10μm 
100μm 
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3.3.1.6. Summary of IHC against PR in rat uteri 
 
PR expression in the uterine profiles of the control tissues was greatest at the 
uterine luminal epithelium, followed by the stroma and least expression in the 
glandular epithelium. The CC, SPPPE and CCPPPE treated tissue had the greatest 
expression of PR in the stroma, followed by the luminal epithelium and least in 
the glandular epithelium. P4 treated tissues had a greater or similar expression of 
PR in the luminal epithelium and glandular epithelium, with less expression in the 
stroma. 
 
PR expression in the stroma of the controls and the P4 treated animals was 
concentrated in the dark layer around the lumen, the expression of PR in the 
single CC and SPPPE treated tissues extended to the glandular epithelium, and 
expression of PR in CCPPPE treated tissues extended to beneath the myometrium. 
 
Expression of PR in the uterine luminal epithelium of ovariectomised untreated 
and saline treated controls was greater in the nuclear membranes than the nuclei, 
and there was little expression in the cytoplasm. Neither of these controls showed 
a concentration of PR expression towards the apex of the cells. The oil and SOOO 
controls as well as the CC, P4, SPPPE and CCPPPE treated tissues had the 
greatest expression of PR in the nuclear membranes, followed by the nuclei and 
least in the cytoplasm. These controls and treatment groups had PR expression in 
the apex of the luminal epithelial cells.  
 
PR expression in the glandular epithelium of the control tissues as well as the CC 
and CCPPPE treated tissues was greatest at the nuclear membranes followed by 
the nuclei and least in the cytoplasm. The P4 treated tissue had similar expression 
of PR in the nuclei and cytoplasm. The SPPPE treated tissue had greater 
expression of PR in the nuclei and less in the cytoplasm in some sections, and in 
other sections the expression of PR was greater in the cytoplasm than the nuclei. 
The controls (except for the SOOO control) did not generally show a 
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concentration of PR in the apex of the glandular cells and the treatment groups 
had a concentration of PR at the apex of the cells. 
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3.3.2. IHC against Bcl­2 (B cell lymphoma/leukemia­2)  
  
3.3.2.1. Bcl­2 expression in ovariectomised, control or placebo rat 
uteri 
 
The results of the immunohistochemistry against Bcl-2 expression in the 
ovariectomised untreated, saline control, oil control and SOOO control treated 
animals was similar and have been presented together. 
 
Bcl-2 expression in the untreated or placebo treated rat uteri was concentrated in 
the luminal epithelium, less concentrated in the glandular tissue and least 
concentrated in the stroma. Fig. 3.3.2.1. shows Bcl-2 expression in the uterus of 
an SOOO treated animal. Expression of Bcl-2 was dispersed throughout the 
stromal tissue and there was not a distinct concentration of Bcl-2 in the dark layer 
surrounding the lumen.   
 
Expression of Bcl-2 in the control tissues of the luminal epithelium appeared 
bubbly. Bcl-2 expression was distinct on the nuclear membranes in some sections 
(Fig. 3.3.2.2.), but its expression was absent in other sections. The nucleus had a 
similar or slightly greater expression of Bcl-2 than the cytoplasm, so if the nuclear 
membrane was not apparent, it was difficult to distinguish between these cellular 
components. The Bcl-2 in the cytoplasm tended to concentrate towards the apex 
of the luminal epithelial cells (Fig. 3.3.2.2.).     
 
Bcl-2 expression in the control tissues appeared frothy in the glandular epithelium 
(Fig. 3.3.2.3.). The nuclei had a greater or similar expression of Bcl-2 compared 
to the cytoplasm (Fig. 3.3.2.3.), although it was not always possible to distinguish 
between the two cellular structures. The nuclear membrane was sometimes, 
although not always, distinguishable, and there was sometimes a concentration of 
Bcl-2 towards the lumen of the gland. 
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Figure 3.3.2.1.  
IHC of Bcl-2 in an SOOO 
treated rat uterus 
Generally,in the control 
sections, the Bcl-2 had the 
greatest expression in the 
luminal epithelium, followed 
by the glands and the least 
expression in the stroma. Bcl-2 
expression was distributed in 
the stroma with some 
concentration close to the 
lumen.  
Figure 3.3.2.2.  
Expression of Bcl-2 in the 
luminal epithelium of an 
ovariectomised control 
animal 
Bcl-2 expression in the luminal 
epithelium of the control 
animals was similar in the 
nucleus and cytoplasm and had 
a bubbly appearance. There 
was some concentration of 
Bcl-2 expression toward the 
apex of the cells.  
Figure 3.3.2.3.  
Expression of Bcl-2 in the 
glandular tissue of an SOOO 
control animal 
Bcl-2 expression in the 
glandular epithelium of the 
control tissues was similar 
between the nuclei and 
cytoplasm, and the glands 
appeared frothy. The nuclear 
membranes were sometimes, 
but not always, distinct. 
10μm 
10μm 
100μm 
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3.3.2.2. Bcl­2 expression in 1.25 mg CC treated rat uteri 
 
Bcl-2 expression in the CC treated rat uteri sections was noticeably different to 
those of the controls (Figs. 3.3.2.1-3.3.2.3). The luminal epithelium of the CC 
treated tissue had a far more concentrated localisation than the glands and the 
stroma had very little localisation. In addition, the luminal epithelium had a 
patchy expression of Bcl-2, which was apparent, even at low power. Fig. 3.3.2.4.. 
shows a typical low power micrograph of CC treated tissue that has been 
immunolocalised against Bcl-2. Bcl-2 expression in the stroma was dispersed, but 
sometimes had a higher concentration surrounding the lumen (Figs. 3.3.3.4 and 
3.3.2.4.). 
 
At higher magnification, it was apparent that the luminal epithelium was 
characterised by patches of Bcl-2 localisation, where some portions of the 
epithelium were localised, and adjacent portions did not express Bcl-2 (Fig. 
3.3.2.5). 
The cytoplasm of the luminal epithelium generally had a greater or equal 
concentration of Bcl-2 when compared to the nuclei, and some nuclei stained, 
whereas others did not (Fig. 3.3.2.5.). The nuclear membrane was usually distinct. 
In some sections, there was a dark spot visible in the nucleus, which was probably 
the nucleolus (not shown).   
  
Bcl-2 expression in CC treated animals appeared frothy in the glandular 
epithelium (Fig. 3.3.2.6.). The cytoplasm and nuclei were generally pale. The 
nuclear membranes were sometimes, but not always, distinct (Fig. 3.3.2.6.). 
Occasionally, there was a concentration of stain in the nucleolus. 
 
 87
 
Figure 3.3.2.4.  
IHC of Bcl-2 in a 1.25 mg CC 
treated rat uterus 
Patchiness of Bcl-2 expression 
was evident around the luminal 
epithelium of a CC treated 
animal. The expression of Bcl-
2 was greatest in the luminal 
epithelium, followed by the 
glands and least in the stroma . 
Bcl-2 expression was dispersed 
throughout the stroma.  
Figure 3.3.2.5.  
Expression of Bcl-2 in the 
luminal epithelium of a CC 
treated animal 
Expression of Bcl-2 was patchy 
in the luminal epithelium, 
where some sections expressed 
Bcl-2 and adjacent sections did 
not express Bcl-2. 
Figure 3.3.2.6.  
Expression of Bcl-2 in the 
glandular tissue of a CC 
treated animal 
Bcl-2 expression in the 
glandular epithelium of CC 
treated animals appeared 
frothy. The cytoplasm and 
nuclei were similar in 
expression, although both 
cellular components were 
generally pale. The nuclear 
membranes were sometimes, 
but not always, distinct. 
10μm 
10μm 
100μm 
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3.3.2.3. Bcl­2 expression in 5 mg P4 treated rat uteri 
 
Bcl-2 expression in the uteri of the P4 treated tissue was greatest in the luminal 
epithelium, followed by the glandular epithelium and had the least expression in 
the stroma. Although Bcl-2 was dispersed throughout the stroma, it was localised 
more intensely around the luminal epithelium. The expression of Bcl-2 in the P4 
treated animals was similar to that seen in the control animals. Fig. 3.3.2.7. shows 
a typical micrograph of Bcl-2 in P4 treated rat uterus tissue. 
 
Unlike the untreated and placebo controls, as well as the CC treated tissue, Bcl-2 
in the P4 treated uterine luminal epithelium was usually concentrated in the nuclei 
(Figs 3.3.2.2, 3.3.2.5 and 3.3.2.8.). The nucleus had a greater concentration than 
the cytoplasm and the nuclear membrane was dark. Bcl-2 in the cytoplasm 
concentrated to the apex of the cells (Fig. 3.3.2.8.). 
 
The nuclei in the uterine glands expressed Bcl-2 at a more concentrated, or 
equivalent level, to the cytoplasm (Fig. 3.3.2.9.). The glandular tissue did not 
appear bubbly, as was the case with the control tissues. The nuclei in P4 treated rat 
uteri were granular and frothy, and a distinct nuclear membrane was observed. 
The glandular contents also localised Bcl-2 strongly (Fig. 3.3.2.9.). 
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Figure 3.3.2.7.  
IHC of Bcl-2 in a 5 mg P4 
treated rat uterus 
Expression of Bcl-2 in P4 
treated animals was greatest in 
the luminal epithelium, 
followed by the glands and 
least in the stroma.  
Figure 3.3.2.8.  
Expression of Bcl-2 in the 
luminal epithelium of a P4 
treated animal 
In the luminal epithelial cells, 
Bcl-2 expression was 
concentrated in the nuclear 
membranes and the apex of the 
epithelial cells. The nuclei had 
a greater expression of Bcl-2 
than the cytoplasm.  
Figure 3.3.2.9.  
Expression of Bcl-2 in the 
glandular tissue of a P4 
treated animal 
Expression of Bcl-2 in the 
glandular epithelium was 
greatest at the nuclear 
membranes. The nuclei had a 
greater or similar expression of 
Bcl-2 compared to the 
cytoplasm.   
10μm 
10μm 
100μm 
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3.3.2.4. Bcl­2 expression in SPPPE treated rat uteri  
 
Unlike the controls, Bcl-2 expression in SPPPE treated tissue was greatest in the 
stromal tissue, followed by expression in the luminal epithelium, which was 
similar to the glands. Bcl-2 expression in the stroma concentrated around the 
luminal epithelium, and decreased in intensity to beyond the glands. Localisation 
did not appear to occur in the tissue immediately surrounding the glands. Fig. 
3.3.2.10. shows the expression of Bcl-2 in the uterine profile of an SPPPE treated 
animal.  
 
Bcl-2 expression in the luminal epithelium of the SPPPE treated tissue was 
concentrated in two “layers”, the first layer was at the apex of the epithelial cells, 
and the second at the basal portion of the cells. The middle section of the luminal 
epithelium was far paler. This gave the epithelium a sandwich-like appearance. 
The basement membrane below the epithelium did not express Bcl-2. 
 
In the uterine luminal epithelium, the nuclei localised Bcl-2 slightly more than the 
cytoplasm, and there was a greater concentration of Bcl-2 along the nuclear 
membrane. Fig. 3.3.2.11. shows a micrograph of Bcl-2 expression in the luminal 
epithelium of an SPPPE treated animal. 
 
The glandular epithelium of SPPPE treated tissue had similar expression of Bcl-2 
in the nuclei and cytoplasm, and both cellular components had a frothy 
appearance (Fig. 3.3.2.12.). The nuclear membranes in the glandular cells were 
not always distinct. Occasionally there was a concentration of Bcl-2 toward the 
apex of the glandular cells.  
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Figure 3.3.2.10.   
IHC of Bcl-2 in an SPPPE 
treated rat uterus 
Expression of Bcl-2 in SPPPE 
treated animals was greatest in 
the dark layer of stroma, and 
the luminal epithelium was 
darker or similar in intensity to 
the glands. 
Figure 3.3.2.11.  
Expression of Bcl-2 in the 
luminal epithelium of an 
SPPPE treated animal 
Bcl-2 expression was greatest 
at the nuclear membranes, and 
expression in the nuclei was 
similar or greater than the 
expression in the cytoplasm. 
Expression of Bcl-2 in the 
cytoplasm was concentrated 
towards both the apex and base 
of the cells. 
 
Figure 3.3.2.12.  
Expression of Bcl-2 in the 
glandular tissue of an SPPPE 
treated animal 
Bcl-2 expression in the 
glandular cells was similar 
between the nuclei and 
cytoplasm. The nuclear 
membranes were not always 
distinct and the glandular 
epithelium appeared frothy. 
There was a slight 
concentration of Bcl-2 
expression at the apex of the 
glandular cells.  
10μm 
10μm 
100μm 
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3.3.2.5. Bcl­2 expression in CCPPPE treated rat uteri  
 
Expression of Bcl-2 in the CCPPPE treated rat tissue was greatest in the luminal 
epithelium, followed by the glands, followed by the stromal tissue. Bcl-2 was 
dispersed in the stroma, and was sometimes more concentrated around the luminal 
epithelium. Fig. 3.3.2.13. shows Bcl-2 expression in a CCPPPE treated rat uterus. 
This was more comparable to the expression in the SOOO control than to the 
SPPPE treated tissue. Patchiness of expression was evident at the lumen, but it 
was not as obvious as in the single CC treatment (Figs 3.3.2.5. and 3.3.2.13.). 
 
The luminal epithelium of CCPPPE treated tissue generally had a greater 
expression of Bax in the cytoplasm than in the nuclei of the epithelial cells (Fig. 
3.3.2.14.). The cytoplasm had a frothy appearance and Bcl-2 expression was 
concentrated towards the luminal aspect of the cells. Some of the nuclei showed 
localisation of Bcl-2, whereas others did not. Bcl-2 was concentrated along the 
nuclear membranes. 
 
The glands appeared bubbly when localised with Bcl-2. The cytoplasm of 
glandular cells generally had a greater expression of Bcl-2 compared to the nuclei, 
and both had a frothy appearance (Fig. 3.3.2.15.). The nuclei were generally pale 
or unstained, with dark nuclear membranes. Bcl-2 in the cytoplasm was 
concentrated in the apex of the glandular cells. 
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Figure 3.3.2.13.  
IHC of Bcl-2 in a CCPPPE 
treated rat uterus 
Expression of Bcl-2 was 
greatest in the luminal 
epithelium, followed by the 
glands and least in the stroma. 
Patchiness was evident in the 
luminal epithelium of CCPPPE 
treated animals, although not to 
the same extent as in the single 
CC treated animals. 
Figure 3.3.2.14.  
Expression of Bcl-2 in the 
luminal epithelium of a 
CCPPPE treated animal 
In the luminal epithelial cells, 
Bcl-2 expression was greater in 
the cytoplasm than the nuclei, 
and there were obvious nuclear 
membranes. The cytoplasm had 
a concentration of Bcl-2 
towards the apex of the cells.  
Figure 3.3.2.15.  
Expression of Bcl-2 in the 
glandular tissue of a 
CCPPPE treated animal 
Bcl-2 expression in the 
CCPPPE treated animals was 
greater in the cytoplasm than 
the nucleus, with an 
aggregation towards the lumen 
of the glands. The nuclear 
membranes were distinct. The 
glandular cells had a foamy 
appearance in both the 
cytoplasm and nucleus.   
10μm 
10μm 
100μm 
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3.3.2.6. Summary of IHC against Bcl­2 in rat uteri 
 
The most striking feature of the uteri treated against Bcl-2 was the patchy 
expression of Bcl-2 in the uterine luminal epithelium of the single CC treated, and 
to a lesser extent in the CCPPPE treated tissues. The patchiness was absent from 
the other treatments and controls. 
 
The expression of Bcl-2 in the controls, single CC, P4 and CCPPPE treated tissues 
was greatest in the luminal epithelium, followed by the glandular epithelium and 
lowest in the stroma. The SPPPE tissue had the greatest expression of Bcl-2 in the 
stroma, followed by the luminal epithelium which was greater or similar in 
expression to the glandular epithelium. 
 
The control tissues had pale stroma when treated against Bcl-2 and the Bcl-2 
expression was concentrated around the dark layer of the lumen, if at all. The 
single CC, P4 and CCPPPE treated tissues had Bcl-2 expression distributed 
throughout the stromal tissue with some concentration at the dark layer. Bcl-2 
expression in the stroma of SPPPE treated tissues extended to the glandular 
epithelium. 
 
Bcl-2 expression in the control tissues was greatest at the nuclear membranes, 
followed by the cytoplasm which had greater or similar expression to the nuclei. 
The CC and CCPPPE tissues were similar to the controls, although these 
treatments had a greater expression of Bcl-2 in the cytoplasm than in the nuclei. 
The P4 and SPPPE treated tissues had the greatest expression at the nuclear 
membranes, followed by the nuclei which were greater or similar to the 
expression in the cytoplasm. All treatment groups had a concentration of Bcl-2 
towards the apex of the luminal epithelial cells, although SPPPE treatment also 
had a concentration of Bcl-2 toward the base of the cells. 
 
In the glandular epithelium, the controls, P4 and SPPPE treated tissues had some 
expression of Bcl-2 at the nuclear membranes, and the nuclei had a greater or 
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similar expression of Bcl-2 than the cytoplasm. The CCPPPE had a greater 
expression of Bcl-2 in the cytoplasm than in the nuclei. The nuclei of the single 
CC treated animals showed more expression of Bcl-2 than the cytoplasm in some 
sections, and less expression in other sections, although generally both the nuclei 
and the cytoplasm were pale.  The glandular tissue of all of the treatment groups, 
except for the P4 treated animals, appeared frothy. 
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3.3.3. IHC against Bax (Bcl­2 – associated X protein) 
 
3.3.3.1 Bax expression in ovariectomised, control or placebo 
untreated rat uteri 
 
The results for the immunohistochemistry against Bax in the ovariectomised 
untreated, saline treated, oil treated and SOOO treated control animals were 
similar and have been presented together.  
 
The uterine profiles of the control or placebo treated tissue generally had a greater 
or similar concentration of Bax expression in the uterine luminal epithelium 
compared to the concentration of Bax in the glands, as seen by the intensity of 
chromagen deposition in these regions. This was similar to the expression of 
Bcl-2 in the untreated rat uterus, which also had the greatest expression of Bcl-2 
in the luminal epithelium, followed by the glandular epithelium and lowest 
expression of Bcl-2 in the stroma (Fig. 3.3.2.1.). Expression of Bax was greater in 
both the epithelium and the glands than in the stroma. Bax expression in the 
stroma was most apparent in the dark layer surrounding the uterine lumen. 
Fig.. 3.3.3.1. shows a low power micrograph of Bax expression in a saline treated 
uterus, which is typical of the control tissues. By contrast, Bcl-2 was lightly 
dispersed throughout the stromal tissue and was not concentrated in the dark layer 
surrounding the lumen.   
 
The distribution of Bax in the control tissues was localised in the nucleus with a 
concentration towards the nuclear membrane in both the uterine luminal 
epithelium and the glandular epithelium. In the cytoplasm, Bax expression was 
concentrated towards the apex of the cells, showing an edge effect. Fig. 3.3.3.2. 
shows a typical micrograph of the luminal epithelium of the control tissues and 
Fig. 3.3.3.3. shows a typical micrograph of the glandular epithelium. 
  
The glandular epithelium had greater expression of Bax in the nuclei than in the 
cytoplasm of the ovariectomised untreated and saline treated animals (Fig. 
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3.3.3.3.), whereas the oil treated and SOOO treated animals had similar 
expression of Bax in both the nucleus and cytoplasm, giving the glandular 
epithelium a frothy appearance (not shown). 
 
 
 
Figure 3.3.3.1.  
IHC of Bax in a saline treated 
rat uterus 
Generally, in control tissues, 
Bax had the greatest expression 
in the luminal epithelium, 
followed by the glands and the 
least expression in the stroma. 
Bax in the stroma was localised 
in a dark layer close to the 
lumen. There was very little 
expression of Bax in the 
myometrium. 
Figure 3.3.3.2.  
Expression of Bax in the 
luminal epithelium of an 
ovariectomised control 
animal 
The Bax was localised in the 
nucleus of the luminal 
epithelium, with a 
concentration at the nuclear 
membrane. In the cytoplasm, 
the Bax was concentrated 
towards the apex of the cells.  
Figure 3.3.3.3.  
Expression of Bax in the 
ovariectomised control 
animal 
Bax was more concentrated in 
the nucleus than the cytoplasm, 
particularly in the nuclear 
membranes.  
In the cytoplasm, Bax was 
more concentrated towards the 
apex of the cells. 
10μm 
10μm 
100μm 
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3.3.3.2. Bax expression in 1.25 mg CC treated animals 
 
Expression of Bax in the uteri of CC treated animals was similar in the luminal 
epithelium and the glandular epithelium. Both types of epithelia were darker than 
the stroma. In the stroma, Bax was expressed closer to the lumen of the uterus, but 
extended in tendrils to the glandular epithelium. There was a noticeable 
expression of Bax in the myometrium, especially when compared to the control 
animals. This can be seen in Fig. 3.3.3.4. Localisation of Bax was more distinct in 
CC treated animals when compared to the control animals (ovariectomised, saline 
treated and oil treated). However, in comparison with the control sections, the 
luminal epithelium and the glandular tissue was generally far paler, indicative of a 
lower expression of Bax. 
 
Expression of Bax in the luminal epithelium was patchy (Figs. 3.3.3.4 and 
3.3.3.5.). The nucleus in the luminal epithelium appeared granular or frothy when 
treated against Bax antibody, with a concentration towards the nuclear membrane 
(Fig. 3.3.3.5.). The cytoplasm also appeared frothy, and was concentrated toward 
the apex of the cell. Bax expression was greater in the nucleus than the cytoplasm 
(Fig. 3.3.3.5.). The patchiness evident in these sections was less pronounced than 
the sections treated for Bcl-2 expression (Fig. 3.3.2.4.). Bcl-2 expression in the 
stroma was dispersed, but sometimes had a higher concentration surrounding the 
lumen. Expression of Bax, by contrast, extended about halfway into the 
endometrium (Figs 3.3.2.4. and 3.3.3.4.). 
 
In the glands, Bax expression seemed concentrated in some nuclei, while other 
nuclei had a lower expression of Bax. The cytoplasm generally had a frothy 
appearance and localised toward the lumen of the glands (Fig. 3.3.3.6.). 
Generally, this edge seemed equivalent in expression to that of the nuclear 
membrane. In the glandular tissue, Bax was most highly expressed in the 
cytoplasmic edge and nuclear membranes, followed by the cytoplasm, and least 
expressed in the nucleus (Fig. 3.3.3.6.). By contrast, the control tissues had greater 
expression in the nuclei than in the cytoplasm (section 3.3.1.1.).  
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Figure 3.3.3.4.  
IHC of Bax in a 1.25 mg CC 
treated rat uterus 
The expression of Bax in CC 
treated sections was similar in 
the luminal epithelium and 
glands, and lower in the 
stroma. Bax expression in the 
stroma extended from the 
lumen to the glandular tissue 
(indicated by the arrows).  
There was a noticeable 
expression of Bax in the 
myometrium. 
Figure 3.3.3.5.  
Expression of Bax in the 
luminal epithelium of a CC 
treated animal 
Expression of Bax appeared 
patchy in the luminal 
epithelium.  
Bax was concentrated in the 
nuclear membrane as well as 
the apical edge of the luminal 
epithelium.  
The stromal nuclei surrounding 
the luminal epithelium were 
darkly stained and numerous. 
Figure 3.3.3.6.  
Expression of Bax in the 
glandular tissue of a CC 
treated animal 
Bax was most concentrated in 
the nuclear membranes, and 
had a bubbly appearance in the 
glandular tissue. The stromal 
cells surrounding the glands 
show expression of Bax. An 
apoptotic cell (ApC) showed 
Bax concentrated in the 
nucleus. 
10μm 
10μm 
ApC
100μm 
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3.3.3.3. Bax in 5 mg P4 treated animals 
 
Expression of Bax in P4 treated animals was greatest in the glandular epithelium, 
followed by the uterine luminal epithelium and least in the stroma. This was 
different to the control tissues, which had the greatest expression of Bax in the 
luminal epithelia. The P4 treated animals did not appear to have localisation of 
Bax in the myometrium. Bax in the stroma was expressed approximately 4-5 
layers deep in the dark layer surrounding the lumen. Fig. 3.3.3.7. shows a typical 
uterus immunolocalised against Bax. 
 
Some nuclei in the luminal epithelium expressed high levels of Bax, whereas 
other nuclei had a lower expression of Bax. Bax was most concentrated in the 
nuclear membranes. Bax was localised in the apex of the luminal epithelium and 
this expression of Bax was similar to the nuclear membranes (Fig. 3.3.3.8.).  
 
In the glands, Bax was expressed intermittently with a granular appearance and 
concentrated towards the nuclear membrane. The cytoplasm appeared frothy and 
Bax was concentrated toward the apex of the cell. Generally, expression of Bax 
was greater in the cytoplasm than the nuclei. Many glandular nuclei of P4 treated 
animals did not express Bax (Fig. 3.3.3.9.). 
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Figure 3.3.3.7.  
IHC of Bax in a 5 mg P4 
treated rat uterus 
Expression of Bax in P4 treated 
animals was greatest in the 
glands, followed by the luminal 
epithelium and least in the 
stroma. Expression in the 
stroma occurred in 4-5 layers 
around the uterine lumen.   
Figure 3.3.3.8. 
Expression of Bax in the 
luminal epithelium of a P4 
treated animal 
In the luminal epithelial cells, 
Bax was concentrated in the 
nuclear membranes and the 
apex of the epithelial cells. The 
cytoplasm had a greater or 
similar expression of Bax 
compared to the nuclear 
contents.  
Figure 3.3.3.9.  
Expression of Bax in the 
glandular tissue of a P4 
treated animal 
Expression of Bax in the 
glands was greatest at the 
nuclear membranes and the 
luminal edge of the glandular 
cells. The nuclei did not always 
express Bax.  
The glandular cells had a 
foamy appearance after 
immunolocalisation with Bax.  
10μm 
10μm 
100μm 
 102
3.3.3.4. Bax in SPPPE treated animals 
 
Expression of Bax in SPPPE treated animals was greatest in the stroma, followed 
by the luminal epithelium, which was slightly darker than the glands.  Expression 
in the stroma extended halfway into the uterus, extending into the stroma beyond 
some of the glands. The area of stroma immediately surrounding the glands did 
not have a strong reaction to the Bax. Fig. 3.3.3.10. shows a typical micrograph of 
Bax  expression in an SPPPE treated uterus. The SPPPE tissue was different to the 
control tissue, as the control tissue had the greatest expression of Bax in the 
luminal epithelium and the least in the stroma. 
 
At a superficial level, the expression of Bcl-2 and Bax mimic each other with 
strong immunolocalisation of both proteins in the stroma and less in the luminal 
epithelium and glands (figures 3.3.2.10 and 3.3.3.10.). However, these similarities 
diminish when details of the glands and the luminal epithelium were examined. 
 
Bax expression in the uterine luminal epithelium was prominent in the nuclei with 
a concentration at the nuclear membranes. Bax expression in the cytoplasm was 
concentrated toward the apex of the cell. The luminal epithelium nuclei were 
darker than the cytoplasm and the nucleus appeared more granular, while the 
cytoplasm appeared smoother. There did not appear to be a cytoplasmic 
concentration of Bax toward the lumen. Fig. 3.3.3.11. shows Bax in the luminal 
epithelium of an SPPPE treated animal. 
 
Bax expression in the glands appeared uneven. The cytoplasm had a greater 
expression of Bax than the nuclei in the glands, and the nuclear membranes were 
clearly defined. Bax expression in the cytoplasm was not concentrated at the apex 
of the glandular epithelium (Fig. 3.3.3.12.).     
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Figure 3.3.3.10.  
IHC of Bax in an SPPPE 
treated rat uterus 
Expression of Bax in SPPPE 
treated animals was greatest in 
the dark layer of stroma, and 
equivalent in the uterine 
luminal epithelium and the 
glands. 
Figure 3.3.3.11. 
Expression of Bax in the 
luminal epithelium of an 
SPPPE treated animal 
Bax was expressed mainly in 
the nuclei of the luminal 
epithelium, particularly at the 
nuclear membranes, with less 
expression in the cytoplasm. 
The nuclei appeared smooth 
and the cytoplasm appeared 
granular. 
 
Figure 3.3.3.12. 
Expression of Bax in the 
glandular tissue of an SPPPE 
treated animal 
Bax expression in the SPPPE 
treated animals gave the glands 
a frothy appearance. 
Expression seemed to be 
greater in the cytoplasm than in 
the nuclei, although Bax 
localised in the nuclear 
membranes. Bax in the 
cytoplasm did not seem to 
especially localise at the 
glandular lumen.  
10μm 
10μm 
100μm 
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3.3.3.5. Bax in CCPPPE treated animals 
 
In CCPPPE treated animals, Bax expression was generally most concentrated in 
the stroma, followed by the luminal epithelium, which was similar to the glands. 
The Bax expressed in the stroma was concentrated  around the lumen, but 
extended to the glands, especially those closer to the lumen (approximately two 
thirds of the stroma immunolocalised against Bax) (Fig. 3.3.3.13.). This 
expression of Bax was similar to that seen in the SPPPE treated animals, although 
the CCPPPE treated animals had a greater intensity of chromagen in the uterine 
luminal epithelium and glandular tissue (Figs 3.3.3.10. and 3.3.3.13.). 
 
Some of the nuclei in the luminal epithelium immunolocalised against Bax and 
some did not, but they all had a dark nuclear membrane (Fig. 3.3.3.14.). The 
luminal epithelial cytoplasm was sometimes darker, and sometimes lighter when 
compared with the nucleus, and there was some expression of Bax towards the 
apex of the epithelial cells (Fig. 3.3.3.14.).    
 
Bax expression in the glandular tissue was more concentrated in the cytoplasm 
than in the nuclei, and the nucleus had a darker nuclear membrane. The cytoplasm 
seemed to concentrate to the apical end of the glandular cells.  Both the nucleus 
and the cytoplasm had a frothy appearance. This can be seen in Fig. 3.3.3.15. 
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Figure 3.3.3.13. 
IHC of Bax in a CCPPPE 
treated rat uterus 
Expression of Bax in CCPPPE 
treated sections was greatest in 
the stroma, followed by the 
luminal epithelium and least in 
the glandular epithelium.   
Figure 3.3.3.14.  
Expression of Bax in the 
luminal epithelium of an 
CCPPPE treated animal 
In the uterine luminal epithelial 
cells, Bax was obvious at the 
nuclear membranes. The nuclei 
were sometimes darker and 
sometimes lighter than 
cytoplasm. The cytoplasm had 
a concentration of Bax towards 
the apex of the cells.  
Figure 3.3.3.15.  
Expression of Bax in the 
glandular tissue of a 
CCPPPE treated animal 
Expression of Bax in the 
glands was greater in the 
cytoplasm than the nucleus, 
with an aggregation towards 
the lumen of the glands. The 
nuclear membranes were 
distinct. The glandular cells 
had a foamy appearance in 
both the cytoplasm and 
nucleus.   
10μm 
10μm 
100μm 
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3.3.3.6. Summary of IHC against Bax in rat uteri 
 
Bax expression in the uterine profiles of the control tissues was greatest at the 
uterine luminal epithelium, which was similar to the glandular epithelium, and the 
least expression in the stroma. The single CC treated animal had a similar 
expression of Bax, with the glandular epithelium and luminal epithelium having 
similar concentrations, and the stroma having a lower expression of Bax. Notably, 
the single CC treated tissue had Bax expression in the myometrium. Expression of 
Bax in the P4 treated animals was greatest in the glands, followed by the luminal 
epithelium and lowest in the stroma. By contrast, both the SPPPE and CCPPPE 
treated tissues had the greatest expression of Bax in the stroma, followed by the 
luminal epithelium which was greater or similar in expression of Bax to the 
glandular epithelium. 
 
Bax expression in the stroma of the control tissues and P4 treated tissues was 
mainly concentrated in the dark layer surrounding the lumen, whereas the single 
CC, SPPPE and CCPPPE treated animals had expression of Bax extending to the 
glandular epithelium. 
 
The luminal epithelium expressed the greatest concentration of Bax at the nuclear 
membranes, followed by the nuclei and least in the cytoplasm for the control 
tissues, single CC, P4 and SPPPE treated tissues. The CCPPPE tissue had the 
greatest expression of Bax in the nuclear membranes, followed by the cytoplasm 
which was greater or similar in expression to the nuclei. All of the treatments, 
except for the SPPPE treated animals, had a concentration of Bax towards the 
apex of the cells. The single CC treated animals had a patchy expression of Bax at 
the luminal epithelium. 
 
Bax expression in the glandular epithelium of the control tissues was greatest in 
the nuclear membranes, followed by the nuclei which was greater (ovariectomised 
untreated or saline treated) or similar (oil treated and SOOO treated) to the 
cytoplasm. The single CC, P4, SPPPE and CCPPE treatments had the greatest 
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expression of Bax at the nuclear membranes, followed by the cytoplasm and least 
in the nuclei. Bax expression was localised in the apex of the glandular cells for 
all of the treatments except for the SPPPE treatment, and the localisation in the 
apex was particularly noticeable in the single CC treated animals. The oil, SOOO, 
single CC and CCPPPE treated tissues appeared frothy after localisation with Bax 
antibody. 
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3.3.4. Overview of IHC in rat uterine compartments  
 
Table 3.3.1. Summary of expression of antibody in rat uterine structures.  
 
The table shows a comparison between treatment groups against antibody.  
The uterine profile indicates the relative levels of expression of antibody in the 
uterine luminal epithelium (LE), glandular epithelium (GE) or stroma (S). 
Concentration of expression in the stroma has been indicated, showing expression 
predominantly in the dark layer (dl), to the glandular epithelium or extending to 
the myometrium.   
Both the uterine luminal and glandular epithelium show the relative expression of 
the antibodies at the nuclear membranes (nmb), nuclei (n) and cytoplasm (c). The 
expression of the antibodies towards the apex of the epithelial cells has also been 
indicated.  
 
Expression has beeen indicated as greater than (>), greater or equal to (≥), equal to 
(=) or in some cases expression was found to be greater in a structure in one 
section, and the same structure was found to have less expression in a different 
section, which has been assigned the symbol “≅”. 
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Treatment Uterine Profile Stroma Luminal Epithelium Glandular Epithelium Other 
     C. to apex  C. to apex  
Ovex PR LE > S > GE Some dl nmb > n  None nmb = n  No apex  
 Bcl-2 LE > GE > S Some dl nmb > n = c To apex nmb > n = c No apex  
 Bax LE ≥ GE > S Around dl nmb > n > c To apex nmb > n > c To apex  
Saline PR LE > S > GE Around dl nmb > n  None nmb ≥ n  No apex  
 Bcl-2 LE > GE > S Some dl nmb > n = c To apex nmb > n = c Some apex  
 Bax LE ≥ GE > S Around dl nmb > n > c To apex nmb > n > c To apex  
Oil PR LE > S > GE Around dl nmb > n > c To apex nmb > n > c  To apex  
 Bcl-2 LE > GE > S Some dl nmb > n = c To apex nmb > n = c Some apex  
 Bax LE ≥ GE > S Around dl nmb > n ≥ c To apex nmb > n > c To apex; Foamy 
appearance 
 
SOOO PR LE > S > GE Around dl nmb > n > c To apex nmb > n = c  To apex  
 Bcl-2 LE > GE > S Some dl nmb > n = c To apex nmb > n = c Some apex  
 Bax LE ≥ GE > S Around dl nmb > n > c To apex nmb > n > c To apex; Foamy 
appearance 
 
CC PR S > LE > GE To glands nmb > n > c To apex nmb > n > c  To apex  
 Bcl-2 LE > GE > S Some dl nmb > c > n To apex nmb > n = c Some apex LE patchy 
 Bax LE = GE > S To glands nmb > n > c To apex nmb = apex 
> c > n 
To apex; Foamy 
appearance 
LE patchy 
Myometrium stained 
P4 PR LE ≥ GE > S Around dl n ≥ c  n = c  To apex  
 Bcl-2 LE > GE > S Around dl nmb > n = c To apex nmb > n = c Some apex  
 Bax GE > LE >S Around dl nmb > c ≥ n To apex nmb > c > n To apex  
SPPPE PR S > LE > GE To glands nmb > n ≥ c To apex nmb > n ≅ c  Some apex  
 Bcl-2 S > LE ≥ GE To glands nmb > n ≥ c To apex and base nmb > n = c Some apex  
 Bax S > LE ≥ GE   To glands nmb > n > c Not to apex nmb > c > n Not to apex  
CCPPPE PR S > LE > GE To myometrium nmb > n > c To apex nmb > n > c  To apex  
 Bcl-2 LE > GE > S Some dl nmb > c > n  To apex nmb > c > n  To apex  
 Bax S > LE = GE   To glands nmb > c ≅ n To apex nmb > c > n To apex  
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3.4.   Enzyme linked immunosorbent assay (ELISA)  
 
3.4.1. Overview of the ELISA analysis  
 
Two technical replicates were analysed per animal and the controls omitting 
primary antibody, secondary antibody and protein homogenate have been 
included. ELISA was performed against PR, Bcl-2 and Bax. The data have been 
presented as medians with the upper (75%) and lower (25%) quartiles. 
Significance was set at the 5% significance level using the Wilcoxon / Kruskal 
Wallis rank sums tests. 
Significant differences were found between the samples for the ELISA against 
Bax, which was further tested using Tukey-Kramer post hoc analysis. 
The results are presented in tables 3.4.1.1 to 3.4.3.3. 
 
Table 3.4.1.1. Results of the χ2 approximation of the ELISA data using the 
Wilcoxon / Kruskal-Wallis rank sums test 
Two technical replicates were taken per animal and tested using the Wilcoxon / 
Kruskal Wallis ranks sums at the 5% level of significance. For probability less 
than 0.05, the chi-squared approximation was used. Results that were significantly 
different have been indicated in bold type.  
 
 Parameter χ2 Approximation 
P> χ2 
1 ELISA against PR 0.1534 
2 ELISA against Bcl-2 0.098 
3 ELISA against Bax <0.001 
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3.4.2. Results of the Tukey­Kramer post hoc analysis for the parameter 
that was significantly different  
 
3.4.2.1. Tukey­Kramer post hoc analysis of ELISA against Bax 
 
The treatment groups were not significantly different to each other, or to the 
controls that omitted primary antibody or omitted protein, but all of the treatment 
groups were different to the control that omitted secondary antibody.  
 
Table 3.4.2.1 Comparisons for all pairs using Tukey-Kramer post hoc 
analysis of ELISA against Bax  
Levels that were not connected by the same letter are significantly different. 
 
Treatment Level 
CCPPPE A  
SPPPE A  
Oil A  
P4 A  
CC A  
Untreated A  
SOOO A  
Saline A B 
Omit primary antibody (anti-Bcl-2) A B 
Omit protein A B 
Omit secondary antibody (anti-rabbit)  B 
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3.4.3. Medians and interquartiles of ELISA results  
 
3.4.3.1. Median and interquartiles of ELISA against PR 
 
Table 3.4.3.1. shows the median and interquartiles of the treatment groups against 
PR. These show that the CCPPPE treatment results in the greatest expression of 
Bcl-2, followed by the oil control and P4 and then SPPPE treatment. However, 
these results were not significantly different to each other at the 5% level.  
 
Table 3.4.3.1. The median and interquartiles for ELISA against PR by 
treatment.  
25Q refers to the 25th interquartile, 75Q refers to the 75th interquartile. 
Measurements were taken as absorbance at 450 nm per 1 μg protein sample. 
Treatment Median 25Q 75Q 
Untreated 0.1055 -0.0994 0.5710
Saline -0.0038 -0.0516 0.2530
Oil  0.0058 -0.0294 0.4790
CC 0.0233 -0.0079 0.4102
P4 0.1262 -0.0236 0.4948
SOOO 0.1815 -0.0362 0.3597
SPPPE 0.1322 0.0992 0.5202
CCPPPE 0.2607 0.0580 0.5489
Omit protein -0.0004 -0.0008 -0.0001
Omit anti-PR 0.2004 0.0769 0.3239
Omit anti-rabbit -0.1716 -0.2647 -0.0785
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3.4.3.2. Median and interquartiles of ELISA against Bcl­2  
 
Table 3.4.3.2. shows the median and interquartiles of the treatment groups against 
Bcl-2. These show that the CCPPPE treatment results in the greatest expression of 
Bcl-2, followed by P4 and SPPPE, and then the untreated and oil controls. 
However, these results were not significantly different to each other at the 5% 
level.  
 
Table 3.4.3.2. The median and interquartiles for ELISA against Bcl-2 by 
treatment.  
25Q refers to the 25th interquartile, 75Q refers to the 75th interquartile. 
Measurements were taken as absorbance at 450 nm per 1 μg protein sample. 
Treatment Median 25Q 75Q 
Untreated 0.2206 -0.0035 0.6499
Saline 0.0048 -0.0533 0.3185
Oil  0.2140 0.0238 0.6623
CC 0.0629 -0.0095 0.4468
P4 0.2428 0.1077 0.6863
SOOO 0.1123 0.0000 0.4035
SPPPE 0.2365 0.1155 0.3777
CCPPPE 0.2771 0.1234 0.3877
Omit protein -0.0001 -0.0002 0.0001
Omit anti-Bcl-2 0.4187 0.1616 0.6759
Omit anti-mouse -0.1410 -0.3089 0.0270
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3.4.3.3. Median and interquartiles of ELISA against Bax  
 
Table 3.4.3.3. shows the median and interquartiles of the treatment groups against 
Bax. These show that the CCPPPE treatment results in the greatest expression of 
Bax, followed by the oil control and P4, then SPPPE, and the single CC treatment. 
However, these results were not significantly different to each other at the 5% 
level.  
 
Table 3.4.3.3. The median and interquartiles for ELISA against Bax by 
treatment.  
25Q refers to the 25th interquartile, 75Q refers to the 75th interquartile. 
Measurements were taken as absorbance at 450 nm per 1 μg protein sample. 
Treatment Median 25Q 75Q 
Untreated 0.0458 -0.0385 0.5805
Saline -0.0025 -0.0902 0.3482
Oil  0.2792 0.0001 0.6462
CC 0.0673 0.0120 0.6700
P4 0.2590 0.0261 0.5263
SOOO 0.0970 -0.0110 0.4861
SPPPE 0.1990 0.1324 0.6713
CCPPPE 0.3213 0.1344 0.6834
Omit protein 0.0003 -0.0040 0.0042
Omit anti-Bax 0.0508 -0.0137 0.0746
Omit anti-rabbit -0.3394 -0.4227 -0.2092
 
 
3.4.4. Summary of the ELISA analysis  
 
Generally, the results for the ELISA against PR, Bcl-2 and Bax did not show any 
significant differences between the different treatment groups or the controls. The 
immunohistochemical results against PR, Bcl-2 and Bax showed marked 
differences between the various uterine compartments. Retrospectively, it would 
have been ideal to isolate the uterine luminal epithelium, glandular epithelium, 
stromal tissue and myometrium and perform ELISA against the uterine 
compartments. 
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CHAPTER 4. DISCUSSION 
 
4.1. Histological and morphometric differences between 
ovariectomised animals treated with CC, P4, SOOO, 
CCPPPE or the vehicle control 
 
There is a brief period during the reproductive cycle when a uterus is receptive to 
a functional blastocyst, known as the window of implantation, and is controlled by 
the ovarian hormones, E2 and P4 (Wang and Dey, 2006). Progesterone binding to 
its receptor affects the downstream events of this process, and the levels of 
progesterone receptors are affected through feedback loops driven by oestrogen 
(Psychoyos, 1967). Clomiphene citrate binds to oestrogen receptors and has both 
oestrogenic and anti-oestrogenic effects on tissues, depending on the tissue and on 
the species (Clark and Markaverich, 1982, Hosie and Murphy, 1995). The binding 
of CC to ERβ acts as an anti-oestrogen (Kurosawa et al., 2010). ERβ has been 
implicated in the decidualisation of the stroma in the rat uterus (Peters et al., 
1995, Tessier et al., 2000), and so the binding of CC with PPPE inhibits the 
decidualisation seen in PPPE treatments via the ERβ receptor. Decidualisation is 
vital to sustain a growing conceptus and animals without a decidual response were 
unable to maintain a viable blastocyst. (Rider et al., 1985) 
 
The aim of this study was to determine some of the effects of a single, high CC 
dose on ovariectomised tissues, and how it compared to a single progesterone 
treatment on ovariectomised tissues. Psychoyos (1973) found that PPPE treatment 
in ovariectomised animals reflected the hormonal regime typical of a pregnant rat, 
and this study also looked at how CC affected PPPE treated animals. 
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4.1.1. Effects of CC, P4, PPPE and CCPPPE on uterine length and breadth 
 
The rat endometrium undergoes a well described plasma membrane 
transformation prior to implantation. The apical membrane of the uterine luminal 
epithelial cells tends to have long, regular microvilli. During early pregnancy, the 
microvilli become flattened and less dense and the membranes of the uterine 
epithelial and trophoblast cells have a flattened area of contact (Murphy and 
Shaw, 1994, Murphy, 2004). This suggests that pregnancy only becomes possible 
with a flattening of microvilli (Murphy, 2004). Moreover, the tight junctions 
between the luminal epithelial cells alter during early pregnancy, with deeper 
lateral tight junctions and disassembly of some focal adhesion molecules under 
the influence of progesterone (Murphy, 2004, Kaneko et al., 2009). Psychoyos 
(1967) found that the hormonal milieu of the oestrus cycle could be replicated in 
ovariectomised rats by a PPPE treatment regime. In this study, the PPPE treated 
animals showed an increase in the long uterine diameter (uterine length) that was 
significantly different to the animals treated with either vehicle controls or a 
single P4 (table 3.1.2.1. and graph 3.1.2.2.). As expected, uterine length is 
probably progesterone dependant requiring multiple doses of progesterone and a 
nidatory oestrogen dose.  
 
The single CC treatment and the CCPPPE treated animals were not significantly 
different to the PPPE treated animals in terms of uterine length, and were not 
different to most of the vehicle controls or to the single P4 treated animals.  
Although the uterine length of the CCPPPE treated animals was not significantly 
different, the CC treatment with PPPE had a reduced uterine length than either 
SPPPE or CC alone, which suggests that the CC dampens the effect of the PPPE 
treatment and may act as an oestrogen antagonist, possibly blocking the nidatory 
oestrogenic effect. 
 
The treatments were not significantly different from each other in terms of the 
short uterine diameter (uterine width). However, they had a greater uterine 
diameter compared to the controls. 
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The single CC treatment animals had a greater uterine width when compared to 
the other treatments (table 3.1.2.2. and graph 3.1.2.2.) and had a distinct 
oestrogenic-like response on uterine width. The parameters of both uterine length 
and uterine width were greater in PPPE treated animals and CCPPPE treated 
animals than the vehicle control animals, and the CC dose tended to decrease the 
length and breadth of the uterus when used in conjunction with PPPE. This effect 
may have been caused by the CC binding to the oestrogen receptors and behaving, 
in this case, as an oestrogen antagonist. Similarly, Brown et al. (1991) found that 
clomiphene blocked oestrogenic-induced increase in uterine weight when both 
oestrogen and clomiphene were administered concurrently over an extended 
period of time. 
 
4.1.2. Effects of CC, P4, PPPE and CCPPPE on the lumen 
 
Lumen length refers to the long luminal diameter as previouslyμ stated in Section 
2.7.1. The results for the lumen length were similar to those of the uterine length 
and width. The CC, SPPPE and CCPPPE treated animals were similar to each 
other and different to the controls in terms of lumen length. The animals treated 
with SPPPE had increased lumen length compared to the controls and single P4, 
but not to the animals treated with a single CC, and the animals treated with 
CCPPPE were similar to the SPPPE treated animals (tables 3.1.1.1., 3.1.2.3. and 
graph 3.1.2.3.). The single CC treatment therefore seemed to affect the luminal 
length similar to that of the PPPE treatment regime animals, and the CC in 
conjunction with the PPPE seems to diminish the luminal length, possibly 
indicating an anti-oestrogenic effect. 
 
The short luminal diameter was not significantly different between the different 
treatment groups, or the controls (table 3.1.1.1.). Morphologically, however, the 
lumens of the control tissues tended to be narrow and straight without tissue 
folding. By contrast the P4 and SPPPE treated animals exhibited occlusion of the 
lumen, which suggests that progesterone promotes the closure of the lumen in a 
normal cycle, and concurs with the results of Ljunkvist (1972). The animals 
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treated with a single CC had a slightly wider lumen than the controls, but not 
significantly so. This would suggest that in terms of lumen occlusion, the CC 
behaves in an oestrogenic manner. The CCPPPE treatment caused extensive 
branching or folding of the lumen (Fig. 3.2.4.), and so increased the surface area 
of the luminal epithelium, possibly diminishing the ability of the implanting 
blastocyst to adhere to the luminal epithelium at the anti-mesometrial pole. 
Similarly, in ovariectomised animals treated with E2 alone, folding of the lumen is 
apparent, suggesting that this folding is oestrogen dependant (Ljungkvist, 1971c, 
Hosie and Murphy, 1992, Hosie and Murphy, 1995). In day 5.5 pregnant animals 
(at the time of implantation), there is tissue folding seen in non-implantation sites, 
whereas implantation sites do not have folding (Scholtz et al., 2008), suggesting 
that a smooth uterine surface may be required for successful implantation. 
 
4.1.3. Effects of CC, P4, PPPE and CCPPPE on the stroma  
 
The stromal width (i.e. stroma perpendicular to the mesometrial/anti-mesometrial 
pole) of the PPPE and CCPPPE treated animals were similar to each other and 
significantly greater than the SOOO control. This result was not unexpected as it 
has been well documented that hyperplasia of the endometrium is under the 
control of the ovarian hormones (Lee and DeMayo, 2004, Paria et al., 2001, 
Wood et al., 2007). The hormones therefore caused an increase in stromal width, 
as previously reported. The stromal width of the CCPPPE treated tissue was 
slightly, although not significantly, lower than the PPPE treated tissue. 
 
A single 1.25 mg CC treatment resulted in significantly greater stromal width than 
the vehicle controls. The CC treatment may act as an oestrogen agonist causing 
cell division in the stromal tissue (Hosie and Murphy, 1992, Hosie and Murphy, 
1995). Implantation in rats occurs at the anti-mesometrial pole (Enders and 
Schlafke, 1967, Abrahamsohn and Zorn, 1993, Tessier et al., 2000), and the 
various treatments did not cause any significant differences of stromal tissue at the 
anti-mesometrial pole (table 3.1.1.1.). The SPPPE treated animals had 
significantly more stromal tissue at the mesometrial pole than the P4 treated 
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animals, although neither treatment group on its own was significantly different to 
the other treatment groups or to the controls. (tables 3.1.1.1. and 3.1.2.5.). The 
CCPPPE treatment, although not significantly different, had less tissue at the 
mesometrial pole than the SPPPE treated tissue. The increase in tissue at the 
mesometrial pole may therefore be inhibited by progesterone, or driven by 
oestrogen, and the CC in conjunction with the PPPE treatment may have an anti-
oestrogenic effect. Expression of PR was lowest in the stroma in animals treated 
with P4 alone, and highest in the stroma of PPPE treated animals (figures 3.3.1.9. 
and 3.3.1.12.).  
 
The dark layer of the control treated tissues extended for 6 to 8 layers beyond the 
lumen and the fibroblasts were triangular or rectangular (Fig. 3.2.1.). The P4 
treated and SPPPE treated animals also had the dark layer extending 6 to 8 layers 
beyond the lumen, but did not extend beyond the glands. The fibroblasts were 
rounded, indicative of decidualisation (Figs 3.2.7. and 3.2.10.). The dark layer of 
the CC and CCPPPE treated animals extended beyond 6 to 8 layers, and was seen 
around the glands (Figs 3.2.4. and 3.2.13.). The fibroblasts were also rounded 
after CC treatment. The decidual reaction does not appear to be diminished by 
CC, but also extended to around the glands. Although not examined in this work, 
it is known that blood supply in the uterus is largely affected by the ovarian 
hormones oestrogen and progesterone. Oestrogens increase blood supply to the 
uterus while progesterone decreases blood supply. To a lesser extent, blood 
supply is also influenced by luteinising hormone, oxytocin, cytokines, 
neurotransmitters and other factors. (Krzymowski and Stefanczyk-Krzymowska, 
2004) 
 
4.1.4. Effects of CC, P4, PPPE and CCPPPE on the luminal epithelium 
 
The single CC, CCPPPE, PPPE and P4 treated animals had a significantly greater 
luminal epithelial height than the vehicle controls (table 3.1.2.6. and graph 
3.1.2.6.). The treatments with CC displayed an epithelium that appeared columnar 
with basal nuclei and obvious long microvilli and the epithelium appeared 
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pseudostratified, suggestive of hyperplasia (Figs 3.2.5. and 3.2.14.). These 
features are usually associated with oestrogen treatment alone (Ljungkvist, 1971c, 
Hosie and Murphy, 1992, Hosie and Murphy, 1995). The PPPE and P4 treatments 
had a single layer of cuboidal epithelium and basally placed nuclei, and correlate 
with the nuclear polarity seen in both rat (Glasser et al., 1988) and human 
(Bentin-Ley et al., 1994) luminal epithelial cells (Figs 3.2.8. and 3.2.11.). 
Interestingly, the CCPPPE had a slightly greater height of epithelial cells than the 
PPPE alone. Oestrogen treatment has been shown to increase the uterine epithelial 
cells from cuboidal to columnar in canine endometria (Ilesanmi et al., 1993), and 
so the CC in this case seemed to have enhanced, rather than diminished, the 
oestrogen agonistic effect in this uterine compartment. The action of progesterone 
contributes to luminal epithelial height, but CC treatment has a far greater effect 
on luminal epithelial height. These features, including the long microvilli, may 
decrease the ability of the blastocyst to implant, possibly by masking the adhesion 
molecules associated with apposition and attachment of the blastocyst (Wang and 
Dey, 2006). The morphology seen in the luminal epithelial height and especially 
the presence of the long microvilli, does not conform to the morphology of the 
plasma membrane transformation. Normally, at the time of implantation, the 
apical surface of the luminal epithelial cells display short or few microvilli and 
may even have pinopods (Murphy, 2004).  
 
4.1.5. Effects of CC, P4, PPPE and CCPPPE on the glandular tissue 
 
In this study, the different treatments did not seem to affect the number of glands 
seen in a section, whether the glands occurred in groups or singly, or how many 
glands opened into the luminal epithelium (table 3.1.1.1.). Hosie and Murphy 
(1992) found that CC treatment resulted in an increase in number of glands 
opening into the uterus. However, these results were obtained using a low 
physiological dose of CC (0.25 mg), whereas the results presented here were at 
the maximal physiological dose of CC (1.25 mg). In humans, the proliferative 
stage (increased oestrogen) is associated with increased nuclear and mitotic 
activity in the glandular tissue, while the secretory stage (high progesterone) is 
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associated with an increase of gland size and increased secretory product 
(Maksem et al., 2007). The control tissues had a concentration of glands at the 
anti-mesometrial pole, as did the P4 treated tissues (Figs 3.2.1. and 3.2.7.). The 
SPPPE treated animals had glands at the anti-mesometrial and mesometrial poles 
(Fig. 3.2.10). The single CC treatment and the CCPPPE treatment had glandular 
tissue at the anti-mesometrial pole as well as dispersed throughout the stroma 
(Figs 3.2.4. and 3.2.13.). This seems to suggest that progesterone, oestrogen and 
CC treatments do not have a noticeable effect on the number of glands seen, but 
the CC and CCPPPE treatments affected the location of the glandular tissues. This 
change in glandular location may also contribute to the low implantation rates 
associated with CC administration. 
 
 
 122
4.2. Immunoassays against PR, Bcl­2 and Bax between 
ovariectomised animals treated with CC, P4, SPPPE, 
CCPPPE or the vehicle control  
 
4.2.1. Expression of PR in the rat endometrium 
 
As mentioned earlier, attachment of the blastocyst to the endometrium occurs 
during a brief window of implantation that is largely controlled by the ovarian 
hormones, oestrogen and progesterone. The action of these hormones is 
modulated by their receptors, ER and PR (Psychoyos, 1969). Progesterone 
receptor expression is mainly controlled by oestrogen and progesterone. Increased 
levels of oestrogen upregulate the levels of PR and increased levels of 
progesterone result in a down regulation of PR expression (Tibbetts et al., 1998; 
Tan et al., 1999, Critchley and Saunders, 2009). Ohna and Fujimoto (1998) found 
that ER, but not PR, levels were lower in clomiphene stimulated cycles in women 
than in normal cycles.  
 
In this study, PR expression in the PPPE, CCPPE and CC treated animals was 
greatest in the stroma followed by the luminal epithelium and least in the 
glandular tissue. In contrast, expression of PR in the P4 treated tissue had the 
greatest expression in the luminal epithelium, followed by the glands and least in 
the stroma. Oestrogen has been reported to decrease PR levels in the uterine 
luminal epithelium and increase levels in the myometrium and stroma (Tibbetts et 
al., 1998, Tan et al., 1999). The results suggest that the CC has an oestrogenic 
effect on PR expression in the uterine compartments and that CCPPPE does not 
inhibit the oestrogen like effect, while P4 has the opposite effect on PR expression 
when compared to E2.  
 
The controls also had the greatest expression of PR in the luminal epithelium, but 
this expression was reduced in the stroma and lowest in the glands suggesting that 
control of PR in the different uterine compartments is not exclusively determined 
by the ovarian hormone levels, but may be affected by other factors. This finding 
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concurs with that of Parczyk and co-workers (1997) who found a 50% decrease in 
PR levels after ovariectomy in hamsters, showing that progesterone and oestrogen 
do not exclusively regulate PR expression. The increased levels of PR in the 
uterine luminal epithelium of ovariectomised animals may be caused by a lack of 
oestrogen or possibly as a result of progesterone depletion or another consequence 
of ovariectomy (Ohta et al., 1993, Parczyk et al., 1997). 
 
Tibbetts et al. (1998) found that PR protein expression in ovariectomised mice 
was intense in the luminal and glandular epithelium, and greatly reduced in the 
stroma and myometrium. This result is reflected in the present study, except that 
control tissue showed low expression in the glandular epithelium.  
 
Expression of PR in CCPPPE treated animals was noticeably extended beyond the 
dark layer, to the limit of the stroma. The P4 treated animals had a concentration 
of PR in the dark cell layer, while CC and SPPPE treatment extended to the 
glandular epithelium. Clomiphene, in conjunction with PPPE, upregulated PR 
expression. As oestrogen upregulates the expression of PR (Critchley and 
Saunders, 2009), the CC, in this case, seems to be acting as an oestrogen agonist, 
by upregulating PR expression on its own and also in conjunction with the PPPE 
treatment. Possibly the initial upregulation of PR by clomiphene is further 
upregulated after the nidatory oestrogen dose in the PPPE treatment.  
 
The expression of PR in the luminal epithelium of CC treated animals was 
apparent along the apical plasma membrane when compared to the single P4 and 
the PPPE treatments, which expressed PR around the nuclear membranes. The 
vehicle control tissue also showed a concentration of PR at the apex of the luminal 
epithelial cells. In the hormone-free state, the expression of PR at the apical 
nuclear membrane is moderate, while the treatment with P4 and PPPE diminishes 
the expression of PR at the apical plasma membrane. However, treatment with CC 
or CCPPPE seems to mimic the hormone-free state, in that PR expression is still 
seen and is more concentrated at the apex of the luminal cells, although PR 
expression is also seen around the nuclear membrane. In the uterine luminal 
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epithelium, CC is in some way inhibiting the movement of the PR from the apical 
membrane and thus possibly preventing the downstream effects of progesterone.  
As PRs are not obvious on the apical surface of the uterine luminal epithelium in 
the PPPE treated tissue, their presence in CCPPPE tissue may in some way 
impede implantation, accounting for the possible low implantation rates seen with 
CC use.  
 
Although PRs have been reported to be present in the implantation sites during 
early pregnancy (Theron, 2010), CC may cause an overexpression of PR in the 
epithelium. This may change the spatial expression of PR such that implantation 
is impaired. 
 
It was noted when viewing the sections treated with CC that the myometrium, and 
particularly, the muscularis externa showed an increased expression of PR. 
Oestrogen has been shown to increase PR levels in the myometrium of 
ovariectomised rats (McCormack and Glasser, 1980) and mice (Tibbetts et al., 
1998, Kurita et al., 2001). Farnell and Ing (2003) showed that the SERMS, 4-OH-
tamoxifen, GW 5638 and EM-800 caused an oestrogenic effect in the outer 
myometrium of ovariectomised ewes. Similarly, the results here show that CC 
caused an oestrogenic agonist effect in the outer myometrium of ovariectomised 
rats.  
 
The expression of PR in the glandular epithelium seems to be unchanged when 
treatment groups are compared to each other, or to the vehicle controls.  
 
Traditionally, the activation of PR has been reported to be induced by oestrogen 
via the oestrogen receptor (ER) (Tan et al., 1999). However, the discovery of the 
two isoforms of ER, i.e. ERα and ERβ have allowed for different possible actions 
of E2 and SERMS on the receptors. Kurosawa et al. (2010) found that CC had 
both an oestrogenic and anti-oestrogenic effect on ERα using 293T cells, whereas 
CC had an anti-oestrogenic effect on ERβ. They postulated that CC may inhibit 
the action of progesterone in the endometrium by the antagonistic effect of CC. 
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Moreover, the work by Ohna and Fujimoto (1998), using sonograms to measure 
endometrial thickness in women, showed that extended CC treatments decreased 
endometrial thickness. This decrease in endometrial thickness had a correlative 
relationship with increased probability of miscarriage. They also found, by 
immunoassay, that CC diminished the numbers of ERs in the endometria in 
women, but did not have a significant effect on PR levels, when compared to 
natural cycles. They postulated that the reduction of oestrogen receptors was more 
important for low pregnancy rates than the decrease in progesterone receptors. 
However, they did not distinguish the expression of the receptors in the different 
uterine compartments and so did not comment on expression in compartments as a 
possibility for low implantation rates. 
 
Published literature shows that CC does not significantly diminish the levels of 
PR in the endometrium (Fritz et al., 1991, Ohno and Fujimoto, 1998, Palomino et 
al., 2005). The results of the ELISA performed concur with these results. 
However, the immunohistochemical analysis of PR expression patently showed 
that treatment with the steroid hormones affected expression in the various uterine 
compartments. Had these compartments been separated, the effects may have 
been better elucidated. 
 
The knockout PRKO (-/-) mice did not show PR expression in the decidual areas 
during early pregnancy (Lydon et al., 1995). Furthermore, the decidual response 
in ovariectomised animals is absent, which is probably caused by the lack of 
circulating progesterone. Therefore, the absence of binding between progesterone 
and PR probably inhibits the transcription of progesterone dependent genes 
(Mahajan and London, 1997) and thus does not allow for decidualisation to occur. 
The decidual response can, however, be induced by progesterone and increased 
levels of PR in mice deficient in ERα expression, suggesting that oestrogen does 
not affect PR expression during decidualisation (Curtis et al., 1999, Paria et al., 
1999). In contrast, the decidualisation reaction in wild type mice (that were not 
ERα deficient) was oestrogen dependent (Curtis et al., 1999). 
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4.2.2. Expression of Bcl­2 and Bax in ovariectomised rat endometria 
 
Tissue remodelling is important during the window of implantation to allow the 
blastocyst to adhere and implant in the receptive endometrium (Wang and Dey, 
2006). Apoptosis is involved in this homeostatic process and the Bcl-2/Bax 
pathways are important to intrinsic apoptosis (Harada et al., 2004, Wang and Dey, 
2006). Bcl-2 protects cells against some forms of apoptosis, but does not promote 
cell proliferation. Bax promotes apoptosis and counters the anti-apoptotic 
properties of Bcl-2 by forming heterodimers with Bcl-2 (Korsmeyer et al., 1993, 
Oltvai et al., 1993, Oltvai and Korsmeyer, 1994). Bcl-2 is localised on the outer 
membranes of the mitochondria, endoplasmic reticulum and nuclear membranes. 
Bax is located in the cytoplasm under cell survival conditions, but translocates to 
the mitochondria during apoptotic conditions (Ogle, 2002). 
 
Shifts in expression of Bcl-2 and Bax in the various endometrial 
compartments 
 
In this study, expression of Bcl-2 in the CC treated and CCPPPE treated animals 
was arbitrarily patchy around the luminal epithelium. The expression of Bcl-2 in 
the CC, P4, CCPPPE and control animals was greatest in the luminal epithelium, 
and lowest in the stroma, where localisation was only seen in the dark layer. The 
SPPPE treated tissue had the greatest expression of Bcl-2 in the stroma, beyond 
the dark layer and low in both luminal and glandular epithelium. The CCPPPE 
treatment appeared to restrict the expression of Bcl-2 in the stroma as well as 
maintaining a high punctuate expression in the luminal epithelium and seems to 
prevent the change of expression from epithelium to stroma. The effect of CC was 
similar to that of the controls, in that expression of Bcl-2 was greatest in the 
uterine luminal epithelium and lowest in the stroma, although CC caused arbitrary 
expression in some sections of the uterine luminal epithelium and surrounding 
stroma, and was absent in other sections, suggesting that some cells in the luminal 
epithelium are sensitive to clomiphene, whilst adjacent cells may not be, and may 
have a more PPPE-like expression of Bcl-2. The expression of Bcl-2 was at the 
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base of the luminal epithelial cells, possibly at the basement membrane, in the 
SPPPE treatment. This might inhibit the attachment of the blastocyst during 
implantation.  
 
The control tissues and the single CC treated tissues had the greatest expression of 
Bax in the uterine luminal epithelium, then glandular epithelium and lowest in the 
stroma. In the control tissues, Bax localisation was confined to the dark layer, 
whereas the CC treatment had localisation extended to the glandular stroma, 
suggesting that CC causes a shift in Bax expression to the stroma. 
 
Expression of Bax in P4 treated tissue was greatest in the glands, followed by the 
luminal epithelium and least in the stroma. This suggests that progesterone shifts 
the expression from the luminal epithelium to the glandular epithelium.  
 
Expression of Bax in both CCPPPE and SPPPE tissues was greatest in the stroma 
followed by the luminal epithelium and least in the glandular epithelium. 
Expression of Bax in the stroma extended to the glandular epithelium.  
 
The levels of Bcl-2 and Bax are maintained in the uterine compartments of the 
SPPPE treated animals, with the greatest expression in the stroma, then the 
luminal epithelium and least expression of both proteins in the glands. In contrast 
the CCPPPE treated tissue shows the same uterine compartment activity as 
SPPPE in terms of Bax expression, but the Bcl-2 expression in CCPPPE treated 
tissue is highest in the luminal epithelium, then the glands and least in the stroma. 
This suggests that CC affects the Bcl-2/Bax ratios and promotes cell survival in 
the luminal epithelium, which may account for the hyperplasia seen in this tissue, 
which has been seen in CC treated tissue (Hosie and Murphy, 1995, Hosie, 1997). 
Wei et al. (2005) have found that the Fas/Fas L system may also affect the 
apoptotic pathways in the epithelia of cycling endometria in an autocrine or 
paracrine fashion. Sato and colleagues (2003) found increased levels of TNF-α 
and Fas and Fas ligand 24 hours after ovariectomy and little change in Bcl-2/Bax 
levels. This suggests that the extrinsic apoptotic pathways of TNF-α and Fas/FasL 
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mediate programmed cell death in ovariectomised mouse uteri, whereas the 
intrinsic Bax/Bcl-2 pathway has little effect (Sato et al., 2003). Theron (2010) 
found that apoptosis induced by the anti-progestin, RU486, was not mediated by 
the Bcl-2/Bax pathway, and she suggested that the Fas/FasL system may promote 
programmed cell death in this treatment. However, Dai et al. (2000) found that 
RU-486 resulted in the upregulation of Bax expression, resulting in an increase in 
the Bax/Bcl-2 ratio and an increase in apoptotic activity. 
 
Shao and co-workers (2009) showed that E2 treatment on ovariectomised rats 
improved recovery from apoptotic damage in the uterine tubes, but did not have a 
protective effect against apoptosis. They also found that chronic treatment with 
CC promoted apoptosis to occur in the isthmus, suggesting that CC has an 
oestrogen antagonistic effect in this tissue. Clomiphene displayed a stronger anti-
oestrogenic effect in the presence of an oestrogen primed uterus (Hosie and 
Stewart, 2006). The single CC treatment may have had insufficient time, or doses, 
to promote the apoptotic pathway, whereas the CC and the E2 in the CCPPPE 
treatment may have promoted the apoptotic pathway. 
 
The expression of Bcl-2 was heavy in the uterine luminal epithelium  and 
diminished in the stroma when treated with CC and P4, but the opposite result was 
seen in the PPPE treated tissue. This shift in the Bcl-2 profile suggests that the 
reduction of Bcl-2 in the epithelium of PPPE treated tissues would allow for 
apoptosis during adherence and infiltration of the attaching blastocyst, whereas 
the increased levels of Bcl-2 in the CC treated animals would inhibit the process 
of apoptosis in this tissue.  
 
The SPPPE treated animals did not express Bax in the apex of the luminal 
epithelial cells, while the other treatments and the control tissues had expression 
of Bax at the apical edge of the uterine luminal epithelium.  
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The single CC treatment had patchy expression of Bax in the luminal epithelium, 
which indicates that the Bax did not shift away from the apex of the epithelial 
cells.  
 
Lai and co-workers (2000) treated ovariectomised rats with oestrogen implants 
and found that oestrogen promoted DNA synthesis and proliferation of the uterine 
epithelial cells. After removal of the oestrogen implants from the animals, they 
found a significant increase in apoptosis. The results in the present study indicate 
a shift to expression of Bcl-2. Bcl-2 promotes cell survival, and as oestrogen 
promotes proliferation and cell survival, it indicates that the CC essentially acts as 
a pro-oestrogen in this case. 
 
Tassell and co workers (2000) found apoptotic activity in the uterine luminal 
epithelium and to a lesser degree in the stromal cells of rats on the day of 
fertilisation. However, on day of implantation, they found an absence of apoptosis 
in non-implantation sites and an extremely high apoptotic index in the uterine 
luminal epithelium as well as the stromal tissue immediately underlying the 
implantation site. This result was mimicked by the PPPE treatment, as expected. 
In contrast, the CCPPPE treatment appeared to reflect the activity of the oestrous-
like state. 
 
Expression of Bcl-2 in the glandular epithelium was similar amongst the treatment 
groups and control tissues, except for the SPPPE treated animals, where the 
expression was very low. This result also suggests that clomiphene prevents the 
transformation of the uterus into a receptive state. In the rhesus monkey, Wei et 
al. (2005) found that the expression of Bcl-2 was high in the glandular epithelium 
during the proliferative phase and diminished during the secretory phase, whereas 
the expression of Bax was high during the secretory phase and was much lower 
during the proliferative phase. 
 
The single CC treated animals expressed Bax in the outer layer of the 
myometrium. This was not observed in the other treatments, and the expression of 
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anti-apoptotic Bcl-2, when treated with a single CC, did not have a high 
expression in the outer myometrium. Burroughs et al. (2000) found that increased 
levels of oestrogen and progesterone promoted both cell proliferation and 
apoptosis in myometria, whereas diminished levels of these hormones promoted 
apoptosis. Since the single CC promotes the intrinsic apoptotic pathway in the 
myometrium and behaves in the opposite way to the expected action of oestrogen, 
it in fact shows anti-oestrogenic activities. 
 
Oestrogens have been shown to modulate the growth, differentiation and 
functions of the myometrium (Clark and Mani, 1994, Benassayag et al., 1999). 
Benassayag and co-workers (1999) found that in human endometria, the 
expression of the oestrogen receptors, ERα and ERβ were differentially expressed 
in pregnant and non-pregnant myometria. Women at the end of their pregnancies 
showed low expression of ERα, which has a high affinity to E2 and activates 
transcription. In contrast, pregnant and non-pregnant women expressed similar 
concentrations of ERβ, which has a low affinity for E2, and inhibits transcription 
(Benassayag et al., 1999). Clomiphene may alter the relative expression of the 
two receptors in the myometrium, thus promoting the intrinsic apoptotic pathway. 
 
Hosie and Stewart (2006) found that CCPPE in ovariectomised rat endometria did 
not significantly affect the incidence of apoptosis when compared to SPPPE 
treated animals. The ELISA results in the present study showed no significant 
differences between Bcl-2 and Bax expression in ovariectomised animals treated 
with CC, P4, SPPPE or CCPPPE. The work performed here was of short duration, 
with either a single treatment, or a PPPE treatment with a single CC treatment. 
Thus the effects of CC over time, or its cumulative effects have not been 
investigated in this study. The effects of both dosage and of time may change the 
concentrations of Bcl-2 and Bax.  
 
However, the immunohistochemical studies showed that CC affected the 
expression of Bcl-2 and Bax in the various endometrial compartments. It is 
possible that changes in expression would have been seen in the myometrium, 
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stroma, glandular epithelium and luminal epithelium had these endometrial 
compartments been isolated from each other and ELISAs performed separately. 
 
4.2.3. Localisation of PR, Bcl­2 and Bax in the rat endometrium 
 
The progesterone receptor isoforms, PRA and B, were decreased in mouse uteri 
after progesterone treatment. PR antagonist treatment was shown to increase PR 
protein isoforms and increase mitochondrial associated apoptosis, particularly in 
the uterine luminal epithelium of mice (Shao et al., 2006). Early pregnancy is 
primed to promote cell survival of the decidua, whereas apoptosis is a greater 
feature later in the pregnancy, (Ogle, 2002). The results of the work done in the 
current study show that treatment with P4 causes the greatest expression of PR, 
Bcl-2 and Bax in the luminal epithelium and least in the stroma. It seems unlikely 
that the single treatment of P4 significantly increased apoptosis in the uterine 
compartments via the Bcl-2/Bax pathway, which was unexpected as progesterone 
has been shown to diminish PR expression and to increase apoptosis. 
Interestingly, the single CC treatment and the CCPPPE treatment both had the 
greatest expression of PR and Bax in the stroma and least in the glandular tissue. 
By contrast, Bcl-2 expression was greatest in the luminal epithelium and lowest in 
the stromal tissue. This may indicate that CC strongly promotes cell survival in 
the endometrial epithelium, and allows for premature apoptosis in the stromal 
tissue, which may have an impact on the low implantation rates seen in 
individuals treated with CC for infertility. 
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CHAPTER 5. CONCLUSION 
 
 
Childlessness has important social and economic consequences for couples and 
the burden of blame for infertility is traditionally attributed to women. However, it 
is estimated that only 40% of infertility cases are attributed to female infertility, 
40% are due to male infertility, and 20% of cases have unknown etiology 
(Bernstein, 1999). Clomiphene citrate is one of the first treatments used for female 
infertility. However, the success rates with clomiphene citrate are low, with a 1 in 
10 probability of getting pregnant compared to normal pregnancy rates 
(Greenblatt et al., 1961, Gazit et al., 1986). 
 
This study investigated the effects of clomiphene when compared to progesterone, 
as well as clomiphene in conjunction with hormonal treatments that were 
reflective of those seen in pregnancy, namely PPPE, in ovariectomised rats. In 
particular, this study focused on the effects of CC, P4, CCPPPE and SPPPE on the 
general microanatomy of the uterine components by viewing haematoxylin and 
eosin sections. It also focused on the expression of the progesterone receptor, the 
anti-apoptotic protein, Bcl-2, and the pro-apoptotic protein, Bax, in the various 
uterine compartments using immunohistochemical and ELISA methods. 
 
The major findings of this study showed: 
 
1. Clomiphene affects the various uterine compartments, including the long 
and short uterine diameters and particularly affects the overall shape of the 
lumen and the uterine luminal epithelial height, as seen by previous 
investigators. 
 
2. The expression of the progesterone receptor was altered by CC treatment 
and this may affect the spatial expression of the PR’s in such a manner as 
to impair implantation. 
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3. Bcl-2 expression with clomiphene treatment was extremely patchy around 
the uterine lumen. This expression may diminish the ability of a viable 
blastocyst to penetrate the epithelium, and in this manner may interfere 
with implantation.  
 
4. The expression of Bax in the different uterine compartments shifted when 
treated with clomiphene, which may also have affected the ability of the 
blastocyst to infiltrate the endometrium during implantation. 
 
5. Clomiphene appeared to behave in a manner that was both oestrogenic and 
anti-oestrogenic. Moreover, clomiphene also seemed to behave in a 
manner unrelated to oestrogen and may affect hormonal pathways that are 
unrelated to oestrogen. 
 
 
Future investigations for this study 
 
1. In order to elucidate the oestrogenic or anti-oestrogenic effects of 
clomiphene more fully, it would have been advantageous to compare the 
treatments to a single E2 treatment.  
 
2. The ELISA results did not show any changes in expression of PR, Bcl-2 or 
Bax, as the entire uterine sections were combined before performing this 
assay. In future, it would be useful to separate the luminal epithelium, 
glandular epithelium, stroma and myometrium for analysis by ELISA. 
 
3. Clomiphene citrate has shown to have a cumulative effect, affected by 
both period of application as well as number of treatments. It would be 
interesting to increase the number of treatments and duration of this 
project to investigate the cumulative effects of CC. 
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4. The progesterone receptor exists in two different isoforms, with different 
downstream effects. The immunoassays used in this study did not 
differentiate between PRA and PRB and it may be of use to further 
distinguish between expressions of these isoforms. 
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APPENDIX A: SOLUTIONS 
 
A. 1.  General solutions 
 
Paraformaldehyde, 4% 
Paraformaldehyde 4 g 
PBS Buffer  100 ml 
Heat to 60 ºC 
Add 4% NaOH drop-wise, until the 4% paraformaldehyde has cleared. 
pH the 4% paraformaldehyde to pH 7.4. 
 
Phosphate buffered saline, pH 7.4 
NaCl   8.0 g 
KCl   0.2 g 
Na2HPO4  1.44 g 
KH2PO4  0.24 g 
Distilled water   800 ml 
Adjust to pH 7.4 with HCl 
Make up to 1 litre with distilled water. 
 
0.01 M Phosphate buffered saline, pH 7.1-7.2 
 NaCl   9.0 g   
 Na2HPO4.12H2O 2.60 g   
 NaH2PO4.2H2O 0.29 g   
 Distilled water  1 000 ml  
pH to between 7.1 and 7.2 
Store: maximum 1 week at room temperature. 
 
Saline (0.9% NaCl) 
 NaCl   9.0 g 
 Distilled water  1000 ml 
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Tris buffered saline (TBS), pH 7.6 
 Tris Base  6.06 g 
 NaCl   8.77 g 
 Distilled water  1 000 ml 
Use HCl to lower pH to 7.6 
 
Tris buffered saline and 0.05% Tween 20 (TBST) 
 TBS, pH 7.6  200 ml 
 Tween 20  100 μl 
 
A.2.  Solutions for haematoxylin and eosin staining 
 
Modified Mayer’s haematoxylin  
 Haematoxylin    4.0 g 
 Distilled water    1 000 ml 
 Sodium Iodate    0.3 g 
 Aluminium Potassium sulphate 50.0 g 
 Citric Acid    1.5 g 
 Chloral Hydrate   75.0 g 
 
Dissolve alum in water (do not heat). Add, in order, haematoxylin, iodate, citric acid 
and chloral hydrate. Filter haematoxylin solution through coarse filter paper. 
 
Eosin stock solution 
Eosin     8.0 g 
Erythrosin    2.0 g 
Distilled water    1 000 ml 
 
Eosin working solution 
Stock Eosin    250 ml 
Distilled water    750 ml 
Calcium Chloride   20 g 
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A.3.   Solutions for immunohistochemistry 
 
3,3’ Diaminobenzidine tetrahydrochloride (DAB) 
 
Option 1: 0.05% DAB (w/v)  - BDH Laboratories 
BDH Laboratory supplies, Poole, England, 1330332P 
• Weigh 1 mg DAB into a bijou bottle. 
• At the start of the day, when one is using the secondary antibody, leave a 
measuring cylinder with 29 ml distilled water at 4 °C. 
• Just before use, add 2 ml Tris-HCl, pH 7.6 to the DAB in the Bijou bottles. 
• Then add 1 ml of 30% perhydrol (Merck, Germany) to the cold distilled water 
to make a 1% solution, mix well. 
• Add 20 μl of the 1% perhydrol to the DAB solution 
o Mix on whirlimix 
o Pipette 30 μl into each well 
o Time individually for 5 minutes 
• Final concentration: 0.05% (w/v) DAB diluted in Tris-HCl with 0.01% 
Perhydrol 
 
Option 2: DAB- Dako Kit 
Dako Ark (Animal Research Kit), Peroxidase 
Dako Cytomation, CA, USA, # K3955 
To mix: 1 ml buffered substrate (bottle 5) 
   Add 1 drop DAB and chromagen (bottle 6) 
   Mix well 
 
Option 3: DAB - Roche Kit 
DAB substrate, Roche, Germany, 1 718 096 
Add 1 part DAB/metal concentrate (10x concentration) 
To 9 parts Peroxide Buffer 
 (i.e. 1/10 dilution) 
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Diluent for anti-sera 
 Tris-saline   100 ml 
 Sodium azide   0.25 g  (Add in fume hood) 
 Bovine serum albumin  5 mg 
 Thyroglobulin   5 mg 
 EDTA    40 mg 
 Swine serum   1 ml 
 
Heat induced antigen retrieval (HIAR) 
 
Option 1: Citrate buffer, pH 6.0       
(10 mM citric acid, 0.05% tween-20) 
Citric acid (anhydrous)  1.92 g     
(Or citric acid monohydrate 2.10 g) 
Distilled Water   1 000 ml 
Mix to dissolve. 
Adjust to pH 6.0 with 1 M NaOH. 
Add 0.5 ml Tween-20 and mix well.     
Store: Room temperature for 3 months, or longer in fridge. 
Note:  This starts with a very low pH 
 Therefore, add 800 ml water, pH to 6.0 and make up to 1 000 ml.   
Then add Tween-20. 
 
Option2: EDTA buffer, pH 8.0      
(1 mM EDTA, 0.05% tween-20) 
EDTA    0.37 g     
Distilled Water   1 000 ml 
Mix to dissolve.  
Adjust to pH 8.0 with 1N NaOH. 
Add 0.5 ml Tween-20 and mix well.     
Store: Room temperature for 3 months, or longer in fridge. 
Note: This buffer often gives high background, so primary antibody can often be 
highly diluted. Is useful for low affinity antibodies or when tissue antigens are not 
intense.
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Option 3: Tris buffer, pH 10.0   
(10 mM Tris base, 0.05% tween-20) 
Tris Base   1.21 g      
Distilled Water   1 000 ml 
Mix to dissolve.  
Adjust to pH 10.0 with 1 M NaOH. 
Add 0.5 ml Tween-20 and mix well.     
Store: Room temperature for 3 months, or longer in fridge. 
Note: Method sometimes causes tissue damage or sections to detach from slides.   
This may be due to the high pH. 
 
Option 4: Tris-EDTA buffer, pH 9.0       
(10 mM Tris base, 1 mM EDTA, 0.05% tween-20) 
Tris Base   1.21 g     
EDTA    0.37 g     
Distilled Water   1 000 ml 
Mix to dissolve. pH is usually at 9.0. 
Add 0.5 ml Tween-20 and mix well.     
Store: Room temperature for 3 months, or longer in fridge. 
Note: This buffer often gives high background, so primary antibody can often be 
highly diluted. It is useful for low affinity antibodies or when tissue antigens 
are not intense 
 
1% Peroxide in PBS 
 Perhydrol (30%)  1 ml  
 PBS    30 ml 
Store at 4ºC for up to 3 months. 
 
Serum block - 1.0% goat serum  
 goat serum   100 μl    
 PBS    9.9 ml 
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A.4.   Solutions for the Lowry­Folin method of protein 
determination 
 
2 mg/ml BSA made up in PBS 
 BSA   0.2 g 
 PBS   100 ml 
 
1% Copper sulphate  
 CuSO4.5H2O  0.1 g 
 Distilled water  10 ml 
 
Folin-Ciocalteu’s phenol reagent (Sigma, F 9252)  
Folin-Ciocalteu’s reagent diluted 1:4 in dH2O 
dilute just before use 
 
2% Sodium carbonate in 0.1M NaOH 
Na2CO3  2 g 
NaOH (0.1 M)   100 ml 
 
2% Sodium potassium tartrate  
NaKC4H4O6.4H2O 0.2 g 
Distilled water  10 ml 
 
A.5.  Solutions for ELISA  
 
Block (0.1% BSA in PBS) 
 BSA   0.1 g 
 PBS   100 ml 
 
0.5 M Sulphuric acid (1 N H2SO4) 
 H2SO4   2.7 ml 
 Distilled water  100 ml  
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APPENDIX B: RECIPES 
 
B.1.   Preparation of 3­aminopropyltriehoxysilane (APES) 
coated slides 
 
1. Wash slides in detergent overnight. 
2. Wash slides in hot running tap water for 30 mins. 
3. Wash slides in distilled water, 2 x 5mins. 
4. Wash slides in 95% alcohol, 2 x 5 mins. 
5. Air dry for 10 mins. 
6. Immerse in freshly prepared 2% silane in acetone for 30 mins. 
300 ml silane is sufficient for 200 slides 
add 6 ml of 3-aminopropyltriehoxysilane (Sigma, A-3648) to 294 ml 
acetone 
7. Dip in acetone 1 – 2 times. 
8. Wash in distilled water twice. 
9. Dry overnight at 42 ºC. 
10. Store at room temperature. 
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B.2.  Haematoxylin and eosin staining 
 
Method 
1. Dewax sections, 2 x 5 mins, xylene 
2. Rehydrate sections, absolute alcohol, 2 x 2 mins 
95% alcohol, 2 mins 
3. Rinse in running tap water  
4. Stain in Haematoxylin, 5 mins 
5. Blue in running tap water 
6. Dip 2-3 times in acid alcohol 
7. Rinse in tap water 
8. Stain in Eosin, 1 min 
9. Rinse in tap water 
10. Dehydrate and clear sections, 
95% alcohol, 2 mins 
absolute alcohol, 2 x 2 mins 
xylene, 2 x 5 mins 
11. Mount in Entellen and view 
 
Results 
 Nuclei   Blue 
 Erythrocytes  Orange 
 Other Tissue  Pink 
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B.3.   Lowry­Folin method for protein determination  
 
Reagent A 
50 ml of 2% Sodium Carbonate in 0.1 M NaOH 
0.5 ml of 1% Copper Sulphate 
0.5 ml of 2% Sodium Potassium Tartrate  
Make up just before use 
 
Reagent B 
Folin-Ciocalteu’s phenol Reagent (Sigma, F 9252) diluted 1:4 in dH2O 
dilute just before use 
 
Standard stock solution 
 2 mg/ml BSA stock made up in PBS. 
 
Table B.3.1. Dilutions of BSA to make up a protein concentration gradient 
 
 
 
Method 
Using the ELISA plates, each well contained, in order: 
1. 50 μl of sample 
2. 200 μl Reagent A → leave for 10 mins (shake) 
3. 50 μl Reagent B  → leave for 30 mins (shake) 
4. Read absorbance at 690 nm.  
[BSA] (μg/ml) Vol (BSA) Vol (PBS) 
2 000 50 μl stock 0 
1 000 50 μl (2 000) 50 μl 
500 50 μl (1 000) 50 μl 
250 50 μl (500) 50 μl 
125 50 μl (250) 50 μl 
62.5 50 μl (125) 50 μl 
31.25 5 0μl (62.5) 50 μl 
 0 0 50 μl 
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APPENDIX C– OPTIMISATION OF METHODS: 
IMMUNOHISTOCHEMISTRY (IHC); 
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
C.1.   Optimisation of IHC against PR, Bcl­2 and Bax 
 
Figure C.1.1. Flow diagram showing optimisation of primary antibody using 
Santa Cruz and Dako antibodies 
 
Sections (4 μm) on APES slides 
pregnant uterus (for PR) or colon (for Bcl-2 and Bax)  
Dewax and rehydrate 
Aspirate excess liquid 
 
Mark with Dako pen 
 
PBS wash, 3 x 2 mins 
 
Quench endogenous peroxidase activity 
1% H202 in PBS, 10 mins 
 
PBS wash, 2 x 5mins 
 
Serum block, 20 mins 
The serum for blocking was made up as follows: 
Primary antibody 
Manufacturer 
of primary Serum used 
Anti-PR and anti-Bax Santa Cruz 1% horse serum in PBS 
Anti-Bcl-2 Santa Cruz 1% goat serum in PBS 
Anti-PR, anti-Bcl-2 and anti-Bax Dako 1% goat serum in PBS 
The serum used was based upon the animal in which the secondary antibody was raised. 
Therefore, since the Santa Cruz secondary for Bax and PR were raised in donkey, horse serum 
was used to block the sections at this step. Similarly, since the secondary for the Dako 
antibodies and the Bcl-2 from Santa Cruz were raised in goat, goat serum was used to block at 
this step. 
 
Aspirate excess liquid 
 
Primary antibody made up in diluent (see appendix A) 
4 °C, overnight, humidified chamber 
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Primary antibodies were used as follows: 
Primary antibody Manufacturer Dilutions 
Anti-PR (rabbit 
polyclonal, C19) 
Santa Cruz,     
sc-538 
1/100; 1/200; 1/400; 1/800; 1/1600; 
diluent only 
Anti-PR (rabbit 
polyclonal) 
Dako, A-0098 1/50; 1/100; 1/200; diluent only 
Anti-Bcl-2 (mouse 
monoclonal, C2) 
Santa Cruz,     
sc-7382 
1/100; 1/250; 1/500; 1/800; 1/1000, 
diluent only 
Anti-Bcl-2 (mouse 
monoclonal) 
Dako, M-0887 1/25; 1/50; 1/100; diluent only 
Anti-Bax (rabbit 
polyclonal, P19) 
Santa Cruz,     
sc-526 
1/100; 1/200; 1/400; 1/800; 1/1600; 
diluent only 
Anti-Bax (rabbit 
polyclonal) 
Dako, A-3533 1/50; 1/100; 1/200; diluent only 
 
Rinse with PBS 
Wash PBS, 2 x 2mins 
 
Secondary antibody  
 
The sections were then incubated with secondary antibody as follows: 
Primary 
antibody 
From Secondary 
antibody used 
From Dilute Diluent used Time 
Anti-PR, 
Anti-Bax 
Santa Cruz Anti-rabbit 
(donkey) 
Santa Cruz, 
sc-2313 
1/500 1% horse 
serum in PBS 
30 mins 
Anti-PR, 
Anti-Bax  
Dako Anti-rabbit 
(goat) 
Dako, P-0448 1/500 PBS 1 hour 
Anti-Bcl-2  Santa Cruz Anti-mouse 
(goat) 
Santa Cruz, 
sc-2005 
1/500 1% goat 
serum in PBS 
30 mins 
Anti-Bcl-2  Dako Anti-mouse 
(goat) 
Dako, P-0447 1/500 PBS 1 hour 
The above table shows the combination of primary and secondary antibodies. It also indicates 
the diluent for the secondary antibodies, and incubation times for the secondary antibodies. 
All of the secondary antibodies were conjugated with horse radish peroxidase (HRP). All 
incubations were done at room temperature. 
 
Rinse with PBS 
Wash PBS, 2 x 2mins 
 
DAB, 5 mins 
 
Rinse with dH20 
Wash with dH20, 1 x 2 mins 
 
Dehydrate, clear and mount 
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Figure C.1.2. Flow diagram showing optimisation of different DABs 
 
Uterus (for PR) or colon (for Bax) sections on APES slides 
Dewax and rehydrate; Aspirate excess liquid 
 
Antigen unmasking 
10mM sodium citrate buffer, pH 6.0 (see appendix A) 
Microwave 2 x 5mins 
  
Cool for at least 20 mins 
Aspirate excess liquid 
Mark with Dako pen 
 
PBS wash, 3 x 2mins 
 
Quench endogenous peroxidase activity 
1% H202 in PBS, 10 mins 
 
PBS wash, 2 x 5mins 
 
Serum block 
1% horse serum in PBS, 20 mins 
Aspirate excess liquid 
 
*Primary antibody made up in diluent, 4 °C, overnight 
 
1/200 anti-PR    1/200 anti-Bax    
Santa Cruz, sc-538    Santa Cruz, sc-526   
  
Wash PBS, 2 x 2mins 
 
Secondary antibody made up in PBS 
Room temperature, 1 hour 
 
1/250 goat-anti-rabbit    1/200 goat-anti-rabbit   
for PR      for Bax    
(Use PBS for -2° antibody control) 
 
Wash PBS, 2 x 2mins 
 
DAB from different manufacturers, 5 mins 
Manufacturer Method to make up DAB 
0.05% DAB (w/v) , BDH Laboratory supplies, 
Poole, England, 1330332P 
0.05% (w/v) DAB diluted in Tris-HCl, pH 7.6 
with 0.01% Perhydrol (see appendix) 
Dako Ark (Animal Research Kit), Peroxidase, 
Dako Cytomation, CA, USA, # K3955 
1 ml buffered substrate (bottle 5), add 1 drop 
DAB and chromagen (bottle 6). Mix well 
Roche Kit, DAB substrate, Roche, Germany, 1 
718 096 
Add 1 part DAB/metal concentrate (10x 
concentration) to 9 parts Peroxide Buffer (i.e. 
1/10 dilution) 
 
Rinse with dH20 
Wash with dH20, 1 x 2 mins 
 
Dehydrate, clear and mount 
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Figure C.1.3. Flow diagram showing IHC using different antigen retrieval 
buffers, and Dako antibodies against Bax, Bcl-2 and PR 
 
Uterus sections (4 μm) on APES slides 
Dewax and rehydrate; Aspirate excess liquid 
 
Antigen unmasking 
Antigen retrieval buffer Composition of buffer 
Citrate buffer, pH 6.0 10 mM Citric acid, 0.05% Tween-20 
EDTA buffer, pH 8.0   1 mM EDTA, 0.05% Tween-20 
Tris-EDTA buffer, pH 9.0 10 mM Tris base, 1 mM EDTA, 0.05% Tween-20 
Tris buffer, pH 10.0 10 mM Tris base, 0.05%Tween-20 
Slides placed in container with unmasking buffer, 
Microwaved at 720 W, 2 x 10 mins 
Left to cool for 20 mins 
 
Aspirate excess liquid 
Mark with Dako pen 
 
PBS wash, 3 x 2 mins 
 
Quench endogenous peroxidase activity 
1% H202 in PBS, 10 mins 
 
PBS wash, 2 x 5 mins 
 
Serum block 
1% goat serum in PBS, 20 mins 
Aspirate excess liquid 
 
Primary antibody made up in diluent, 4°C, overnight 
Primary antibody Manufacturer Dilution 
Anti-PR Dako, A-0098 1/25, 1/50 
Anti-Bcl-2 Dako, M-0887 1/50, 1/100 
Anti-Bax Dako, A-3533) 1/50, 1/100 
  
Wash PBS, 2 x 2mins 
 
Secondary antibody made up in PBS 
Room temperature, 1 hour 
 
1/250 goat-anti-rabbit   1/250 goat-anti-mouse 
 For PR and Bax     for Bcl-2 
(Use PBS for -2° antibody control) 
 
Rinse with PBS 
Wash PBS, 2 x 2mins 
 
DAB (Roche, 130332P), 5 mins 
 
Rinse with dH20 
Wash with dH20, 1 x 2 mins 
 
Dehydrate, clear and mount 
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Figure C.1.4. Flow diagram showing IHC with different concentrations of 
Primary antibodies against Bax, Bcl-2 and PR 
 
Uterus sections (4 μm) on APES slides  
Dewax and rehydrate 
Aspirate excess liquid 
 
Antigen unmasking 
Tris-EDTA buffer, pH 9.0 
Microwave 2 x 10mins 
 
Cool for at least 20 mins 
Aspirate excess liquid 
Mark with Dako pen 
 
PBS wash, 3 x 2mins 
 
Quench endogenous peroxidase activity 
1% H202 in PBS, 10 mins 
 
PBS wash, 2 x 5 mins 
 
Serum block 
1% goat serum in PBS, 20 mins 
Aspirate excess liquid 
 
Primary antibody made up in diluent 
4°C, overnight, humidified chamber 
Primary antibody Manufacturer Dilution 
Anti-PR Dako, A-0098 1/50, 1/100, 1/200, diluent only 
Anti-Bcl-2 Dako, M-0887 1/25, 1/50, 1/100, diluent only 
Anti-Bax Dako, A-3533 1/50, 1/100, 1/200, diluent only 
 
Rinse with PBS 
Wash PBS, 2 x 2 mins 
 
Secondary antibody made up in PBS 
Room temperature, 1 hour 
 
1/250 goat-anti-rabbit (Dako, P-0448)  1/250 goat-anti-mouse (Dako, P-0447) 
 for PR and Bax     for Bcl-2 
 
Rinse with PBS 
Wash PBS, 2 x 2 mins 
 
DAB, 5 mins 
 
Rinse with dH20 
Wash with dH20, 1 x 2 mins 
 
Dehydrate, clear and mount 
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C.1.5.   Results from optimisations of IHC 
 
It was found that the most optimal primary and secondary antibodies for IHC 
were supplied by Dako. 
The optimal concentrations for the primary antibodies were 1/50 anti-Bax, 1/50 
anti-Bcl-2 and 1/50 anti-PR. 
The optimal concentrations for the secondary antibodies were 1/200goat-anti-
rabbit IgG/HRP for Bax, 1/200 goat anti-mouse IgG/HRP for Bcl-2 and 1/250 
goat-anti-rabbit IgG/HRP for PR  
 It was found that the optimal primary antibody concentrations were: 1/50 anti- 
Bax (Dako), 1/50 anti-Bcl-2 (Dako) and 1/50 anti-PR (Dako). 
The best secondary antibodies to use were supplied by Dako, and were incubated 
for 1 hour in PBS. 
The best heat induced antigen retrieval method used, was microwaving the 
sections twice in Tris-EDTA buffer pH9.0. 
The best chromagen to use was the diaminobenzidine supplied by Roche. 
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C.2.  Optimisation of ELISA against Bcl­2, Bax and PR 
 
Figure C.2.1. Optimisation of primary and secondary antibodies for ELISA 
against Bcl-2, Bax and PR 
100 μl of 1/100 uterus protein sample in PBS  
incubated in a well of a 96 well Nunc maxisorb plate 
2 hours at room temperature in a humidified chamber 
 
Aspirate plate 
 
Wash 0.9% saline, 3 x 
 
Block (200 μl  of 0.1% BSA in PBS)  
on a shaker, 1 hour 
 
Aspirate 
 
Wash 0.9% saline, 4 x 
 
100 μl primary antibody made up in block (0.1% BSA in PBS) 
incubated, 2 hours on a shaker 
The  primary antibodies were applied at decreasing concentrations along the rows: 
Primary Antibody Dilution 
Anti-PR (Santa Cruz, sc-538) 1/100; 1/200; 1/400; 1/800; 1/1600; 1/3200; 1/6400; 1/12800; 
1/25600 
Anti-Bcl-2 (Santa Cruz, sc-7382) 1/100; 1/200; 1/400; 1/800; 1/1600; 1/3200; 1/6400; 1/12800; 
1/25600 
Anti-Bax (Santa Cruz, sc-526) 1/100; 1/200; 1/400; 1/800; 1/1600; 1/3200; 1/6400; 1/12800; 
1/25600 
 
Aspirate 
 
Wash 0.9% saline, 4 x 
 
100 μl secondary antibody made up in block (0.1% BSA in PBS) 
Incubate for 1½ hours at room temperature on a shaker  
The secondary antibodies were applied at decreasing concentrations along the columns  
Primary (diluted 
along rows) 
Secondary (diluted 
along columns) 
Secondary dilutions 
Anti-PR Donkey-anti-rabbit (Santa 
Cruz, sc-2313) 
1/100; 1/200; 1/500, 1/1 000; 1/2 000; 1/4 000; 
1/8 000; 1/10 000 
Anti-Bcl-2 Goat-anti-mouse (Santa 
Cruz, sc-2005) 
1/100; 1/200; 1/500, 1/1 000; 1/2 000; 1/4 000; 
1/8 000; 1/10 000 
Anti-Bax Donkey-anti-rabbit (Santa 
Cruz, sc-2313) 
1/100; 1/200; 1/500, 1/1 000; 1/2 000; 1/4 000; 
1/8 000; 1/10 000 
 
Aspirate 
 
Wash with 0.9% saline, 4 x 
 
Add 70 μl soluble BM Blue POD substrate 
Leave to incubate in the dark 
 
Stop reaction with 50 μl 0.5 M sulphuric acid 
 
Read A450 
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Figure C.2.2. Optimise protein concentration, incubation of protein samples 
and incubation of primary antibodies for ELISA against Bcl-2, Bax and PR 
 
Two 96 well Nunc maxisorb plates were used 
100 μl of 10 μg/ml uterus protein sample 
Plate 1 was incubated overnight at 4 ºC in a humidified chamber and plate 2 was incubated at 
room temperature for 2 hours on a shaker 
Protein Sample Protein dilution Incubation of protein 
Sample 1 = 
1156μg/ml 
1/50 = 23.12 μg/ml; 1/100 = 11.56 μg/ml; 1/200 = 
5.78 μg/ml; 1/400 = 2.89 μg/ml; 1/800 = 1.45 
μg/ml; 1/1600 = 0.73 μg/ml; PBS alone 
Overnight at 4 ˚C (plate 
1) 
Sample 2 = 
4892μg/ml 
1/50 = 97.84 μg/ml; 1/100 = 48.92 μg/ml; 1/200 = 
24.46 μg/ml; 1/400 = 12.23μg/ml; 1/800 = 6.12 
μg/ml; 1/1600 = 3.06 μg/ml; PBS alone 
Overnight at 4 ˚C (plate 
1) 
Sample 1 = 
1156μg/ml 
1/50 = 23.12 μg/ml; 1/100 = 11.56 μg/ml; 1/200 = 
5.78 μg/ml; 1/400 = 2.89 μg/ml; 1/800 = 1.45 
μg/ml; 1/1600 = 0.73 μg/ml; PBS alone 
Room temperature, 2 
hours, shaker (plate 2) 
Sample 2 = 
4892μg/ml 
1/50 = 97.84 μg/ml; 1/100 = 48.92 μg/ml; 1/200 = 
24.46 μg/ml; 1/400 = 12.23μg/ml; 1/800 = 6.12 
μg/ml; 1/1600 = 3.06 μg/ml; PBS alone 
Room temperature, 2 
hours, shaker (plate 2) 
The protein samples were duplicated at 100 μl/well for incubation with anti-PR, anti-Bax and anti-
Bcl-2. 
 
Aspirate plate 
 
Block (200 μl of 0.1% BSA in PBS)  
on a shaker, 1 hour 
 
Aspirate 
 
Wash 0.9% saline, 3 x 
 
100 μl primary antibody made up in block (0.1% BSA in PBS) 
incubate room temperature, 2 hours, shaking  (plate 1)or 
overnight, 4 °C, humidified chamber (plate 2) 
Sample Primary antibody Manufacturer Incubation of Primary 
antibody 
Samples 1 and 2 1/500 anti-Bcl-2 Santa Cruz, sc-7382 Room temperature, 2 hours, 
shaking (plate 1) 
Samples 1 and 2 1/100 anti-Bax Santa Cruz, sc-526 Room temperature, 2 hours, 
shaking (plate 1) 
Samples 1 and 2 1/100 anti-PR Santa Cruz, sc-538 Room temperature, 2 hours, 
shaking (plate 1) 
Samples 1 and 2 1/500 anti-Bcl-2 Santa Cruz, sc-7382 Overnight at 4 ˚C (plate 2) 
Samples 1 and 2 1/100 anti-Bax Santa Cruz, sc-526 Overnight at 4 ˚C (plate 2) 
Samples 1 and 2 1/100 anti-PR Santa Cruz, sc-538 Overnight at 4 ˚C (plate 2) 
 
Aspirate 
 
Wash 0.9% saline, 4 x 
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100μl secondary antibody made up in block (0.1% BSA in PBS) 
Incubate for 1½ hours at room temperature on a shaker 
 
1/1000 donkey-anti-rabbit   1/1000 goat-anti-mouse   
for PR and Bax    for Bcl-2    
 
Aspirate 
 
Wash with 0.9% saline, 4 x 
 
Add 70 μl soluble BM Blue POD substrate 
Leave to incubate in the dark 
 
Stop reaction with 50 μl 0.5 M sulphuric acid 
 
Read A450 
 
 
C.2.3. Results of Optimisation of ELISA 
 
It was found that the optimal concentration of protein to use was 100 μl of  
10 μg/ml protein and that it was best to leave the protein to incubate overnight at  
4 °C in a humidified chamber. 
The optimal concentrations of primary antibodies were 1/100 anti-Bax, 1/500 
anti-Bcl-2 and 1/100 anti-PR 
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APPENDIX D: EXAMPLE OF STATISTICAL ANALYSIS 
 
An example of statistical analysis used to analyse the data in this work. The 
example used shows the analysis of the height of the luminal epithelium.  
 
Oneway Analysis of EPI AVE By Treatment  
E
P
I A
V
E
5
6
7
8
9
10
11
12
13
CC CCPPPE Oil Ovex P4 SOOO SPPPE Saline
Treatment 2
All Pairs
Tukey-Kramer
 0.05
 
Wilcoxon / Kruskal-Wallis Tests (Rank Sums) 
Level Count Score Sum Score Mean (Mean-Mean0)/Std0 
CC 11 919.5 83.5909 4.664 
CCPPPE 11 841 76.4545 3.741 
Oil 12 323.5 26.9583 -2.788 
Ovex 11 297.5 27.0455 -2.641 
P4 15 811.5 54.1000 1.017 
SOOO 12 230.5 19.2083 -3.841 
SPPPE 10 731.5 73.1500 3.140 
Saline 12 310 25.8333 -2.941 
1-way Test, ChiSquare Approximation 
ChiSquare DF Prob>ChiSq
74.8539 7 <.0001
Means Comparisons 
Dif=Mean[i]-
Mean[j] 
CC CCPPPE SPPPE P4 Ovex Oil Saline SOOO
CC 0.0000 0.8963 1.2337 3.0016 4.7329 4.7686 4.7867 5.1343
CCPPPE -0.8963 0.0000 0.3374 2.1053 3.8366 3.8723 3.8903 4.2380
SPPPE -1.2337 -0.3374 0.0000 1.7679 3.4992 3.5349 3.5530 3.9006
P4 -3.0016 -2.1053 -1.7679 0.0000 1.7313 1.7670 1.7851 2.1327
Ovex -4.7329 -3.8366 -3.4992 -1.7313 0.0000 0.0357 0.0538 0.4014
Oil -4.7686 -3.8723 -3.5349 -1.7670 -0.0357 0.0000 0.0181 0.3657
Saline -4.7867 -3.8903 -3.5530 -1.7851 -0.0538 -0.0181 0.0000 0.3476
SOOO -5.1343 -4.2380 -3.9006 -2.1327 -0.4014 -0.3657 -0.3476 0.0000
 
Alpha= 0.05 
  
Comparisons for all pairs using Tukey-Kramer HSD 
 
q* Alpha 
3.10683 0.05 
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Abs(Dif)-
LSD 
CC CCPPPE SPPPE P4 Ovex Oil Saline SOOO
CC -1.1706 -0.2743 0.0342 1.9118 3.5623 3.6227 3.6407 3.9884
CCPPPE -0.2743 -1.1706 -0.8622 1.0155 2.6660 2.7263 2.7444 3.0920
SPPPE 0.0342 -0.8622 -1.2277 0.6471 2.2997 2.3594 2.3775 2.7251
P4 1.9118 1.0155 0.6471 -1.0024 0.6415 0.7038 0.7218 1.0694
Ovex 3.5623 2.6660 2.2997 0.6415 -1.1706 -1.1103 -1.0922 -0.7446
Oil 3.6227 2.7263 2.3594 0.7038 -1.1103 -1.1208 -1.1027 -0.7551
Saline 3.6407 2.7444 2.3775 0.7218 -1.0922 -1.1027 -1.1208 -0.7731
SOOO 3.9884 3.0920 2.7251 1.0694 -0.7446 -0.7551 -0.7731 -1.1208
 
Positive values show pairs of means that are significantly different. 
 
 
 
Level     Mean
CC A       11.337350
CCPPPE A B     10.441000
SPPPE   B     10.103638
P4     C   8.335727
Ovex       D 6.604425
Oil       D 6.568719
Saline       D 6.550660
SOOO       D 6.203038
 
Levels not connected by same letter are significantly different 
 
 
 
 
 
 
